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Abstract 
 
Type 1 diabetes is a T cell mediated autoimmune disease, often presented in children. 
Development of T1D is a chronic progression, wherein memory CD4+ T cells (CD4+ Tm) 
are believed to play a pivotal role in mediating autoimmune responses. It has been 
proposed that dysfunction in effector memory cells may contribute to autoimmunity in T1D. 
Using a unique cohort of age- and gender-matched children with T1D, their non-diabetic 
siblings and unrelated healthy control children, we undertook a detailed immunological 
study, including circulating CD4+ Tm cell counts, and activation, proliferation, effector 
responses and apoptosis in reactivated CD4+ Tm cells during TCR stimulation induced by 
anti-CD3/anti-CD28 mAb. 
We found T1D was associated with a reduced circulating CD4+ Tm cell count, and a similar 
reduction in circulating CD4+ Tm cells was also evident in the siblings. In both children with 
T1D and siblings, the reduced circulating CD4+ Tm cell counts were resulted from a 
decrease in the central memory CD4+ T cells. In reactivated CD4+ Tm cells, no intergroup 
difference in proliferation was found across the cohorts. Reactivated CD4+ Tm cells from 
children with T1D and siblings acquired CD25+ phenotype at a higher proportion when 
compared to controls. In addition, reactivated CD4+ Tm cells from children with T1D and 
siblings were capable of mounting exaggerated effector responses through effective 
transitioning from central memory (CD62L+) to effector memory (CD62L-) phenotype. The 
exaggerated effector responses were characterised by elevated IFN-γ and IL-10 
production in T1D patients and elevated IFN-γ production in the siblings. These 
exaggerated Tem responses were also accompanied by an increase in Fas-independent 
mitochondria-associated apoptosis, which eliminated approximately 50% of the CD4+ Tem 
cells in T1D and siblings, but only one third of CD4+ Tem cells in controls. The increased 
apoptotic response in reactivated CD4+ Tm cells from children with T1D inversely 
correlates with their reduced blood CD4+ Tm counts, suggesting that the susceptibility to 
reactivation-induced apoptosis may be associated with an altered in vivo dynamics of 
blood CD4+ Tm cells in T1D.  
In conclusion, this study has revealed a novel hyperactive phenotype of reactivated CD4+ 
Tm cells in T1D patients and their siblings. In these cells, an exaggerated activation and 
Tem phenotype were counterbalanced by heightened apoptotic response. Whether the 
exaggerated activation, Tem phenotype and apoptosis herein induced in reactivated CD4+ 
Tm cells by polyclonal TCR stimulation also operates across other T cell lineages (e.g. 
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CD8+ T cell lineages) as well as in response to islet-specific antigen challenge is warranted 
in further studies. Nonetheless, this study provides new insights for further defining 
mechanisms underlying T1D pathophysiology, and illuminates specific immune cell 
lineages, biologically relevant surface receptors, cytokines, and biochemical pathways for 
therapeutic targeting.  
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Chapter 1 General Introduction 
1.1 Definition of type 1 diabetes 
Type 1 diabetes (T1D) is an autoimmune form of diabetes, characterized by immune-mediated 
destruction of insulin-producing β cells in the pancreatic islets [1, 2]. The β cell functions to sense 
blood glucose and release insulin to maintain physiological glucose level. The lack of insulin, 
resulted from β cells destruction, leads to loss of blood glucose control and hyperglycaemia, with 
clinical symptoms such as polydipsia, polyphagia and polyuria, and secondary complications such 
as heart disease, vision impairment and kidney failure [3, 4]. T1D is fatal unless managed with daily 
and life-long administration of exogenous insulin [3]. Diagnosis of T1D conventionally include 
fasting blood glucose higher than 7mmol/L [5], any blood glucose of 11.1mmol/L or higher with 
symptoms of hyperglycaemia, or an impaired 2 hour oral glucose tolerance test [6]. A recent update 
to the guidelines for diabetes diagnosis included glycated haemoglobin (HbA1c) of 6.5% of higher, 
which indicates the level of average blood glucose concentration over 3 months and hence reflects a 
relatively long-term glycaemic exposure [7]. 
1.2 T1D Epidemiology 
T1D is classically present during childhood or adolescence, with 50% of patients diagnosed by the 
age of 18, hence is used to be named juvenile diabetes [8]. Unlike other autoimmune disease, the 
incidence of T1D is not female-biased, instead it is more common in boys and men [9, 10], and a 
similar prevalence was found in first degree relatives who were at risk of developing T1D [11]. 
Retrospective studies on the incidence of T1D in children show a rapid increase worldwide in the 
last 50 years with particularly high incidence rate in developed countries [12], and the incidence of 
T1D has doubled in Australia in the last 20 years [13]. Australia is in the top 10 countries for 
incidence of T1D in children under age 15, with the highest incident rate of T1D recorded among 
children between 10-14 years of age [8], and is still reporting 6 new cases a day and an annual 
increase rate of 3.2% [14]. The high prevalence of T1D in young population is creating a huge 
social and financial burden worldwide. 
T1D is a multi-factorial disease resulted as a consequence of both genetic predisposition and largely 
unknown environmental factors, and their interactions in a stochastic fashion [1, 15]. Due to the 
genetic component of T1D, the risk of disease development in siblings of diabetic children is 
increased compared with the general population [16].  
CHAPTER 1                                   INTRODUCTION 
16 
 
1.3 T1D Etiology 
1.3.1 Genetics of susceptibility 
Despite rare cases of monogenic diabetes, T1D is generally considered a polygenic disorder. A 
number of loci have been identified from genome-wide associated study (GWAS) to affect disease 
susceptibility [17, 18]. The strongest genetic susceptibility is found in the human leukocyte antigen 
(HLA) region on chromosome 6p21, which account for 50% of genetic risks of T1D.  For example, 
the HLA DR3-DQ2 and DR4-DQ8 haplotypes are associated with highest genetic susceptibility 
[19]. These genes encode class-II major histocompatibility complex (MHC) on antigen presenting 
cells (APC) [20], which are involved in presentation of antigen peptides to the T cell receptor (TCR) 
on CD4
+ 
T cells and therefore influence adaptive immune responses.  
In addition to the HLA-associated risk, a number of non-HLA loci have been identified to be 
associated with T1D predisposition, such as the protein tyrosine phosphatase non receptor 22 
(PTPN22) gene on chromosome 1p13, the insulin (INS) gene region on chromosome 11p15, the 
high-affinity alpha chain of IL-2 receptor (IL2RA) gene on chromosome 10p15, the SH2B3 gene 
involved in T cell signalling, and the CTLA4 gene involved in T cell recognition of antigen and 
immune regulation [17, 18]. These genes accounts for modest risk of T1D, but they encode for 
products associated with antigen-driven T cell immunological responses and regulation, particularly 
affecting interactions between APC, self-antigen and CD4
+ 
T cells, and collectively could lead to 
establishment of autoimmunity and breaking of self-tolerance.  
1.3.2 The role of environment factors in developing T1D 
Despite the strong genetic links, the globally increasing incidence of T1D in the last two decades 
[15], especially the rise of T1D in children with low genetic risk, can only be explained by an 
penetrance of the environment impacts [13, 21]. An increasing number of environmental influences 
have been postulated for T1D [22], from infant feeding and diet [23], sun exposure and vitamin D 
deficiency [24], to viral infections [25].  
Studies purposed to examine infant feedings and their association with T1D development in 
children with HLA-conferred susceptibility to T1D suggested that breastfeeding, late exposure to 
cow milk protein and solid foods (cereal, oats and rice), and dietary supplementation of omega 3 
fatty acids may reduce the risk of T1D [26-29], but many of the results are contradictory or 
inconclusive. In addition, studies analysing dietary glycaemic index (GI) and glycaemic loading 
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with development of β cell autoimmunity in children with genetic risk of T1D concluded with no 
association between high GI diet and seroconversion to autoantibody positivity [30].  
Vitamin D deficiency has been suggested as another environmental factor, and a number of studies 
have shown that the lack of sun exposure and vitamin D intake may increase the incidence of T1D 
in genetically predisposed children [24, 31]. In addition, maternal vitamin D deficiency may also 
increase the risk of T1D in off-springs [32]. It has been suggested that vitamin D may contribute to 
immune modulation and thereby protect or arrest an ongoing immune activations [31]. However, a 
recent larger multi-centre study across Europe proved that neither vitamin D nor circulating 25-
hydroxyvitamin D concentrations throughout childhood were associated with increased risks of β 
cell autoimmunity or progression to T1D [33].  
The incidences of T1D onset do display seasonal variations, with more cases diagnosed in autumn 
and winter [9, 34]. Although the seasonality pattern appears to be dependent on the geographical 
position, this concept supports role of seasonal infections in initiating the pathogenic process of 
T1D.  
The association of viral infection with T1D has been extensively studied in both experimental 
animal models and in seroepidemiological human studies. Two major mechanisms were proposed 
for the role of viral infection in T1D progression: either via a direct cytolytic effect on β-cells, or by 
triggering a local inflammation that leads to autoimmune process and β-cell destruction [22, 35]. 
Within the growing list of viruses that have been associated with T1D, a family of gut-borne 
enterovirus viruses, such as coxsackievirus and rotavirus have received particular attentions and are 
shown to play a role in progression to T1D [25, 36-38]. A number of clinical studies have detected 
coxsackievirus and enterovirus infections in islets of T1D patients [39, 40], suggested clear islet 
tropism of these viruses. Virus spreading into the islets may induce local inflammation [41], 
increase islet exposure to danger-sensing APCs  [42] and promote recruitment of cytolytic T cells to 
inflamed islets [43]. In addition, the structural homology between viral protein and β-cell 
autoantigens has been suggested for a molecular mimicry and cross-reactivity effect in diabetes-
associated autoimmune responses. For example, a strong immunogenic peptide of rotavirus have 
high sequence similarity to T cell epitopes in the tyrosine phosphatase-related islet antigen 2 (IA-2) 
and glutamic acid decarboxylase 65 (GAD65), and  are capable of strong binding to T1D 
susceptibility-associated HLA-DRB1 molecules to elicit T cell proliferation response [44]. In 
genetically predisposed children at risk of T1D, presence of enterovirus RNA in serum has also 
been shown to strongly associate with progression to clinical T1D onset [45]. However, clearance 
of viral infections by the immune system is relatively fast (normally within weeks), and the adaptive 
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immune responses generally abate after contraction, therefore the rapid viral clearance is in 
disparity with chronic development of T1D. In addition, children with T1D and their non-diabetic 
siblings from the same family have similarly exposure to the infections but are different in disease 
susceptibility. So, the mechanisms manifesting disease in children with T1D whilst maintaining 
tolerance in siblings cannot be simply explained by islet exposure to infections. In fact, a recent 
large multi-centre study using next generation sequencing techniques to search patient plasma 
samples for a series of viruses, including influenza A virus, respiratory virus and gastrointestinal 
virus during the period of seroconversion, failed to establish any association between viral infection 
and T1D onset [46]. Overall, despite numerous evidences linking viral infections with T1D 
progression, no major conclusion with an unequivocal influence on T1D pathogenesis have been 
identified. A new strategy focusing on viral infections in immune cells, such as APC and T cells, 
and subsequent induction of stress in the immune system will be of interest. 
1.3.3 Familial aggregation of T1D 
Familial aggregation of T1D has been recognised for many years [47-49], and about 10-15% of 
newly diagnosed children have an affected first degree relatives [50]. We and others have also 
published a number of papers comparing immunological characteristics between children with T1D 
and their first degree relatives [51, 52].  However, the risk of developing islet autoimmunity varies 
depending on which relative(s) have T1D, and siblings often develop T1D more frequently than 
parents or offspring of T1D patients [53]. Indeed, risk of T1D increases when genetic predisposition 
and environmental factors are combined. Studies with monozygotic twins revealed that the 
concordance rate of developing T1D was approximately 35-50% [54, 55]. In non-identical twins, if 
one child has T1D the chance for the other child to develop T1D is approximately 15-20% if two 
HLA DR3/DR4-DQ8 haplotypes are shared, or approximately 5-6% if one HLA haplotype is shared, 
or less than 1% if neither is shared [56]. The risk of a child of a T1D father to develop T1D is about 
6%, whereas a lower risk of 2% is in children born to a T1D mother [57, 58]. All the above first 
degree relatives to T1D patient have higher risk of developing T1D than the general population 
(0.4%), suggesting a clear familial aggregation of T1D [59]. The familial risk of developing T1D is 
summarised in Table 1.1.  
It is also worth noting that the predisposition on insulin gene confers approximately 10% of the 
familial aggregation of T1D, but if combined with predisposition on the HLA alleles, the familial 
aggregation of T1D raised to 50% [60, 61]. Therefore, the familial aggregation of T1D is likely due 
to inherited and shared polymorphisms of a combination of susceptible genes, both HLA- and non-
HLA-associated. In addition to similar genetic background, the shared living environment is also 
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critical in triggering T1D. Studies on the discordance of T1D in monozygotic twins revealed that 
environmentally-induced epigenetic modifications, such as DNA hypermethylation, post-
translational modification of histone and activation of microRNA, are likely mechanistic 
explanations involved in environmental impacts [18, 62]. Another interesting evidence is that 
siblings of T1D patients diagnosed before age 5 have a five-fold higher risk of developing T1D than 
those siblings diagnosed between 5 and 15 years of age, suggesting that T1D with an onset before 
age 5 may be a marker for high familial risk [63].  
Table 1.1 Risks of developing T1D in individuals having an affected relative   
Siblings Risk Reference 
Overall 6% [57] 
   Identical twin <50% [54, 55] 
   HLA identical 15% [56] 
   HLA haploidentical 6% [56] 
   HLA non-identical 1% [56] 
Offspring Risk  
Overall 5% [57] 
   Father who has T1D 6% [58] 
   Mother who has T1D 2% [58] 
 
1.3.4 Heterogeneity of T1D 
Although most cases of the T1D represents an autoimmune disorder, featuring presence of islet 
autoantibodies and HLA-associated hyper-immune responses, there are still about 10-30% of T1D 
patients who do not have the typical autoantibodies and their specific immunological pathogenesis 
remains unclear [64]. A subset of these individuals is found to have a monogenic form of diabetes, 
such as the maturity onset of diabetes of the young (MODY) [65]. In addition, despite most T1D 
onset occurs during childhood, there are also cases of adult onsets, for example the latent 
autoimmune diabetes of adult (LADA), which has typical disease characteristics of lowered C-
peptide and presence of autoantibodies against the islets [66]. LADA represents a subtype of T1D 
with slower disease progression [67], and has no much difference on the genetic basis between 
childhood T1D [68]. Overall, T1D is a disease with heterogeneity, whose genetics, pathogenic 
processes and phenotypes present with marked variations [2].  
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1.4 Pathophysiology of T1D 
T1D is an autoimmune disease, resulted from a false targeting of self-islet antigens by the immune 
system. Several islet and β cell-antigens have been identified as target antigens in human T1D. 
These include (pro)insulin, GAD65, IA-2, islet-specific glucose-6-phosphatase catalytic subunit-
related protein (IGRP), zinc transporter 8 [69], and the most recently identified chromogranin A 
(WE-14 peptide) [70, 71]. These β cell-antigens, which are normal proteins also present in healthy 
individuals, are believed to be targeted, processed and transported by surrounding APC to draining 
pancreatic lymph nodes (LN) for specific T cell priming.  
Development of T1D is a chronic process with a progressive loss of β cells over a number of years. 
The immunogenic and physiological events that occurred at disease initiation and progression are 
still to be elucidated in human. With the experimental animal models, such as the non-obese 
diabetic (NOD) mouse and the BioBreeding (BB) rat, the disease progression has been extensively 
studied and numerous studies demonstrating mechanisms involved in the disease development have 
been published and linked to pathological evidences from T1D patients.  
Studies employing animal models of autoimmune diabetes suggest that an insulitis phase 
characterized by sequential recruitments of immune cells into the pancreatic islets precedes the T1D 
onset, and a model of T1D progression has been proposed [15, 72, 73]. In this progression model, a 
combination of genetic susceptibility and environmental triggers leads to initial β cells damage and 
islet inflammation. Interaction between the damaged β cells and resident macrophages and dendritic 
cells (DC) signals for recruitment of cytotoxic T cells to the inflamed islets [74]. β cell antigens, 
possibly together with infective agents, are processed and transported by DC to draining pancreatic 
LN and are presented  to CD4
+
 T cells in a pro-inflammatory context [74, 75]. The activated 
effector CD4
+ 
T cells confer multiple helper functions, including helping B cells in their 
seroconversion to produce autoantibodies, and promoting cytotoxic T cells for a second wave of β 
cell attack [73]. At this time, multiple immune cells infiltrating the pancreatic islets work 
synergistically and further damage the β cells via mechanisms such as direct β cell kill by 
perforin/granzyme or Fas-FasL interactions between β cells and CD4+ T cells [72, 73, 76]. Further 
damage induces the stressed β cells to release more β cell-antigens, which are in turn spread wider 
by APC such as infiltrated B cells (epitope spreading), and result in further recruitment of effector 
CD4
+
 T cells and cytotoxic CD8
+
 T cells to exacerbate the β cell damage [15]. At the same time, 
impaired number and/or function of regulatory T (Treg) cells permit peripheral expansion of 
autoreactive T cell and systematic breaking of tolerance against β cells [77-79]. Progressively, this 
vicious cycle leads to severe loss of β cell mass and T1D onset in NOD mice.  
MHC-I 
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In T1D patients, by the time of clinical onset, more than 80% of functional β cell mass is destroyed, 
and this may continue to worsen in established disease where islets can be almost devoid of β cells 
[2, 80]. Studies on the post mortem tissue from newly-diagnosed T1D patients confirmed insulitis 
and found infiltration in the islets of mixed mononuclear cells from both innate and adaptive 
immune systems at clinical onset [81-84]. Evidence of insulitis and infiltration of immune cells in 
human T1D mirror the observations in NOD mice [84].  
1.4.1 Antigen presenting cells  
APC belong to the innate immune system. They sense “danger” signals, such as foreign antigens, 
infections and tissue damage, and process and present the “danger” signals to T cells in the adaptive 
immune system. In the pancreatic islets of T1D patient, the early infiltrated APC were mainly 
comprised of CD68
+
 macrophages, and their numbers remained consistent during phases of insulitis 
[84]. Besides their normal phagocytic activity, these islet-infiltrating macrophages are believed to 
contribute to insulitis and initial phase of β cell death by secreting proinflammatory cytokines such 
as interleukin (IL)-1b [80, 84], which stimulates Fas expression on β cells in T1D patients [85].  
In addition to macrophage, CD20
+
 B cells were also found in islet infiltrates in T1D patients, and 
they appeared to be recruited to the islets later in the insulitis once β cell damage was already 
established [84]. However, it is unlikely that the B cells detected in the inflamed islets were 
antibody producing, because CD20 expression is lost when B cells differentiate into antibody-
secreting plasma cells [86]. In fact, more recent evidences suggest that antibody production function 
is not required for T1D to occur [87]. Therefore, the B cells in the islet-infiltrates of T1D patients 
are more likely eliciting antigen presenting activity. As APC, B cells are specialised in binding 
soluble antigens via surface immunoglobulin and thus effectively present sequestered antigen to 
CD4
+ 
T cells [88]. Accumulated research interests in B cells in T1D has resulted in a recent phase II 
clinical trial, where depletion of B cells preserved C-peptide concentration and reduced insulin 
requirement in newly diagnosed T1D patients for one year [89]. However, this anti-B cells therapy 
failed to show difference between treatment and placebo group at the second year [2].  
DC are another type of professional APC, able to transport loaded antigens from the peripheral 
tissue to the draining LN, where they present antigens to T cells [90, 91]. Because of this mobile 
capacity, DC have been proposed to play a critical role in initiating T cell autoimmune responses in 
NOD mice [74]. However, unlike observations from the NOD mice, DC were not reported to be in 
the islet infiltrates in T1D patients. Instead, CD11c
+
 DC loaded with islet autoantigens such as 
proinsulin, GAD and IA-2 have been detected in spleen and peripheral LN of T1D patients [92]. 
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Therefore, DC in T1D patients are likely to have exited the islets, and are actively executing their 
antigen presenting function by interacting with T cells to induce islet-autoreactivity.  
The most important function of APC is to recognise danger signals. In the healthy, DC maintain 
tolerance to self-antigens and dead cells derived from physiological turnover by remaining 
immature [91, 93, 94]. Although occasionally, transient DC activation and subsequent T cell 
activation occur where self-antigens from damaged tissue are targeted for house-keeping purpose, 
majority of such transient responses are “benign” and do not result in pathological autoimmunity 
[95]. The reason for DC to lose tolerance to self-islet antigens in human T1D is still unknown, but a 
few mechanisms based on results from NOD mice have been proposed [96].  
As professional APC, DC are involved in educating T cells in both central and peripheral tolerance. 
In NOD mice, it has been suggested that defects in thymic DC may lead to low efficiency in 
negative selection of specific autoreactive T cell precursors [97], and evidence from elevated clonal 
deletion threshold for autoreactive T cells in thymus supported this idea [98, 99]. Therefore, it is 
possible that due to defective thymic negative selection autoreactive T cells may have escaped from 
central tolerance and entered the periphery. However, autoreactive T cells specific for islet antigens 
are also detected in peripheral blood of healthy individuals [100, 101], suggesting that defects in 
central tolerance cannot explain the breaking of tolerance in human T1D.  
In the periphery, DC from NOD mice are found to be in a hyperactive state upon stimulation, owing 
to an elevated NF-κB activation [102-104]. The hyperactive DC have increased expression of co-
stimulatory molecules and can influence the local milieu by secreting a number of proinflammatory 
cytokines, including IL-1β, TNF-α and IL12p70, which either have direct cytotoxic effects on β 
cells or promotes activation of CD4
+ 
T and CD8
+ 
T cells [75, 105, 106]. Direct evidence of DC 
involvement in the T1D pathology is derived from a study demonstrating that ablation of DC in 
NOD mice blocked autoreactive CD4
+
 T cell activation and T1D development, whereas adoptive 
transfer of DC into DC-ablated NOD mice restored β cells-specific T cell autoimmunity [107]. 
However, in T1D patients peripheral DC exhibit mostly an immune phenotype with a decreased T 
cell stimulatory capacity, due to a defective activation of NF-κB pathway, compared to healthy 
individuals [108-110]. The discrepancies in DC phenotype and functions between NOD mice and 
T1D patients are interesting, and both suggest that dysregulation of NF-κB pathway are associated 
with defective DC, but can occur in disparate ways that nevertheless influence peripheral tolerance 
[97]. In addition to DC functions, we also demonstrated reduced circulating DC counts in T1D 
patients [111], as well as in their non-diabetic siblings [52], implying that DC defects may occur 
prior to T1D onset and may be from a bone marrow origin [110].  
CHAPTER 1                                   INTRODUCTION 
23 
 
Overall, a major challenge still remains to identify the role of APC in maintaining tolerance to 
“benign” autoimmunity and losing tolerance in pathological autoimmunity. 
1.4.2 T cells and autoimmune responses in the chronic development of T1D 
The key role of mature APC is to present processed antigens to CD4
+ 
T cells, and inevitably much 
attention has been focused on the role of T cells in autoimmune destruction of  β cells in T1D  [112, 
113]. In diabetic patients, both CD4
+ 
T and CD8
+ 
T cells are present in islet infiltrates, and the 
increased number of these cells correlated with the decreased insulin-positivity in the islets [82, 84]. 
In addition, autoreactive CD4
+ 
T and CD8
+ 
T cells have also been found in the peripheral blood 
circulation in patients with T1D [101]. However, evidence from NOD mice suggest that  CD8
+ 
T 
cells alone are unable to induce T1D [114, 115], they require vital help from CD4
+ 
T cells for their 
activation, expansion and induction of tissue specificity [116-120]. The CD4
+ 
T cells are also 
essential for helping B cells in their differentiation, class switching and expansion, via co-
stimulatory interaction such as CD40L-CD40 [73, 88]. The highest genetic risk for developing T1D 
is associated with predispositions on the HLA Class II alleles, suggesting that the peptide-binding 
activity between antigen-presenting cells and the CD4
+ 
T cells may be the main drive of the disease 
initiation [15].  
In NOD mice, evidence of pathogenic CD4
+ 
T cells recognising peptides of insulin and subsequent 
recruiting to islets has been reported [121]. In the islets, CD4
+
 T cells help activating CD8
+
 T cells 
by producing IL-2 [122-124]. They can also directly kill β cells by secreting IFN-γ to promote Fas 
expression on β cells, and by subsequent ligation of β cell Fas with FasL on activated CD4+ T cells 
[115, 125].  
During the chronic progression of T1D, autoreactive CD4
+
 T cells specific for β cell-antigens 
should be in vivo antigen-experienced memory CD4
+
 T (Tm) cells [126]. In comparison to naïve T 
(Tn) cells, CD4
+ 
Tm cells are less stringent for antigen-binding, can bypass the accessary co-
stimulatory requirement, and respond faster to cognate antigen stimulation [120, 127]. In patients 
receiving pancreas segmental transplantation from their non-diabetic identical twins, the quick 
recurrence of  β cells destruction (6-12 weeks post-transplantation) has provided strong evidence for 
the role of immune memory in autoreactive T cells [128]. Another evidence shows that, despite the 
presence of GAD65-and insulin-reactive CD4
+
 Tn cells in both healthy and diabetic children, it is 
unique for T1D patients and at-risk individuals to harbour autoreactive clones in their circulating 
CD4
+
 Tm pool [101, 129]. In addition, these autoreactive CD4
+ 
Tm have uniquely undergone 
extensive in vivo proliferation, as evident in their eroded telomeres, and are in a late activation state 
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expressing CD25 (IL-2 receptor) and full-activation marker CD134 (surface molecule OX40, TNF-
receptor). These results indicate that the CD4
+ 
Tm cells have been in vivo primed and expanded in 
T1D patients in contrast to healthy individuals [101], and the autoreactive CD4
+ 
Tm cells are 
descendants of proliferated effector T cells which are activated and ready to confer specific 
autoimmune responses.  
CD4
+ 
Tm cells represent a hallmark of the acquired immune system. They are resulted from clonal 
expansion and differentiation of antigen-specific effector T cells, and confer protection against 
experienced antigens upon secondary challenge. The specific immune memory persist for a lifetime 
[130]. In vitro studies have identified two phenotypically and functional distinct subsets of human 
CD4
+ 
Tm cells, the central memory (CD4
+
 Tcm) and effector memory T (CD4
+
 Tem) cells [131]. 
The Tcm cells express CD62L and CCR7, home to lymph nodes for self-renewal and act as a “stem 
cell like” inventory of antigen-experienced memory; whereas the Tem cells have down-regulated 
lymphoid homing receptors and patrol through peripheral non-lymphoid tissues [132, 133]. 
Following TCR triggering at secondary challenge, the reactivated CD4
+ 
Tcm cells produce 
predominantly IL-2 [134], and generally propagate into non-effector state and remain uncommitted. 
Reactivated CD4
+ 
Tem cells retain effector phenotype and produce cytokines of the prototypic Th-
1, Th-2 or Th-17 effector lineage imprinted at primary responses [130, 131, 133]. 
Clinical trials targeting CD4
+ 
Tm cells in T1D patients have been recently reported. A multi-centre 
trial studying the immune-modulatory effect of co-stimulation blockade in T1D patients showed 
that blocking of co-stimulation with CTLA-4 immunoglobulin fusion proteins (Abatacept) prevent 
full T cell activation and slowed reduction of β cell function for over 2 years [135], and more 
importantly this effect seemed to be associated with drug-induced contraction of peripheral CD4
+ 
Tcm cells [136]. Comparing to the placebo group, a decrease of blood CD4
+
 Tcm cells in the 
treatment group was associated with slower a rate of C-peptide decline [136]. Therefore, 
quantification of peripheral CD4
+ 
Tcm cells has been suggested as a surrogate immune marker for 
C-peptide decline in human T1D. 
Another recent trial targeted CD4
+ 
Tem cells, and investigated whether drug-mediated depletions of 
CD4
+ 
Tem cells as well as CD4
+ 
Tcm cells will arrest autoimmunity and preserved functions of 
residual β cells in newly diagnosed T1D patients. In this trial, immuno-depletion CD4+ Tem cells 
and CD4
+ 
Tcm cells with anti-CD2 (Alefacept) preserved C-peptide and lowered insulin 
requirement in T1D patients for up to 1 year. Additionally, such depletion did not affect the Treg 
cells in patients [137].  
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Similar CD4
+
 Tm-focused study has been reported in NOD mice, where disease could be prevented 
by artificially guiding CD4
+ 
Tm cells away from an 'effector' memory phenotype towards a 
'regulatory' memory phenotype [138]. Collectively, these new evidences have suggested that CD4
+
 
Tm could be a useful target in preserving β cells functions in T1D patients. More importantly, these 
studies are leading towards a new strategy with specific immune target, rather than broadly 
eliminating immune cells.  
1.4.3 Immune regulation of T1D 
In healthy, peripheral immune regulation limit the expansion of pathogenic effector T cells to 
maintain tolerance. In T1D patients, however dysfunctional regulation impairs peripheral tolerance 
and permits activation and proliferation of autoreactive CD4
+ 
Tm cell to mediate chronic 
autoimmune response [97]. Therefore, an impaired immune regulation may reinforce autoimmunity 
during the T1D development.  
Generally, a defective immune tolerance can be a result of a deficiency or functional impairment in 
Treg cells. The Treg cells are another important component of the CD4
+
 T cell compartment. 
Human Treg cells express transcription factor FoxP3 and high level of surface IL-2 receptor CD25, 
and have down-regulated surface IL-7 receptor CD127 [139]. Treg cells exert their regulatory 
function by suppressing activation of other effector cells, via a variety of mechanisms including: (1) 
cell-cell contact possibly involving CTLA-4 binding, (2) cytokine ‘‘deprivation’’ by CD25 binding 
of IL-2, (3) bystander suppression via secretion of anti-inflammatory cytokines such as TGF-β, IL-
10 and IL-35, and (4) direct cytolytic activity through granzyme B and perforin release [140].  
Several studies have examined the frequency and temporal activities of Treg cells in both NOD 
mice and in T1D patients, however the results are inconclusive. In NOD mice, Treg cells presented 
in islet infiltrates are shown to be unstable and undergo increased apoptosis [79], and impaired 
suppressive functions or loss of Treg have been associated with rapid β cell destruction and diabetes 
onset [78, 141, 142]. In T1D patients, Treg cells are very rarely found in the islet infiltrates [84]. 
Although some have reported  defective suppressor function and temporal reduction of human Treg 
cells in T1D patients [77, 143, 144], there are also a number of studies found unaffected Treg 
number and function in both NOD mice [145, 146] and T1D patients [52, 147, 148].  
These conflicting findings on Treg cells in T1D are possibly due to different methods used for 
detection and isolation of Treg cells, different model systems being employed (in vitro vs. in vivo, 
NOD mice vs. human), and/or different age-groups being examined (children vs. adult). To date, 
majority of the reports on Treg cells in T1D patients only reflects a transient or temporal state of the 
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Treg cell pool. Considering the plasticity nature of Treg cells [69, 149] and possible local 
inflammation Treg cells may encounter, the immune regulation conferred by Treg cells may be 
better studied in a longitudinal design, where co-development of immune dysregulation and T cell 
autoimmunity may be monitored, and the breaking of β cell tolerance from “benign” autoimmunity 
to pathological autoimmunity may be understood.  
In summary, APC, T cells and Treg cells may be the main cellular players in the autoimmune 
development during T1D progression, and together they orchestrate the disease onset. However, 
T1D is a T cell-mediated autoimmune disease, and accumulated evidences suggest that CD4
+ 
Tm 
cells may be a promising avenue for understanding the disease, therefore this PhD thesis chose to 
investigate CD4
+ 
Tm cells in patients with T1D.  
 
1.5 Research aims of this study 
By recruiting a unique cohort of age- and gender-matched children with T1D, their non-diabetic 
siblings and unrelated healthy control children, this study is designed to undertake a detailed 
immunological study of peripheral blood CD4
+ 
Tm cells in these children subjects.  
We hypothesize that, due to difference in underlying disease the immunological characteristics and 
functions of CD4
+ 
Tm cells vary between children with T1D, their non-diabetic siblings and 
unrelated control children. We aim to identify immune signatures specific to children with T1D, by 
examination across the cohorts of circulating CD4
+
 Tm cell counts, and activation, proliferation, 
effector responses and apoptotic response in reactivated CD4
+ 
Tm cells during TCR stimulation.  
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Chapter 2 Assessment of CD4+ T cells in the peripheral blood of children with 
T1D, their non-diabetic siblings and unrelated healthy controls 
2.1 Introduction 
T1D is a T cell mediated autoimmune disease, characterised by infiltration of specific T cells into 
the pancreatic islets and T cell-dependent damage of the insulin-producing β cells in the islets. 
Studies of pancreatic tissue from post-mortem T1D patients have found CD4
+
 and CD8
+
 effector T 
cells present in islet infiltrates, and their numbers inversely correlated with beta cells mass and 
insulin contents in the islets [84, 150]. In contrast, regulatory T cells (Treg) that suppress effector T 
cells were very rarely detected in islet infiltrates [84, 151]. Due to the inaccessibility of islets from 
living T1D patients, the role of effector T cells in the immunopathogenesis of T1D is still unclear. 
However, examining circulating T cells in peripheral blood of T1D patients may be an indirect 
reflection of events occurring in islets [15, 152]. In addition, studies comparing circulating T cells 
and their effector functions between T1D patients and their non-diabetic siblings may further 
provide valuable insights into T cell immunopathogenesis and help in identifying T1D-specific T 
cell immune signatures. 
Although both CD4
+
 and CD8
+ 
T cells have been detected in islets of T1D patients, the CD4
+ 
T 
cells are believed to play a central role in mediating and maintaining the pathological autoimmunity 
[121, 153-155], whereas CD8
+ 
T cells may become dominant in the β-cell destruction stage [84, 
115, 150]. CD4
+  
T cells provide helps to CD8
+ 
T cells in their activation, survival and induction of 
tissue specific responses [117, 119], and then CD8
+ 
T cells kill β cells with cytolytic proteins such 
as perforin and granzyme B [156, 157]. Depletion of CD4
+ 
T cells, or a genetic deficiency in CD4
+ 
T cells in mouse models of T1D protected the animals from insulitis and diabetes, suggesting that 
CD8
+ 
T cells alone are insufficient to induce diabetes without help from CD4
+ 
T cells (reviewed in 
[115]). There are also evidence from animal models showing that CD4
+ 
T cells can also directly 
interact and kill β cells, possibly through the Fas-FasL associated death pathway [76, 158, 159]. 
Additionally, the CD4
+ 
T cells also provide help to B cells in their seroconversion [73] and antigen 
presentation [160, 161].  
During the chronic progression of T1D, the pathogenic CD4
+ 
T cells are experienced with islet 
antigens and have acquired memory phenotype [101, 126]. Studies show that T1D patients and at-
risk siblings uniquely harbour autoreactive CD4
+ 
T cells, specific for islet antigens such as glutamic 
acid decarboxylase (GAD) 65 and insulin, in their peripheral memory T cell pool, whereas healthy 
control subjects do not [101, 129]. In addition, the autoreactive memory CD4
+ 
T (CD4
+ 
Tm) in T1D 
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patients and at-risk siblings are found to have undergone substantial in vivo proliferation, indicating 
that they are in vivo primed and have expanded much more than their naïve CD4
+ 
T (CD4
+ 
Tn) 
counterparts [101]. Furthermore, the circulating autoreactive CD4
+ 
Tm cells express activation 
marker CD25 and a late stage activation marker CD134 [162, 163]. 
Generation of the autoreactive CD4
+ 
Tm cells in T1D patients is still not clearly understood, but it is 
possible that chronic exposure to islet antigens may continuously challenge and activate CD4
+ 
T 
cells (both directly through cognate T cell receptor (TCR) and indirectly through bystander 
activations [164]), leading to an emerging of autoreactive CD4
+ 
T cells from the naïve T cell pool to 
the memory T cell pool in the absence of an effective immune regulation. The central role for CD4
+ 
Tm cells in driving T1D development was highlighted in recent clinical trials. A trial using co-
stimulation blocking agent CTLA-4 antibody to prevent full T cell activation showed that blocking 
of CD4
+ 
Tm cell activation slowed β-cell destruction [135, 136], and another trial aimed to deplete 
memory T cells by anti-CD2 antibody reported that drug-mediated depletions of CD4
+ 
Tm cells 
preserved C-peptide level and β cell function in newly diagnosed T1D patients up to 1-2 years 
[137]. These studies clearly point towards CD4
+ 
Tm cells as being a promising immune target for 
T1D; however current knowledge about CD4
+
 Tm cells in T1D patients is limited. 
Chronic immune activation and inflammation may alter the composition and dynamics of peripheral 
CD4
+ 
T cell subpopulations. It has been shown that ongoing immune activation induced by an array 
of pro-inflammatory cytokines can result in a constant differentiation of CD4
+ 
Tn cells as well as 
transition of central memory CD4
+ 
T(cm) cells into effector memory CD4
+ 
T(em) cells in T1D 
patients [165]. The CD4
+ 
Tcm and CD4
+ 
Tem cells together comprise the CD4
+ 
Tm pool, but they 
are functionally distinct [131]. The Tcm cells express CD62L and CCR7, and home to lymph nodes 
for self-renewal, whereas the Tem cells have down-regulated lymphoid homing receptors, patrol 
through peripheral non-lymphoid tissues and differentiate into effector T cells (such as Th1, Th2 or 
Th17 lineages) upon reactivation [132, 133]. In our previous study, we analysed the proportions of 
CD4
+ 
Tn, CD4
+ 
Tcm and CD4
+ 
Tem cells in children with T1D, their siblings and controls, and 
showed comparable frequencies of these CD4
+ 
T cell subsets across the three subject groups. A 
correlation analysis found no significant correlation between these CD4
+ 
T cell lineages and T1D 
associated clinical characteristics, such as age, age of diagnosis and disease duration [52] 
(Appendix F2, attached publication). These data suggested that T1D progression was not associated 
with alterations in the relative composition of blood CD4
+ 
T cells. In this chapter, we hypothesize 
that chronic exposure to islet autoantigens may have an impact on absolute number of the CD4
+ 
T 
cell lineages in patients with T1D, which differentiate them from their non-diabetic siblings and 
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healthy population. To address this hypothesis, we performed quantitative analyses on absolute 
numbers of CD4
+ 
T cell lineages in the peripheral blood of children with T1D, their non-diabetic 
siblings and control subjects.  
Since a number of studies have suggested T1D manifests features of chronic T cell activation [162, 
163], in this chapter we asked whether ex vivo activation status of blood CD4
+ 
T cells can 
discriminate between children with T1D, siblings and controls.  By measuring the expression of a 
conventional activation marker CD25, we compared in pre-activation in circulating blood CD4
+ 
T 
cell across the cohorts. We also determined the expression of CD3 as part of TCR complex on 
CD4
+ 
T cells and subsets, and this result provided fundamental evidence of whether CD4
+ 
T cells 
from T1D, sibling and control subjects were able to respond to TCR-induced stimulation at a 
similar magnitude. In addition, expression of CD127 (IL-7 receptor α chain), which is involved in 
homeostatic T cell proliferation and maintenance, was assessed on blood CD4
+ 
T cells. 
Subsequently, in order to address whether our T1D cohort possesses a defective immune regulation 
in comparison to siblings and controls, absolute numbers and proportions of CD25
+
CD127
lo/- 
blood 
Treg cells [139] were determined in children with T1D, their siblings and controls. Lastly, we 
hypothesize that chronic antigen challenge and development of autoimmunity will result in CD4
+ 
T 
cells exhaustion in T1D, and to address this hypothesis we measured spontaneous apoptosis ex vivo 
in CD4
+ 
Tn and CD4
+ 
Tm cells obtained from children with T1D, siblings and controls.  
It was also our interest to compare the overall immune status between children with T1D, non-
diabetic siblings and healthy controls. In our previous work, we reported relative lymphopenia in 
both children with T1D and their siblings, compared to controls [52]. Lymphopenia has been 
suggested to precede diabetes onset and result in homeostatic expansion of pathogenic autoreactive 
CD4
+ 
Tm cells in NOD mice [166]. In humans, lymphopenia is reported in other forms of 
autoimmune diseases such as coeliac disease [167-169], and the immunological mechanisms 
underlying the lymphopenia-induced autoimmunity was recently revealed in patients with multiple 
sclerosis iatrogenically-induced with lymphopenia by immunodepleting treatment [170]. In this 
chapter, by examining clinical full blood counts we provided a more comprehensive analysis of 
blood immune cells, particularly blood lymphocytes, in children with T1D, siblings and controls.  
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2.2 Material and Methods 
2.2.1 Research subjects  
Between January 2011 and December 2013, 31 children with T1D and 45 non-diabetic siblings 
were recruited from the Queensland Diabetic Centre at the Mater Children’s Hospital, Brisbane. 
T1D was diagnosed according to the definition of the World Health Organization [5]. The age range 
of recruited children with T1D was between 5.5 and 16 years, which is similar to the age 
distribution of children with highest incident rate of T1D in Australia [14]. All diabetic children 
were treated with insulin, 10 of which were newly diagnosed (disease duration <0.5 year) and the 
other 21 had established T1D for longer than 1 year. The diabetic children were screened for islet 
autoantibodies, including GAD and IA-2, and 78% of the diabetic children were positive for GAD 
(of which 13% were only positive for GAD and 65% were positive for both GAD and IA-2) and 
75% of the diabetic children were positive of IA-2A (of which 10% were only positive for IA-2 and 
65% were positive for both GAD and IA-2). Four diabetic children were negative for both screened 
autoantibodies. Glycated haemoglobin (HbA1c) at test was measured in children with T1D as 
additional guideline for average blood glucose concentration over 3 months prior to the test [6, 7]. 
Seventeen diabetic children had HLA-DQ genotyping data, of which 16 possessed high risk 
haplotypes such as DQA1*05:01/ DQB1*02:01 (DQ2.5) and/or DQA1*03:01/ DQB1*03:02 
(DQ8), and the one diabetic child who didn’t possess the high risk HLA haplotype had 
DQA1*02:01/DQB1*02:02 (DQ2.2) and DQA1*05:05/ DQB1*03:01 (DQ7.5), which is the trans-
isoform of DQ2.5. Body mass index (BMI) was measured in children with T1D, and age-corrected 
BMI Z-score (standard deviation score) was calculated based on population data published by 
WHO, by using an WHO Anthroplus software [171]. There was no difference in BMI Z-scores 
between diabetic boys and diabetic girls (P=0.345). All siblings had normal blood glucose levels. 
One sibling was positive for autoantibodies to GAD and IA-2 at the time of recruitment. None of 
the siblings was diagnosed with T1D during the course of the study.  
A total number of 29 age- and gender-matched unrelated control children were recruited. These 
control children included 3 healthy volunteers, 2 children returned for follow-up checks to previous 
surgery of fractured nose, and children from elective operation lists for non-autoimmune and non-
inflammatory conditions at the Mater Children’s Hospital. The children recruited from the elective 
operation lists included those scheduled for tonsillectomy (for recurrent tonsillitis, n=10), 
adenoidectomy (for adenoid hypertrophy without infection, n=8) and inferior turbinate reduction 
(for impaired breathing, no infection, n=6), and blood samples were collected from these subjects 
before their elective operations. Considering that the children undergoing operation may have 
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differing measures in the CD4
+ 
Tm immune profiles, especially in children with recurrent tonsillitis, 
we examined full blood counts and absolute numbers of CD4
+ 
T cell subsets retrospectively, 
between control children undergoing operations and the healthy control children from outside 
hospital. Comparable blood counts and absolute number of peripheral blood CD4
+ 
T cell lineages 
were observed, therefore we justified that the children recruited from the elective operation list were 
valid controls for this study and data obtained from these control children were included in this 
thesis.  
All subjects were free of any infection or medication (except for insulin for T1D patients) within 
two weeks prior to blood sampling. Detailed subject characteristics are shown in Table 2.1. This 
study was approved by the Human Research Ethics Committee of the Mater Hospital (Ethics 
Number MHS HREC 771C). Informed consents were obtained from parents or guardians of the 
children subjects. Please refer to Appendix A1 for ethics approval and Appendix B for patient 
information sheet.  
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Table 2.1  Characteristics of research subjects used in this thesis.  
 
T1D Siblings Controls 
Numbers of subjects 31 45 29 
Age (years ± SD) 11.7 ±  2.4 12.4 ± 3.2 10.8 ± 2.8 
Male/Female  18 (58%) 28 (62%) 17 (59%) 
Age at diagnosis (years, ± SD) 8.3 ± 3.3 - - 
Disease Duration (years, median (range)) 2.0 (0.2-8.6) - - 
Patients with ≥ 1 islet autoantibody (number (%)) † 27 (87%) 1 (2%) NR 
HbA1c at test (%, ± SD) 8.3 ±1.4 NR NR 
C-peptide at diagnosis (nmol/L, median (range)) 0.17 (0.1-1.2) NR NR 
Subjects with high risk HLA-DQ haplotype ‡ 16 (94%) NR NR 
BMI at test (Kg/cm
2 ± SD)  19.7 ± 2.8 NR NR 
Age-corrected BMI (Z-score ± SD) 0.68 ± 0.89 NR NR 
Categorical variables such as gender, islet antibody positivity and HLA-DQ are presented as counts 
and percentages. For continuous variables, as indicated parametrically distributed data are presented 
as mean ± SD, and non-parametrically distributed data as median with minimum to maximum 
ranges. There was no significant difference in age (P=0.13) or gender (P=0.92) across the cohorts. 
Intergroup comparison of age was by Kruskal-Wallis test, and gender-matching was by Chi-Square 
test for categorical data. †Islet autoantibodies screened included GAD and IA-2 antibody. ‡ High 
risk HLA-DQ haplotypes included DQA1*05:01/DQB1*02:01 (DQ2.5), and/or DQA1*03:01/ 
DQB1*03:02 (DQ8). NR, not recorded. BMI, body mass index. Please refer to Appendix C for 
patient information of each individual subject.   
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2.2.2 Blood samples 
Peripheral venous blood samples (10-20ml, dependent on age) were obtained from the subjects in 
EDTA Vacutainer tubes (BD Diagnostics). An aliquot (200µl) of the fresh blood was subjected for 
full blood count on an automated blood analyser (CELL-DYN Sapphire, Abbott Diagnostics; or 
UniCel DxH800, Beckman Coulter) at the Mater Hospital Pathology lab, and the remaining blood 
was used in preparation for subsequent assays. All blood samples were processed at room 
temperature within 2 hours of collection.  
2.2.3 Enumeration of blood T cells by multi-parameter flow cytometry  
The absolute numbers of blood T cell subsets were determined by a single platform TruCOUNT 
assay (BD Bioscience), previously validated and optimised in our laboratory [52, 111, 172]. This 
multi-colour flow cytometry assay allows direct and simultaneous quantification of multiple cell 
types in a small sample volume. Briefly, 50μl of fresh blood was mixed in a TruCOUNT tube with 
a cocktail of fluorescent-conjugated monoclonal antibodies (mAb) including human CD45-APC-
H7, CD3-Pacific Blue, CD4-FITC, CD8-PE-Cy7, CD45RO-PE and CD62L-APC for Tn/Tm 
discrimination, or a cocktail of fluorescent-conjugated monoclonal antibodies (mAb) including 
human CD45-APC-H7, CD3-Pacific Blue, CD4-FITC, CD8-PE-Cy7, CD25-APC and CD127-PE 
for phenotypic characterisation. Expression of T cell surface markers, such as CD3, was measured 
as median fluorescent intensity (MFI) by flow cytometry, with reference of non-CD3-expressing 
population such as blood granulocytes. All antibodies were from BD Bioscience, unless otherwise 
specified. The antibody-labelled blood was erythrocyte-lysed by FACS lysing buffer (BD 
Bioscience). Each TruCOUNT tube also contained a microsphere comprised of a known number of 
fluorescent microbeads, and the blood/microbeads mixture was acquired by flow cytometry (FACS-
LSRII; BD Bioscience). The absolute number of blood T cells was calculated with reference to the 
number of microbeads acquired and the fixed volume of blood tested. The following calculation 
was used: 
Absolute number of target cells/ µL blood = 
 
Number of target cells acquired on flow cytometer 
Number of microbeads acquired on flow cytometer
 × 
Number of microbeads in test tube 
Blood volume tested (µL)
 
2.2.3 Detection of spontaneous ex vivo apoptosis in T cells 
Spontaneous apoptosis of CD4
+ 
T cells was assessed in PBMC by labelling with apoptosis marker 
Annexin-V, as previously described [173]. Annexin-V is a recombinant protein, and interacts 
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strongly and specifically with phosphatidylserine that has translocated from the inner to the outer 
membrane of a cell during apoptosis. Briefly, freshly Ficoll-isolated PBMC were labelled with mAb 
of CD3-Pacific Blue, CD4-FITC, CD8-PE-Cy7, CD45RO-PerCp-Cy5.5 (BioLegend), followed by 
washing and resuspending in Annexin-V binding buffer before incubating with Annexin-V-PE mAb 
(BD, Bioscience). Immediately after labelling, PBMC were analysed by flow cytometry for 
spontaneous apoptosis in naïve and memory subsets of CD4
+ 
T cells, and apoptosis was defined as 
Annexin-V
+
 cells. All flow cytometry data were analysed by FlowJo software (version 7.6.5, 
TreeStar Inc.). 
2.2.4 Statistical analysis 
The sample size (number of subjects per group) was calculated by using a statistical program 
(sample size for comparing means) provided by a statistician at the Mater Research. The type I error 
(alpha) and study power were conventionally defined as 0.05 and 0.8 respectively. From our 
previous study [52, 174], we know intergroup difference in means (e.g. difference in mean 
lymphocyte count between children with T1D and controls was 1020 lymphocytes/µL blood) and in 
standard deviations (e.g. standard deviation for lymphocyte count in each group was approximately 
1000/µL), and we calculated that in order to obtain an 80% chance (power) to detect an intergroup 
difference in blood counts with a significant level of 0.05 (alpha), at least 18 subjects per group was 
required. Similar sample size calculation was used for detecting intergroup differences in absolute 
number of blood T cell subsets and subsequent functional assays, as addressed in later chapters of 
this thesis. In order to obtain statistical power of this study, patients with newly diagnosed and 
established T1D were not discriminated.  
Additionally, because of the relatively small number of subjects available in this study, we applied 
stringent comparison methods for statistical analysis throughout this study. Therefore, comparisons 
between the three subject groups were performed by Kruskal Wallis test and associated post-hoc 
Dunn’s multiple comparison test, and for comparisons within the same subject group between two 
time points or two different conditions Mann-Whitney test were performed. Correlation was 
evaluated by Spearman’s test, and rank correlation coefficient r was reported if the correlation was 
significant. Differences were considered statistically significant when P<0.05, and significance was 
denoted as * P<0.05, ** P<0.01, *** P<0.001, and **** P<0.0001. Statistical analysis was 
performed on GraphPad Prism software version 6.03. 
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2.3 Results 
2.3.1 Absolute numbers of blood CD4
+ 
T cell subsets in children with T1D, siblings and 
controls 
We began our investigation by assessing absolute numbers of CD4
+ 
T cells and its subsets in the 
peripheral blood of children with T1D (n=22), their siblings (n=37) and controls (n=22), by using 
multiparametric flow cytometry and TruCOUNT beads (Fig 2.1A). Across the cohorts, we observed 
no statistical intergroup difference in the absolute number of total CD4
+ 
T cells, defined within the 
total CD3
+ 
T cell compartment. Within the CD4
+ 
T cells, the absolute numbers of CD4
+ 
Tn cells 
was also comparable between the subject groups, and the CD4
+ 
Tn cells appeared to be a dominant 
population in all subjects with a CD4
+ 
Tn: CD4
+ 
Tm ratio generally around 2:1 (T1D=2.21:1, 
siblings=2.01:1, controls=1.98:1; P=0.69). However there was a significant decrease in the absolute 
number of CD4
+ 
Tm cells in children with T1D (median=278 cells/µL blood) when compared to 
controls (median=366 cells/µL blood, P=0.024). The absolute number of CD4
+ 
Tm was also lower 
in siblings (median=308 cells/µL blood, P=0.067), but the difference was not statistically 
significant when compared to controls (Fig 2.1B). It is interesting that only the CD4
+ 
Tm cell 
number was significantly different, when the CD4
+ 
Tn and the total CD4
+ 
T cell numbers in T1D 
were comparable with controls. This is probably due to the slight increase in the larger population 
of CD4
+ 
Tn cells in T1D, which counteracted the CD4
+ 
Tm reduction and resulted in an overall 
comparable number of total CD4
+ 
T cell count between cohorts.  
In controls and siblings, the absolute numbers of total CD4
+ 
T cells and CD4
+ 
Tn cells were 
inversely correlated with age, but such correlation disappeared in children with T1D (Fig 2.1B). 
During normal development, peripheral CD4
+ 
Tn cells display an age-dependent decrease due to 
thymic involution and reduced thymic output [175], and since the CD4
+ 
Tn represents 2/3 of the 
total CD4
+ 
T cell population in children, the age-correlation of CD4
+ 
Tn cells was also reflected in 
the total CD4
+ 
T cells. There was no correlation between age and the absolute number of CD4
+ 
Tm 
cells in any subject group. This may be expectable because development of immune memory varies 
between individuals, and fluctuation in CD4
+ 
Tm cell numbers has been reported during normal 
children’s growth [175]. In children with T1D, the CD4+ Tm count did not correlate with any T1D 
associated clinical characteristics, such as age of diagnosis, disease duration, c-peptide level, 
HbA1c, insulin dose or BMI-Z score. Within the T1D and sibling families, a pair-wise familial 
analysis found no correlation in the absolute number of CD4
+ 
Tm cells between children with T1D 
and their non-diabetic siblings (P=0.42, Fig 2.1C). There was no familial correlation in the absolute 
numbers of total CD4
+ 
T cells (P=0.53) or CD4
+ 
Tn cells (P=0.122) either (data now shown).  
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Since the development of CD4
+
 T cell is age-dependent and fluctuation may occur during immune 
memory formation, we divided our subjects into smaller age subgroups (5-9, 10-14 and 15-19 
years) and compared absolute numbers of CD4
+ 
T cells, CD4
+ 
Tn cells and CD4
+ 
Tm cells within 
each age subgroup. By this method, we found an interesting distortion in CD4
+ 
T cell subsets in 
T1D when compared to controls, which is somehow also evident in the siblings. In younger diabetic 
children and siblings between 5-9 years, the absolute numbers of total CD4
+ 
T cells (T1D 
median=1075 cells/µL, sibling median=965 cells/µL), CD4
+ 
Tn cells (T1D median=784 cells/µL, 
sibling median=687 cells/µL), and CD4
+
 Tm cells (T1D median=251 cells/µL, P=0.018; sibling 
median=245 cells/µL, P=.0.056) all appeared to be lower than their counterparts in the control 
group (CD4
+
 T median=1369 cells/µL, CD4
+
 Tn median=983 cells/µL, CD4
+
 Tm median=415 
cells/µL), and this is most pronounced in the CD4
+ 
Tm cell counts. In age between 10-14 years, 
there was no significant intergroup difference in the absolute numbers of any CD4
+ 
T cell subsets. 
However, in the age group between 15-19 years, the absolute numbers of total CD4
+ 
T and CD4
+ 
Tn 
cells in T1D were elevated, clearly opposite the decreasing trend seen in the controls. Such 
reversing trend was also evident in the CD4
+
 Tm count, and appears to be shared between T1D and 
their siblings of this age subgroup (Fig 2.1 D). Due to the relatively low number T1D subjects in the 
5-9 age subgroup (n<10), we were not able to further correlate the absolute numbers of CD4
+ 
T cell 
subsets with T1D patients’ clinical characteristics. Nevertheless, these data suggest that absolute 
numbers of the CD4
+ 
T cell lineages (total CD4
+ 
T cells, CD4
+ 
Tn cells and CD4
+ 
Tm cells) in 
children with T1D failed to follow an age-dependent decrease as observed in the control children, 
mostly due to the lowered cell counts in younger ages between 5-9 years. This distortion in the 
CD4
+ 
T cells of children with T1D may be of immunological importance.  
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Figure 2.1 Enumeration of blood CD4
+ 
T, CD4
+ 
Tn and CD4
+ 
Tm cells in children with T1D 
(n=22), siblings (n=37) and controls (n=22). (A) Representative dot plots demonstrate gating strategy for 
total CD4
+ 
T cells, CD4
+ 
Tn (CD4
+
CD45RO
-
) and CD4
+ 
Tm (CD4
+
CD45RO
+
) cells in peripheral blood. (B) 
Each panel presents comparison of cell counts (left) and correlation of respective cell counts with age in each 
subject group (right). (C) Familial analysis of absolute number of CD4
+ 
Tm cells between children with T1D 
and their siblings. (D) Absolute numbers of CD4
+ 
T cells and its subsets in age subgroups of T1D subjects, 
siblings and controls. Data are presented as median (bar) in scatter plots, and as mean ± SEM in symbol-line 
graphs. Statistics: Kruskal-Wallis test and post-hoc multiple comparisons. Correlation analyses: Spearman’s 
test with rank correlation coefficient r, if significant. 
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The CD4
+ 
Tm cell pool is comprised of central memory (Tcm) and effector memory (Tem) 
phenotypes. To understand which memory subsets contributed to the decrease in CD4
+ 
Tm cells in 
T1D subjects, we further discriminated CD4
+ 
Tcm (CD45RO
+
CD62L
+
) and CD4
+ 
Tem 
(CD45RO
+
CD62L
-
) cells within the total CD4
+ 
Tm cell population, by expression of CD62L (Fig 
2.2 A). The absolute numbers of CD4
+ 
Tcm and CD4
+ 
Tem were determined in a sub-cohort of 
subjects (T1D, n=14; siblings, n=20; controls, n=12). A significant decrease in the absolute number 
of CD4
+ 
Tcm cells was evident in children with T1D (median=177 cells/µL blood, P=0.014) as well 
as in the siblings (median=171 cells/µL blood, P=0.036), when compared with controls (median= 
225 cells/µL blood). The absolute number of CD4
+ 
Tem cells was not significantly different 
between subject groups (Fig 2.2 B, left). Therefore, in children with T1D the reduction in CD4
+ 
Tm 
cells was largely the result of a lowered CD4
+ 
Tcm count, whereas in siblings the reduced CD4
+ 
Tcm cells was compensated by a slight increase in CD4
+ 
Tem cells thus overall resulting a 
comparable number of total CD4
+
 Tm cells between siblings and controls. The CD45RO
-
CD62L
-
 
terminally differentiated effector memory T (Temra) cells represented a negligible proportion 
within the CD4
+ 
T cells, with very low number of events presented on flow cytometry, preventing 
accurate analysis of the absolute number of this population, so was not analysed.  
For absolute number of CD4
+ 
Tcm or CD4
+ 
Tem cells, no age-related correlation was found in any 
subject group (Fig 2.2 B, right), and in children with T1D there was no correlation between the 
absolute number of CD4
+ 
Tcm or CD4
+ 
Tem cells and any clinical characteristics such as age of 
diagnosis, c-peptide level, HbA1c, insulin dose or BMI-Z score. There was also no familial 
correlation in absolute number of CD4
+ 
Tcm or CD4
+ 
Tem cells between T1D and their siblings 
(Fig 2.2 C).  
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Figure 2.2 Assessment of blood CD4
+ 
Tm cell subsets in children with T1D (n=14), siblings 
(n=25) and controls (n=12). (A) Representative dot plots demonstrate gating strategy for CD4
+ 
Tcm (CD4
+
CD45RO
+ 
CD62L
+
) and CD4
+ 
Tem (CD4
+
CD45RO
+
 CD62L
-
) subsets within the total 
CD4
+ 
T cells. (B) Absolute number of blood CD4
+ 
Tcm and CD4
+ 
Tem cells (left) were compared 
across the cohorts, and correlated with age in each subject group (right). (C) Familial analysis of 
absolute number of blood CD4
+ 
Tcm and CD4
+
 Tem cells between children with T1D and their 
siblings. Data are presented as median (bar) in scatter plots. Statistics: Kruskal-Wallis test and 
associated post-hoc multiple comparisons. Correlation analyses: Spearman’s test. 
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Having found a significant decrease in the absolute number of blood CD4
+ 
Tm cells in children with 
T1D, which may be explained by a decrease in the absolute number of CD4
+ 
Tcm cells, we asked if 
the change in absolute numbers affects the relative composition of the blood CD4
+ 
T cell 
compartment in children T1D.  
Within the total blood CD3
+ 
T cell population, we determined the percentage of CD4
+ 
T cells, and 
within the total CD4
+ 
T cell population we determined the percentages of CD4
+ 
Tn, CD4
+
 Tcm and 
CD4
+ 
Tem cells. Across the cohorts, there was no statistical difference in the frequency of total 
CD4
+ 
T cells, or any of its subsets (Fig 2.3). This result complements our previous findings [52], 
and confirmed that the proportions of CD4
+ 
Tn, CD4
+ 
Tm, CD4
+ 
Tcm and CD4
+ 
Tem subsets within 
total CD4
+ 
T cell population in children with T1D were comparable to those in siblings and 
controls, despite their reduced absolute numbers in CD4
+ 
Tm cells.  
 
 
Figure 2.3 Percentages of total blood CD4
+ 
T cells and its subsets in children with T1D, 
siblings and controls. Percentages were calculated within respectively labelled parent populations. 
T1D n=22, siblings n=37, and controls n=22. Data are presented as median (bar) in scatter plots. 
Statistics: Kruskal-Wallis test and post-hoc multiple comparisons.    
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2.3.2 Assessment of blood CD8
+ 
T cell subsets in children with T1D, siblings and controls 
Although the focus of this chapter is blood CD4
+ 
T cells, the blood CD8
+
 T cells, as another 
important component of human T lymphocyte, was also assessed for absolute and relative numbers 
across the 3 subject groups.  
As demonstrated previously in Figure 2.1, total blood T cells (CD3
+ 
) were gated within leukocytes 
(CD45
+ 
) population in erythrocyte-lysed whole blood, and their absolute number and proportion 
were compared between children with T1D, their siblings and controls. Across the cohorts, the 
absolute number of total T cells was significantly lower in T1D (median=1645 cells/µL blood) and 
siblings (median=1614 cells/µL blood), when compared with controls (median=1904 cells/µL 
blood, P=0.038 and P=0.014 respectively). However, the proportion of total T cells within the 
leukocytes was comparable between the 3 subject groups (Fig 2.4 A). Thus, the reduced absolute 
number of total T cells may be due to reduced leukocyte count in children with T1D and their 
siblings, when compared to the controls.  
Within the total blood T cells, we gated on the CD8
+ 
T cells and quantified the absolute numbers 
and proportions of CD8
+
 T cells and associated lineage subsets in the 3 groups of subjects (Fig 2.4 
B). A decrease in the absolute number of total blood CD8
+ 
T cells were evident in children with 
T1D (median=455 cells/µL blood) and the siblings (median=445 cells/µL blood), compared to 
controls (median=623 cells/µL blood, P= 0.017 and P=0.037 respectively), which may explain the 
reduced total CD3
+
 T cells in these two cohorts, given that the absolute number of CD4
+ 
T cells was 
similar across the cohorts (Fig 2.1B), and absolute numbers of minor populations of CD4
- 
CD8
-
 T 
cells and CD4
+ 
CD8
+
 T cells were also comparable between the 3 groups (intergroup P= 0.27 and 
P=0.12, Fig 2.1A, data not shown). Proportion of CD8
+
 T cells, calculated with the total CD3
+ 
T 
cells, was comparable across the cohorts (Fig 2.4 C).    
Same as for CD4
+ 
T cells, within the CD8
+ 
T cell compartment we determined the absolute numbers 
and proportions of CD8
+  
Tn and CD8
+ 
Tm cells, and in a sub-cohort of subjects (T1D, n=14; 
siblings, n=25; controls, n=12) we discriminated CD8
+ 
Tcm (CD45RO
+
CD62L
+
), CD8
+
 Tem 
(CD45RO
+
CD62L
-
) and terminally differentiated effector memory CD8
+ 
Temra (CD45RO
- 
CD62L
-
) cells by expression of CD45RO and CD62L. It is worth noting that the Temra subset in CD8
+
 T 
cell compartment represents a substantial population, accounting for 15-20% of the total CD8
+ 
T 
cells (Fig 2.4B), unlike those in the CD4
+ 
T cell compartment (Fig 2.1A).  
We observed no significant difference in absolute number of CD8
+ 
Tn cells across the cohort, but 
did find a significant lower absolute number of CD8
+ 
Tm cells in children with T1D (median=70 
cells/µL blood) and the siblings (median=89 cells/µL blood), when compared to controls 
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(median=138 cells/µL blood; P=0.026 and P=0.014 respectively). However, the lowered CD8
+ 
Tm 
cell counts in children with T1D and their siblings could not be supported by any significant 
decrease in the absolute number of CD8
+
 Tcm or CD8
+ 
Tem subsets in these subjects, although a 
slightly lowered count was evident in both of these subset in T1D and siblings and collectively may 
contribute to the overall reduction in CD8
+
 Tm cell in children with T1D and the siblings.  
There was also no significant difference in the absolute number of the CD8
+
 Temra subsets across 
the cohorts. The proportion of all CD8
+
 T cell lineage subsets was too comparable across the 
cohorts (Fig 2.4 C). 
Interestingly, although absolute number of CD8
+ 
T cells was decreased in both children with T1D 
and the siblings, the correlation between age and the absolute number of CD8
+
 T cells disappeared 
in children with T1D, while was still preserved in the siblings (Fig 2.4 D). This result is similar to 
the correlation analysis for CD4
+
 T cells (Fig 2.1 B and C), where a stepwise loss of correlation to 
age was observed. A pair-wise familial analysis showed no correlation in the absolute number of 
CD8
+ 
T cells between children with T1D and their siblings, but there was a significant familial 
correlation in the absolute number of CD8
+ 
Tm cells (Fig 2.4 E).  
Therefore, the immune distortion in children with T1D was not only limited to CD4
+ 
T cells, it may 
have a global effect also involving CD8
+ 
T cells.  
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Figure 2.4 Assessment of total blood CD3
+ 
T cells, CD8
+ 
T cells and CD8
+ 
T cell subsets in 
children with T1D, siblings and controls. (A) Comparisons of absolute number and proportion of 
total CD3
+ 
T cells across the cohorts (T1D n=22, siblings n=37, controls n=22). (B) Representative 
dot plots demonstrate gating strategy for total CD8
+ 
T cells and its lineage subsets in peripheral 
blood by expression of CD45RO
 
and CD62L. (C) Comparison of absolute numbers (Top panel) 
and proportions (Lower panel) of CD8
+ 
T cells and its lineage subsets across the cohorts (CD8
+ 
Tm 
subsets were analysed in a sub-cohort of T1D n=14, siblings n=25, and controls n=12). (D) 
Correlation of absolute number of CD8
+ 
T cells with age in each subject group. (E) Familial 
analysis of absolute number of CD8
+ 
T cells between T1D and siblings. Data are presented as 
median (bar) in scatter plots. Statistics: Kruskal-Wallis test and post-hoc multiple comparisons. 
Correlation analyses: Spearman’s test with rank correlation coefficient r, if significant. 
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2.3.3 Phenotype characterisations of blood CD4
+ 
T cells and subsets  
As part of T cell receptor (TCR), CD3 is a surface protein expressed on T cells, and is responsible 
for effective signal transduction to mount an activation response upon antigen presentation. By 
using flow cytometry, we measured expression of CD3 on blood CD4
+ 
T cells and its subsets, as an 
implication of whether these cells from T1D, siblings and controls were capable of responding to a 
TCR-induced stimulation at similar magnitude. As demonstrated in Figure 2.5 A, expression of 
CD3, measured as median fluorescent intensity (MFI) with reference to non-CD3 expressing blood 
granulocytes, was comparable on blood CD4
+ 
T cells, CD4
+ 
Tn cells, and CD4
+ 
Tm cells across the 
cohorts.  
To understand whether the proposed repetitive islet antigen challenge may have resulted in chronic 
immune activation in children with T1D, we compared activation status of blood CD4
+ 
T cells 
between children with T1D (n=8), their siblings (n=14) and controls (n=11), by measuring the 
proportion of activated CD4
+
CD25
+ 
cells in blood. As shown in Figure 2.5 B and C, the proportion 
of CD25
+
 cells was comparable between groups. In addition to being a stable activation marker, cell 
surface CD25 is also part of the IL-2 receptor (α chain of IL-2R), and is involved in binding of IL-2 
for essential T cell survival and proliferation during immune activation. In our cohorts, the 
expression of CD25 on the surface of blood CD4
+ 
T cells was at a similar level between the T1D, 
sibling and control groups (Fig 2.5 C). Collectively, these data suggest that there was no particularly 
elevated in vivo immune activation in CD4
+ 
T cells from children with T1D, when compared with 
the non-diabetic siblings and controls.  
We also examined expression of CD127 (IL-7 receptor α) on blood CD4+ T cells, because both 
CD25 and CD127 are equally important for T cell homeostasis with regards to maintenance and 
survival [176]. Additionally, CD25 and CD127 share a similar co-receptor (IL-2R γ chain) for high 
affinity binding of IL-2 and IL-7, and for effective signal transduction following receptor/cytokine 
interactions. Our data show that there was no significant intergroup difference in the proportion of 
CD4
+
CD127
+
 cells or levels of CD127 expression across the cohorts (Fig 2.5 D).  
The proportion of blood Treg cells, defined as CD25
+
CD127
lo/- 
population as previously described 
in humans [139], was measured and compared between children with T1D, their sibling and 
controls. Across the cohorts, Treg cells generally account for 3-4% of the total blood CD4
+ 
T 
population, and there was no statistical difference in the absolute number of blood Treg cells 
between T1D, sibling and control groups (Fig 2.5 E). This result compliments our previous findings 
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[52], and confirmed that the frequency of peripheral blood Treg cells in children with T1D was not 
compromised, when compared with non-diabetic siblings and control children.  
It has been suggested in the literature that autoreactive CD4
+ 
T cells with memory against islet auto-
antigens have undergone substantial in vivo proliferation, and consequently may have shortened 
telomeres and increased susceptibility to apoptosis [101]. Therefore, we measured spontaneous 
apoptosis in CD4
+ 
Tm and CD4
+ 
Tn cells ex vivo in PBMC from children with T1D (n=6), siblings 
(n=9), and controls (n=7). Across the cohorts, the occurrence of spontaneous apoptosis was at a 
very low level in both CD4
+ 
Tn cells (T1D median=5.04%, siblings median=4.2%, control median 
=6.19%; intergroup P=0.875) and CD4
+ 
Tm cells (T1D median=6.59%, siblings median=3.95%, 
control median=4.75%; intergroup P=0.817), and there was no intergroup difference (Fig 2.5 F).  
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Figure 2.5 Phenotypic characterisations of peripheral blood CD4
+ 
T, CD4
+ 
Tn and CD4
+ 
Tm cells 
in children with T1D, siblings and controls. (A) Representative histograms and quantitative analysis of 
CD3 expressions on blood CD4
+ 
T, CD4
+ 
Tn and CD4
+ 
Tm cells across the cohorts (T1D n=22, siblings 
n=37, controls n=22), with reference to non-CD3-expressing blood granulocytes (grey). (B) A sub-cohort of 
T1D (n=8), siblings (n=14) and controls (n=11) were further analysed for expression of CD25, CD127 and 
frequency of Treg cells in blood CD4
+ 
T cells. Representative dot plots and histograms demonstrate gating 
strategies for CD25
+ 
cells (upper panel), and CD127
+ 
cells (lower panel) within blood CD4
+ 
T cells, as well 
as blood Treg cells defined as CD25
+
CD127
dim/- 
population, with reference to non-CD25 and non-CD127-
expressing blood granulocytes (grey). (C) Proportion of in vivo pre-activated CD25
+ 
cells and CD25 
expression. (D) Proportion of CD127
+
 cells and CD127 expression. (E) Proportion and absolute number of 
blood Treg cells. (F) Spontaneous apoptosis in CD4
+ 
Tn and CD4
+ 
Tm cells measured from PBMC of T1D 
(n=6), siblings (n=9) and controls (n=7). Data are presented as median (bar) in scatter plots. Statistics: 
Kruskal-Wallis test and post-hoc multiple comparisons.  
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2.3.4  Full blood counts confirmed relative lymphopenia in T1D and siblings compared to 
controls  
Previously, we reported reduced lymphocyte counts in children with T1D and their siblings, 
compared to the controls [52]. In this chapter we followed up on this lead and investigated full 
blood count results in more details with our current cohorts of subjects. In the white blood cell 
(WBC, or leukocyte) compartment, we observed a significant decrease in WBC count in both 
children with T1D (median=6150 WBC/µL blood) and their siblings (median=6600 WBC/µL 
blood), when compared with controls (median=9105 WBC/µL blood, P<0.0001 and P=0.0001 
respectively), although these counts were still within the general normal range for children 
(Appendix G, Full Blood Count Reference Ranges, Mater Hospitals, Brisbane, Australia). 
Additionally, due to such leukocyte reduction, especially in younger subjects between 5-9 years of 
age, the age-leukocyte correlation normally observed in healthy children was missing in children 
with T1D and their siblings (Fig 2.6 A and B).  
The major leukocyte subpopulations, including neutrophils, lymphocytes, and monocytes were also 
reduced in children with T1D, and the lymphocytes number in siblings was significantly lower than 
that in controls (P=0.0021, Fig 2.6 A). In controls, lymphocyte counts very tightly correlated with 
age of subjects (P=0.0001). Such correlation was also seen in siblings but to a lesser extent 
(P=0.0033), whereas in children with T1D there was no such correlation at all (P=0.97), both owing 
to the reduced lymphocyte numbers in younger subjects between 5-9 years of age (Fig 2.6 B). There 
was no correlation with age evident in the other subpopulations of leukocytes, and the reduced total 
leukocytes and its subpopulations did not correlated with any T1D associated characteristic (age of 
diagnosis, C-peptide level, HbA1c, insulin dose or BMI-Z score). Eosinophil (intergroup P=0.21) 
and basophil (intergroup P=0.18) counts were both comparable across the cohorts. 
Therefore, we were able to confirm our previous finding of relative lymphopenia in children with 
T1D and the siblings, and herein report additionally that multiple deficits in lymphocytes, 
neutrophils and monocytes collectively contribute a reduction in total leukocyte count in children 
with T1D, whereas in siblings the reduction in leukocytes was mainly due to reduced lymphocytes. 
By dividing the subjects into age subgroups (5-9, 10-14 and 15-19 years), we found that the relative 
lymphopenia were mostly presented in younger T1D and sibling children between 5-9 years of age, 
and in children aged 15-19 such distortion disappeared. This finding is very similar to the 
evaluation of blood CD4
+ 
T and CD8
+ 
T cells by TruCOUNT assay, and all suggest a particular 
immune distortion in blood lymphocyte and associated T cell compartments in younger children 
with T1D and their siblings. 
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Figure 2.6 Assessment of white blood cells in children with T1D, siblings and controls. (A) 
Each panel presents intergroup comparisons of respectively labelled blood immune cell counts (left) 
and its correlation with age in each subject group (right). T1D n=28, siblings n=42, controls n=24. 
(B) Assessment of white blood cells and its sub-compartments in age subgroups of children with 
T1D, siblings and controls. Data are presented as median (bar) in scatter plots, and as mean ± SEM 
in symbol-line graphs. Statistics: Kruskal-Wallis test and post-hoc multiple comparisons. 
Correlation analysis: Spearman’s test with rank correlation coefficient r, if significant. 
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T cells are a major component of blood lymphocytes, composing around 70% of the lymphocyte 
population, and CD4
+ 
T cells and CD8
+ 
T cells account for 40% and 25% of the total lymphocytes, 
respectively in normal children between 5-16 years of age [175]. Analyses between blood 
lymphocyte count (obtained from clinical haematology counter) and the absolute numbers of blood 
T cell lineages (obtained from TruCOUNT assay and flow cytometry) show that, across the cohorts 
blood lymphocyte counts correlated very tightly with the absolute number of total CD3
+ 
T cells, 
total CD4
+ 
T and CD8
+
 T cells, and CD4
+ 
Tn cells. A correlation between lymphocyte count and the 
absolute number of CD8
+ 
Tn cells was only found in siblings, but not in T1D or controls. There was 
no correlation between lymphocyte count and the absolute number of CD4
+ 
Tm cells or CD8
+
 Tm 
cells in children with T1D and their siblings, but such correlation was preserved in controls (Fig 
2.7).  
Therefore, the strong link between lymphocytes counts and T cell compartment suggests that the 
immune distortion (particularly in CD4
+ 
Tm and CD8
+ 
Tm cells) observed in children with T1D and 
to some lesser extent in the siblings is specially affecting the T cells. In fact, the absolute number of 
blood B cells, defined as total CD20
+ 
cells, was comparable between children with T1D (n=9), 
siblings (n=16) and controls (n=12, intergroup P=0.18, data not shown).  
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Figure 2.7 Correlations between blood lymphocyte counts and absolute numbers of blood 
T cell subsets, including (A) total CD3
+ 
T cells, (B) total CD4
+ 
T cells, and CD4
+ 
Tn and CD4
+ 
Tm 
subsets, and (C) total CD8
+ 
T cells, and CD8
+ 
Tn and CD8
+ 
Tm subsets. Correlation analysis: 
Spearman’s test with rank correlation coefficient r, if significant.  
  
CHAPTER 2                                  ASSESSMENT OF CD4
+ 
Tm CELLS IN PERIPHERAL BLOOD 
51 
 
Another interesting observation was seen in the red blood cell (RBC) compartment. An increase in 
RBC numbers, and raised concentrations of haemoglobin and haematocrit were detected in both 
children with T1D and their siblings, when compared to the controls (Fig 2.8). The increased 
number of RBC was positively correlated with age in diabetic children, but had no correlation with 
any T1D associated clinical characterisation (age of diagnosis, C-peptide level, HbA1c, BMI-Z 
score or insulin dose). The raised concentrations of haemoglobin and haematocrit were also age-
dependent in T1D and siblings, particularly at 10-14 years of age. Additionally, the haemoglobin 
(P=0.027, Spearman r=0.5457) and haematocrit (P=0.0025, Spearman r=0.5484) appeared to 
positively correlate with age of diagnosis in children with T1D. The RBC distribution width was 
comparable between the three groups (intergroup P=0.129), suggesting no variation in RBC sizes 
despite the increased numbers and higher volume percentages of RBC (haematocrit) in T1D and 
siblings’ blood. There was no statistical difference between platelet counts in children with T1D 
(median= 282.5 cells/ml blood), siblings (median=284 cells/ml blood) and controls (median= 293.5 
cell/ml, intergroup P=0.924).  
Lastly, because children with T1D and their siblings shared some similar abnormalities in WBC and 
RBC compartments, we ran a familial pair-wise analysis for these blood determinants, and found 
familial correlations in WBC, neutrophil, lymphocyte and RBC numbers, as well as haemoglobin 
and haematocrit between children with T1D and their siblings (Fig 2.9). These results suggest that 
the shared observations of relative leukopenia, relative lymphopenia and relative polycythaemia 
(increased RBC counts) in T1D and siblings may be a result of genetic/environmental driven 
immune system distortion, particularly in younger ages. Although all these parameters are still 
within the general normal range for children, and hence cannot be considered pathological, however 
these subtle changes may potentially alter the overall immune competencies in these subjects, and 
may be associated with potential risk of developing autoimmunity.   
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Figure 2.8 Assessment of red blood cells in children with T1D, siblings and controls. (A) 
Each panel presents intergroup comparisons of respectively labelled parameters (left) and its 
correlation with age in each subject group (right). T1D n=28, siblings n=42, and controls n=24. (B) 
Assessment of parameters from the RBC compartment in age subgroups of T1D, siblings and 
controls. Data are presented as median (bar) in scatter plots, and as mean ± SEM in symbol-line 
graphs. Statistics: Kruskal-Wallis test and post-hoc multiple comparisons. Correlation analysis: 
Spearman’s test with rank correlation coefficient r, if significant. 
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Figure 2.9 Familial analyses of WBC and RBC results between children with T1D and 
siblings from the same family. Top panel: familial correlations in numbers of WBC, neutrophils, 
lymphocyte and monocytes. Lower panel: familial correlations in RBC numbers, haemoglobin and 
haematocrit. Number of families=28. Correlation analysis: Spearman’s test with rank correlation 
coefficient r, if significant.  
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2.4 Discussion 
In this chapter, we focused on blood CD4
+ 
T cells, enumerated and phenotypically characterised 
blood CD4
+ 
T cells and its associated subsets in children with T1D, their siblings and controls, with 
the aim of identifying T1D-specific immune signatures reflected in circulating T cells.  
By determining absolute numbers in the peripheral blood, we found that children with T1D had a 
reduced number of circulating CD4
+ 
Tm cells, which may be largely explained by a decrease in the 
CD4
+ 
Tcm cell subset. A similar decrease of CD4
+ 
Tcm cells was also evident in the siblings. 
Generally, in healthy children CD4
+ 
Tcm cells are the predominant population in the CD4
+ 
Tm 
pool, circulating between lymph nodes within the lymphatic system and acting as a “stem cell like” 
inventory of antigen-experienced memory. Reduction in this population may reflect certain 
genetic/environmental-driven impact on the immune memory, which resulted in a distortion in the 
CD4
+ 
Tm cells particularly in younger children with T1D (5-9 years old) and to some extent in the 
siblings. In addition to CD4
+ 
T cells, we also investigated the CD8
+
 T cell compartment, and found 
that the immune distortion was not only limited to CD4
+ 
T cells, but to have a global impact 
affecting the CD8
+  
T cells and CD8
+ 
Tm cells in children with T1D and their siblings.  
However, it is worth noting that evaluation of the CD4
+ 
Tcm and CD4
+ 
Tem subsets, as well as the 
CD8
+
 Tcm and CD8
+
 Tem subsets, were performed within a smaller sub-cohort of subjects, which 
has less statistical power than the originally designed sample size. It will be of our interest in future 
research to re-evaluate these results in a larger cohort. 
The exact reason for the CD4
+ 
Tm cells reduction in T1D is unclear, although two possible 
explanations may be proposed: (1) chronic auto-antigen challenges have resulted in a proportion of 
pre-committed CD4
+ 
Tcm cells transitioning into CD4
+ 
Tem phenotype and migrating out of the 
circulation into target tissues, such as pancreatic islets; and (2) the chronically stimulated CD4
+ 
Tm 
cells, especially a proportion of pre-committed CD4
+ 
Tcm cells, may be sensitive to apoptosis and 
are subsequently eliminated from the circulation.  
In order to understand these observations and test the speculations, we characterised the phenotypes 
of blood CD4
+ 
T cells in children with T1D, siblings and controls. An assessment of CD25 
expression on blood CD4
+ 
T cells did not provide evidence of increased in vivo pre-activation in 
circulating CD4
+ 
T cells in children with T1D, and there did not appear to be any difference in 
spontaneous apoptosis between CD4
+ 
Tm cells from the subject groups. In addition, the CD4
+ 
Tm 
cells from all subjects expressed comparable level of CD3/TCR, indicating similar potential of 
responding to a TCR-induced stimulation at a similar magnitude, although the TCR antigen-binding 
affinity and transduction of downstream activation signals were not addressed in this study. The 
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CD127 expression on blood CD4
+ 
T cells was also similar across the cohorts, indicating comparable 
ability of homeostatic maintenance in these cells. Therefore, the reason for the decreased CD4
+ 
Tm 
cells in children with T1D is still not clear. 
While we were studying the CD4
+ 
T cells and its CD4
+ 
Tm subset, we were also interested in the 
clinical haematology data as readout for the overall immune status in children with T1D. 
Collectively, our full blood count results suggest that T1D manifestation may be associated with a 
relatively compromised immune system featuring multiple deficits involving both innate and 
adaptive immune system, wherein lymphocytes may be the mostly affected population given its 
decrease was most significant within the WBC compartment. These results complement our 
previous findings, and together support the hypothesis that lymphopenia and multiple immune 
deficiencies may provide supportive immune background for development of autoimmune diseases. 
In human, lymphopenia, possibly triggered by viral infections [177, 178], has been identified in a 
number of autoimmune disorders, including rheumatoid arthritis [177], multiple sclerosis [178], 
T1D [179], systemic lupus erythematosus [180] and Sjogren’s syndrome [181], and has been 
suggested to be causal to organ specific autoimmune responses [170, 182]. Interconnection between 
multiple immunodeficiency and systemic autoimmunity have also been reported [183], and it is 
believed that lymphopenia-induced compensatory expansion drives the development of increased 
pathogenic T effectors in the periphery [184]. A classic study with NOD mice even proved that 
lymphopenia favours enrichment of autoreactive CD4
+ 
T cells during homeostatic proliferation, and 
generates autoimmune diabetes in vivo [166]. Taken together, it implies that in a compromised 
immune system subtle changes such as decreased ability to clear infections (e.g. neutrophil) as well 
as alteration in adaptive immunity (e.g. lymphopenia and distortion in memory T cells) may permit 
chronic inflammatory responses and perpetual immune activation, which eventually leads to 
systemic autoimmunity.  
In addition, we were surprised by the relatively increased RBC numbers and associated raises in 
haemoglobin and haematocrit concentrations in both children with T1D and their siblings. While 
anaemia and low haemoglobin have been associated with adverse events and kidney complications 
in T1D patients [185], it has also been suggested that T1D patients may have higher haemoglobin 
and increased RBC than generally population [186]. The reason for such RBC increase is unknown, 
but it could be primarily due to abnormality in the bone marrow, such as myeloproliferation that 
results in excessive red blood cell production, or it could be a result of increased haemo-
concentration from dehydration secondary to poor glycaemic control. However, the latter cannot 
explain increased RBC counts in the siblings, who have normal blood glucose level. For children 
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with T1D, RBC count (P=0.431), haemoglobin concentration (P=0.640) and haematocrit 
concentration (P=0.879) all had no correlation with HbA1c (n=28), therefore glycaemic control is 
unlikely causal to the RBC alterations. But interestingly, the relative polycythaemia (high RBC 
counts) was tightly correlated between T1D and siblings within the same family, suggesting this 
shared condition may be genetically linked and possibly bone-marrow haematopoiesis derived.  
Nevertheless, the haematology parameters (WBC and RBC counts) in all subjects were still within 
the general normal range, and thus cannot be considered pathological. However, subtle changes in 
the blood immune system may alter the overall immune competency, and our data may be 
considered of potential clinical importance not only for interpreting immune competency in T1D 
but also for predicting of disease onset and potential complications, for example high haemoglobin 
has been reported as a risk factor for proliferative retinopathy in T1D patients [187]. 
Collectively, this chapter has uncovered a very interesting immune distortion, characterised by 
relative lymphopenia that globally affecting both blood CD4
+ 
Tm cells and the CD8
+
 T cell 
compartment, particularly of younger children with T1D, aged between 5-9 years. Surprisingly, 
such immune distortion was somehow also observed in the non-diabetic siblings of the same age 
range, although to a lesser extent. These results may suggest a shared genetic/environmental driven 
impact on the immune system of these young children, which may potentially alter their overall 
immune competency and tolerance, and project them a potential risk of developing autoimmunity.  
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Chapter 3 Reactivation, differentiation and proliferation of CD4+ Tm cells from 
children with T1D, their siblings and unrelated healthy controls 
3.1 Introduction 
Memory CD4
+ 
T cells generated after infection or antigenic challenge constitutes a pool of 
defences, preventing the host from a diversity of recurrent immune attacks or diseases, and 
represents an important feature of the adaptive immune system. In previous chapter, we reported 
that under a relative lymphopenia condition, the absolute number of blood CD4
+ 
Tm cells was 
reduced in children with T1D, when compared with controls. In this chapter, we sought to 
determine functional features of CD4
+ 
Tm cells, and we hypothesize that during CD4
+ 
Tm 
reactivation, T1D patients differ from the siblings and controls in a number of functional responses, 
including immune activation, phenotypical differentiations, cytokine profiles, and proliferation.  
During recall immune responses against recognized antigens, resting CD4
+ 
Tm cells can be 
reactivated at lower threshold (lower dose of antigen presented) and with less requirement for co-
stimulatory signals than in their primary responses. Both central (CD4
+ 
Tcm) and effector (CD4
+ 
Tem) memory T cells respond to reactivation. The reactivated CD4
+ 
Tcm cells produce 
predominantly IL-2 [134], and generally propagate into non-effector state and remain uncommitted, 
with a small proportion of the reactivated CD4
+ 
Tcm cells may differentiate into CD4
+ 
Tem 
phenotype if the stimulation persists [130, 132]. A study with newly diagnosed T1D patients 
showed that an increase in the blood CD4
+ 
Tcm cells was significantly associated with C-peptide 
decline, and drug-mediated reduction in CD4
+ 
Tcm cells preserved C-peptide level and slowed β-
cell destruction [136]. Reactivated CD4
+ 
Tem cells retain effector phenotype and produce cytokines 
of the prototypic Th-1, Th-2 or Th-17 effector lineage imprinted at primary responses. It has been 
proposed that dysfunction in CD4
+ 
Tem cells may contribute to autoimmunity in T1D, and was 
shown in NOD mice that artificially guiding of CD4
+ 
Tm cells away from an 'effector' memory 
phenotype towards a 'regulatory' memory phenotype could prevent T1D [138]. Therefore, 
exaggerated response in both CD4
+ 
Tcm and CD4
+ 
Tem subsets could have adverse effects. Upon 
reactivation, a small proportion of CD4
+ 
Tm cells can also express FoxP3 transcript and 
differentiate into memory-derived Treg cells [188]. However, it is unclear whether the CD4
+ 
Tm-
derived Treg are effective in suppressing effector CD4
+ 
T cells, as accumulating evidence suggest 
that human Treg cells have plasticity and depending on the type of stimulations they can co-produce 
IFN-γ or IL-17 [189, 190].  
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In T1D, reactivation of CD4
+ 
Tm cells can expand potential pathogenic autoreactive T cells, and 
both CD4
+ 
T-derived IFN-γ-producing Th1 and IL-17-producing Th17 effector cells have been 
reported to be involved in mediating β cells damage in T1D patients [188, 191]. Pathogenic 
expansion of autoreactive CD4
+ 
Tm cells in T1D patients occur independent of the presence of Treg 
cells, whereas the autoreactive CD4
+ 
Tm cells in healthy subjects can be effectively controlled by 
Treg cells [129]. Nevertheless, reactivation of the heterogeneous CD4
+ 
Tm cell pool may provoke a 
diversity of immune responses, and by comparing response profiles of CD4
+ 
Tm cells, such as 
activation and differentiation, between children with T1D, their non-diabetic siblings and unrelated 
healthy control children, functional signatures specific to T1D immune memory may be uncovered.   
Following reactivation, the CD4
+ 
Tm cells undergo robust proliferation to expand responding cells 
specific to recall antigens. Proliferation of CD4
+ 
Tm cells has been extensively studied in mouse 
models, and generally it is thought that memory T cells respond to recurrent antigens faster than 
naïve T cells by initiating proliferation quicker and dividing more rapidly thereafter [192]. 
However, there is also evidence suggesting that after antigen challenge CD4
+ 
Tm cells were quick 
to respond in terms of reactivation and exerting effector functions such as cytokine release, but 
these cells were slow to divide and proliferation onset could occur as late as 3 days after antigen 
challenge, possibly due to the particular order of costimulatory molecule expression in the local 
environment[193]In addition, CD4
+ 
Tm proliferation can be affected by cytokine production during 
recall responses, resulting in a shorter period of proliferation than in the primary response, even if it 
was against the same antigen [194].  
In humans, the proliferative potential and kinetics of CD4
+ 
Tm cells during TCR-reactivated recall 
response is very much less understood, in contrast to the cytokine-driven proliferation occurred 
during homeostasis [133, 195]. This important information is particularly missing in studies with 
T1D patients [196], so it is still unknown how CD4
+ 
Tm cells from T1D patients multiply (e.g. 
length of lag phase, doubling time) in response to TCR-driven reactivation.  
In this chapter, we studied functional responses exhibited during reactivation of CD4
+ 
Tm cells 
from children with T1D, siblings and unrelated healthy controls. By inducing ex vivo TCR 
stimulation with anti-CD3 and anti-CD28, we assessed activation responses, phenotypical 
differentiations, proliferation kinetics and cytokine profiles in CD4
+ 
Tm cells. Overall, the data 
suggests that upon TCR-reactivation, CD4
+ 
Tm cells from children with T1D displayed a number of 
different responses when compared with controls, and some of which were surprisingly shared with 
their non-diabetic siblings. 
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3.2 Material and methods 
3.2.1 Cell preparation 
In addition to the children subjects, healthy adult donors were recruited for the studies described in 
this chapter to serve the purpose of assay optimisation (Ethics number MHS HREC 1407AP, 
Appendix A2).  
Peripheral blood mononuclear cells (PBMC) were separated from whole blood of children subjects 
and adult donors, by Ficoll-Hypaque (GE Healthcare, Australia) and isogradient centrifugation at 
400 x g for 20min at room temperature in swinging buckets rotors without brake (J6-MI, Beckman 
Coulter). The separated PBMC was washed twice and resuspended in cold MACS buffer (Miltenyi 
Biotec, consisting PBS and 2% bovine serum albumin and 1mM EDTA, pH 7.2). Autologous serum 
was extracted from whole blood collected in serum separation tubes (Vacutainer SST II, BD 
Diagnostics) by centrifugation at 1000 x g for 10 min at room temperature (Heraeus Multifuge 3SR, 
Thermo Scientific).  
CD4
+ 
Tm cells were purified from PBMC by negative magnetic separation on automated magnetic 
cell sorter (AutoMACS, Miltenyi Biotec; or EasySep Human CD4
+ 
Tm enrichment kit, 
STEMCELL Technology). The negative fraction collected contained CD4
+
CD45RO
+
 memory cells, 
and had excluded cells expressing surface antigens of CD8 (T cells), CD45RA (naïve T cells), 
human leukocyte antigen-DR (HLA-DR
+
 cells), CD11c (dendritic cells), CD14 (monocytes),  CD16 
(monocytes and myeloid dendritic cells), CD19 and CD20 (B cells), CD34 (hematopoietic 
progenitor cells), CD56 (natural killer cells), CD66c (granulocytes), and CD235A (erythrocytes). 
The purity of CD4
+ 
Tm cells was determined on flow cytometer by labelling with anti-CD3-Pacfic 
blue, anti-CD4-APC, anti-CD45RA-FITC and anti-CD45RO-PE, and the purity was generally 
between 90-95% (Fig 3.1A). The purified CD4
+ 
Tm cells were washed twice and resuspended in 
culture medium, containing RMPI-1640, penicillin (100U/ml), streptomycin (100U/ml), 2mM L-
glutamine, 10mM HEPES (Life Technologies) and 10% v/v of heat-inactivated autologous serum 
(56°C for 30min).  
3.2.2 CD4
+ 
Tm cell ex vivo reactivation 
The purified CD4
+
 Tm cells obtained from children subjects were reactivated (1 x 10
5
 cells/ 200µl/ 
well) in culture medium in the presence of plate-coated anti-CD3 mAb (50µl of anti-CD3 at 2µg/ml 
in PBS, eBioscience) and soluble agonistic anti-CD28 mAb (1µg/ml, BD Bioscience) for 5 days at 
37°C in 96-well round bottom culturing plates (Costar, Corning; or Falcon, BD Bioscience). After 
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overnight (day1) and at the end of the 5-day culture, the CD4
+
 Tm cells were harvested and 
examined for activation, differentiation, and cytokine production.  
3.2.3 Cell staining and flow cytometry  
At harvest, the reactivated CD4
+ 
Tm cells were washed twice with MACS buffer. The activation 
phenotype was determined by staining the CD4
+ 
Tm cells with anti-CD25-APC, and phenotype 
memory subsets in reactivated CD4
+ 
Tm cells was determined by staining the CD4
+ 
Tm cells with 
anti-CD62L-PE. For intracellular cytokine expression, at the last 4 hours prior to harvest the CD4
+ 
Tm cells were stimulated with phorbol-12-myristate-13-acetate (PMA, 25ng/ml, Sigma) and 
ionomycin (500ng/ml, Sigma), and at the last 2 hours of culture Golgistop (10 fold diluted with 
RPMI, 1µl / 1x10
5
 cells / 200µl /well) was added to retain cytokines within the cells. At harvest, the 
CD4
+ 
Tm cells were washed with MACS buffer, labelled with anti-CD3-Pacific Blue mAb, fixed 
and permeablized (FoxP3 Fixation/Permeabilization Kit, eBioscience), and stained with mAbs 
against intracellular cytokines or their isotype controls for 1h before analysed on flow cytometry. 
Intracellular expression of transcription factors T-bet (APC-conjugated, BioLegend) and FoxP3 
(PE-conjugated, eBioscience) in reactivated CD4
+ 
Tm cells were analysed following the same 
protocol with exclusion of PMA/ionomycin and Golgistop. Relevant isotype control mAb were 
used for intracellular staining of cytokines and transcription factors. Apoptosis was measured in 
reactivated CD4
+ 
Tm cells by labelling with Annexin-V-PE (BD Bioscience) in Annexin-V binding 
assay. Please refer to Appendix D for full list of mAb and cell staining reagent used in this chapter.  
3.2.4 Cytometric bead array (CBA) assay for cytokine detection in culture supernatants 
Secreted cytokines by reactivated CD4
+ 
Tm cells were measured in supernatants by CBA assay (BD 
Bioscience) and flow cytometry, following the manufacture’s protocol. A multiplex of 
Th1/Th2/Th17 cytokines, including IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α, and IL-17 were 
determined. Cell-free medium (RPMI supplemented with autologous serum) was analysed to 
establish baseline cytokine levels carried over from the autologous serum. Standard curve was 
produced for each cytokine by FCAP software, and detection limit was drawn from the linear range 
of each standard curve.   
3.2.5 Proliferation assays 
Tritium (
3
H)-thymidine incorporation assay and carboxyfluorescein diacetate succinimidyl ester 
(CFSE) dilution assay were used to address proliferation of CD4
+ 
Tm cells cultured in the presence 
(reactivated cells) or absence (resting cells) of anti-CD3/anti-CD28 stimulation. In (
3
H)-thymidine 
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incorporation assay, 1µCi/1 x 10
5
cells/200ul/well of 
3
H-thymidine (Perkin Elmer) was added to the 
reactivated or resting CD4
+
 Tm cells at the last 12-14h of the 5-day culture. The radiolabeled CD4
+ 
Tm cells were harvested onto glass fibre filter-mats by a Filtermate Harvester (PerkinElmer), before 
submerged in liquid scintillation solvent. The radioactivity emitted from harvested CD4
+ 
Tm cells 
was measured as count per minute on a scintillation beta-counter (MicroBeta TriLux, PerkinElmer).  
In the CFSE dilution assay, the fluorescence intensity of CFSE halves every time a cell divides, 
thus allows tracing of cell division by measuring dilutions of CFSE intensity. The purified CD4
+ 
Tm cells were labelled with CFSE (Molecular Probes, Life Technologies) at a concentration of 
2.5µM of CFSE per 1 x 10
6
 cells in PBS for 5 min at 37°C, and the CFSE-labelling was quenched 
by adding cold medium (RPMI + 5% v/v FCS). The CFSE-labelled CD4
+ 
Tm cells were washed 
with culture medium and then cultured as described above. Proliferation kinetics was determined on 
day 1, 3 and 5 of culture by measuring fluorescence intensity of CFSE on flow cytometry, and was 
quantified as 
Proliferation Index =
Total number of cells in all generations after reactivation
Computed number of parent cells theoretically present before division
 ,  
Precursor frequency=
Computed number of parent cells theoretically present before division - Number of undivided cells (Division 0)
Computed number of parent cells theoretically present before division
 x100% 
The proliferation index is a measure of fold increase in cell number over the course of reactivation, 
and reflects expansion potential of reactivated CD4
+ 
Tm cells, while the precursor frequency 
calculates the proportion of CD4
+ 
Tm cells in the starting population that is able to respond to the 
anti-CD3/anti-CD28 stimulation and participate in division. The CFSE assay was validated and 
optimised with CD4
+ 
Tm cells from healthy adult donors, before assaying with CD4
+ 
Tm cells from 
children with T1D, their siblings and controls.  
3.2.6 Statistical analysis  
As described in Chapter 2, Kruskal-Wallis test and post-hoc Dunn’s multiple comparisons were 
used for intergroup comparisons, and Mann-Whitney test was used for within group comparisons. 
Statistical analysis was performed on GraphPad Prism software version 6.03. 
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3.3 Results 
3.3.1 Optimisation of ex vivo CD4
+ 
Tm cells reactivation induced by anti-CD3/anti-CD28 mAbs 
Polyclonal stimulation with anti-CD3 and anti-CD28 mAb provides a combination of TCR 
engagement and co-stimulation to achieve generalised reactivation of the heterogeneous CD4
+ 
Tm 
pool. However, weak stimulation with insufficient strength of antigenic signals may not be able to 
detect difference in response between T1D and control groups, whilst high antigenic stimulation 
with excessive strength may result in activation-induced cell death (AICD) in CD4
+ 
Tm cells [197]. 
Therefore, in order to induce optimal stimulation ex vivo, the TCR stimulation strength was titrated 
by using gradually increased concentrations of anti-CD3 mAb. The concentration of anti-CD28 
mAb was kept constant at 1µg/ml [198], since CD4
+ 
Tm cell reactivation was less dependent on co-
stimulation than their naïve counterparts. An optimal strength of TCR-induced stimulation was 
determined by multiples parameters, including level of activation, cell expansion and proliferation, 
and apoptosis in reactivated CD4
+ 
Tm cells.  
Purified CD4
+ 
Tm cells obtained from children with T1D (n=3), their siblings (n=3) and controls 
(n=3) were stimulated in culture with gradually increased concentration of anti-CD3 mAb at 
1µg/ml, 2µg/ml, 5µg/ml, and 10µg/ml, pre-coated on 96-well round bottom plate, and in 
combination with soluble agonistic anti-CD28 (1µg/ml) for 5 days (Fig 3.1 A). On day 5, 
reactivation of CD4
+ 
Tm cells was assessed by measuring proportion of cells expressing the stable 
activation marker CD25 [199]. We observed a clear dose-dependent response for activation in CD4
+ 
Tm cells from control children, with a mean percentage of activation at 36.5%, 39.4%, 45.6% and 
52.6% in 1µg/ml, 2µg/ml, 5µg/ml, and 10µg/ml of anti-CD3 mAb stimulated cells, respectively. 
However, this dose response was less clear in CD4
+ 
Tm cells from children with T1D and their 
siblings, due to their heightened activation responses, regardless of the strength of anti-CD3 signal 
(Fig 3.1 B and C left). Purified CD4
+ 
Tm cells receiving no stimulation under the same culture 
conditions showed no activation.  
The level of apoptosis was also significantly higher in reactivated CD4
+
 Tm cells from children 
with T1D, in every dose of the anti-CD3 mAb stimulation, when compared with controls. This 
increased apoptotic response was somehow followed by the reactivated CD4
+ 
Tm cells from the 
siblings, but to a lesser extent (Fig 3.1 B and C right). These results may suggest a higher 
propensity to AICD in reactivated CD4
+ 
Tm cells from children with T1D and their siblings, and 
will be investigated more comprehensively in Chapter 4. In terms of dose response, the level of 
apoptosis was significantly lower in CD4
+ 
Tm cells receiving 1µg/ml (T1D P=0.011, siblings 
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P=0.013, controls P=0.0035) and 2µg/ml (T1D P=0.015, siblings P=0.075, controls P=0.0088) of 
anti-CD3 mAb, than receiving 10µg/ml of anti-CD3 mAb (Fig 3.1 C right).  
Based on these observations, it is likely that the dose of 2µg/ml anti-CD3 mAb, which is widely 
used in literatures [188, 200, 201], would induce effective activation responses without inducing 
increased apoptosis in reactivated CD4
+ 
Tm cells, therefore the dose of anti-CD3 mAb used 
hereafter was 2µg/ml.    
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Figure 3.1 Anti-CD3 mAb dose responses of reactivated CD4
+ 
Tm cells from children with 
T1D, their siblings and controls. (A) Representative dot plots show gating strategy of CD4+ Tm 
cells pre- and post-purification from a diabetic child. (B) Representative dot plots demonstrate 
gating strategy used to define activated (CD25+ cells) and apoptotic (Annexin+/7AAD+/-) cells 
measured on day 5 in reactivated CD4+ Tm cells from children with T1D (n=3), siblings (n=3) and 
controls (n=3). (C) Activation and apoptotic response in reactivated CD4+ Tm cells receiving 
gradually increased doses of 1, 2, 5 or 10µg/ml of anti-CD3 mAb, in combination with anti-CD28 
mAb (1µg/ml). Data are presented as mean ± SEM. Statistics: Kruskal Wallis test and post-hoc 
multiple comparisons.   
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3.3.2 Reactivation of CD4
+ 
Tm cells ex vivo in children with T1D, siblings and controls 
Within the determined strength of anti-CD3 stimulation, we examined the level of ex vivo TCR-
induced reactivation in purified CD4
+ 
Tm cells from children with T1D (n=14), siblings (n=24) and 
controls (n=16), by measuring expression of CD25 on day 1 and day 5 of cultures. As shown in 
Figure 3.2 A, TCR-engagement (with anti-CD3 mAb) and co-stimulation (with anti-CD28 mAb) 
promoted activation of CD4
+ 
Tm cells in all subject groups, however, the reactivated CD4
+ 
Tm cells 
in children with T1D and siblings exhibited higher percentages of activated CD25
+
 cells (T1D 
median = 71.4% and sibling median = 63.9%) than in controls (median = 45.4%). It is possible that 
an increased proportion of CD4
+ 
Tm derived Treg cells could contribute to the increase in CD25
+
 
cells observed in children with T1D and their siblings. By intracellular staining of transcription 
factor Foxp3 in reactivated CD4
+ 
Tm cells, we evaluated memory-derived inducible Treg cells in all 
subject groups, and found that CD4
+ 
Tm-derived Treg cells generally accounted for less than 15% 
of reactivated CD4
+ 
Tm cells, and the proportion was comparable across the cohort and had no 
significant change over the course of reactivation (Fig 3.2 B). These results suggest that the 
increased activation response in reactivated CD4
+ 
Tm cells from children with T1D and their 
siblings was not due to expansion of CD4
+ 
Tm-derived Treg cells, and is likely due to their intrinsic 
heightened sensitivity to TCR stimulation.  
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Figure 3.2 Reactivated CD4
+ 
Tm cells from children with T1D and their siblings exhibited 
higher activation response than the controls. T1D n=14, siblings n=24, and controls n=16. (A) 
Purified CD4+ Tm cells were ex vivo reactivated with anti-CD3/anti-CD28 mAbs for 5 days. 
Representative dot plots demonstrate expression of activation marker CD25 on reactivated CD4
+ 
Tm cells from each subject group. Scatter plot show proportion of CD25
+
 cells within the 
reactivated CD4
+ 
Tm population measured on day 1 and day 5 of culture. (B) Intracellular 
expression of transcription factor FoxP3 was measured to quantify CD4
+ 
Tm-derived Treg cells in 
children with T1D (n=5), siblings (n=8) and control (n=6). Representative dot plots show CD4
+ 
Tm 
cells stained with FoxP3 mAb or relevant isotype control mAb. Scatter plot shows proportion of 
FoxP3
+ 
cells within CD4
+ 
Tm cells measured on day 1 and day 5 of culture. Data are presented as 
median. Statistics: within group comparison between day 1 and day 5 was done by Mann-Whitney 
test; intergroup comparison was by Kruskal-Wallis test and post-hoc multiple comparisons.  
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3.3.3 Memory phenotype, differentiation and cytokine profile of reactivated CD4
+ 
Tm cells 
Since the reactivated CD4
+ 
Tm cells from children with T1D and siblings displayed enhanced level 
of activation responses, we next performed in-depth analyses of memory phenotypes and functional 
differentiations in reactivated CD4
+ 
Tm cells.  
For memory phenotypes, we measured proportions of CD4
+
 Tcm and CD4
+ 
Tem cells on day 1 and 
day 5 of cultures in reactivated CD4
+ 
Tm cells from children with T1D (n=12), siblings (n=22) and 
controls (n=10). We found that proportions of CD4
+ 
Tcm cells were markedly reduced in 5-day 
reactivated CD4
+ 
Tm cells from children with T1D and siblings, when compared with day 1, while 
the proportions of CD4
+ 
Tem cells were increased reciprocally. In contrast, the proportions of 
CD62L
+ 
Tcm and CD62L
- 
Tem cells in reactivated CD4
+ 
Tm cells from controls were maintained 
similar as of the beginning of culture (Fig 3.3 A). Reduced CD4
+ 
Tcm to CD4
+ 
Tem ratios in T1D 
subjects and siblings confirmed the increase in CD4
+ 
Tem proportions in T1D and siblings but not 
in controls (Fig 3.3 B). Collectively, these data suggest that the ex vivo TCR stimulation have 
promoted changes in memory subsets in children with T1D and their siblings.  
Based on the above results, three possibilities may be speculated: 1) the CD4
+ 
Tem cells from 
children with T1D and siblings were sensitive to stimulation and have proliferated excessively, so 
that the relative proportion of CD4
+ 
Tem cells has increased; or 2) the CD4
+ 
Tcm cells in children 
with T1D and siblings were sensitive to reactivation-induced cell death and underwent increased 
level of apoptosis, so that the relative proportion of CD4
+ 
Tcm cells has decreased; or 3) the ex vivo 
TCR stimulation has promoted increased transition of CD4
+ 
Tcm cells into the CD4
+ 
Tem 
phenotype, so the proportion of uncommitted CD4
+ 
Tcm cells has reduced in children with T1D and 
siblings when compared to control. Due to constraints associated with small blood volume obtained 
from children subjects, we were not able to purify CD4
+
CD62L
+ 
Tcm and CD4
+
CD62L
- 
Tem cells 
at the beginning of culture and delineate their proliferation and apoptosis separately. However, by 
phenotypically distinguishing CD62L
+ 
Tcm and CD62L
- 
Tem cells within the total reactivated 
CD4
+ 
Tm cells, we were able to address these two memory subsets respectively for their cytokine 
profiles, proliferation (this chapter) and apoptosis (chapter 4).   
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Figure 3.3 Sizes of the CD62L
+ 
Tcm and CD62L
- 
Tem compartments in the reactivated 
CD4
+ 
Tm cells. At day 1 and day 5 of culture, reactivated CD4
+ 
Tm cells were harvested, labelled 
with CD45RO and CD62L, and analysed for distribution of CD62L
+ 
Tcm and CD62L
-
 Tem cells by 
flow cytometry. Gates were set up for inclusion of live CD4
+ 
Tm cells based on FSC and SSC, and 
then Tcm and Tem cells were distinguished within the CD45RO gates by their expressions of 
CD62L. T1D (n=12), siblings (n=22), and controls (n=10). (A) Proportions of the CD62L
+ 
Tcm 
cells and the CD62L
-
 Tem cells were measured on day 1 and day 5 of culture within the total 
reactivated CD4
+ 
Tm cells. (B) Ratio of CD62L
+ 
Tcm to CD62L
-
 Tem cells was calculated for day 1 
and day 5. Data are presented as median. Statistics: within group comparison between day 1 and 
day 5 was done by Mann-Whitney test; intergroup comparison was by Kruskal-Wallis test and post-
hoc multiple comparisons.  
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By CBA assay, we measured an array of secreted cytokines from Th-1 (IL-2, IFN-γ and TNF-α), 
Th-2 (IL-4, IL-6 and IL-10) and Th-17 (IL-17A) lineages in reactivated CD4
+ 
Tm cells from 
children with T1D (n=7), siblings (n=11) and controls (n=9), on day 1 and day 5 of culture. Cell-
free medium, containing only RMPI and autologous serum, was used was a negative control, and no 
cytokine was detected in cell-free media.  
As an essential growth factor for proliferation and differentiation, IL-2 is mostly produced by CD4
+ 
Tcm cells in the memory pool [130]. During CD4
+ 
Tm cell reactivation, IL-2 was detected in day 1 
supernatants at comparable concentrations across the cohorts (P=0.92), and by day 5 the 
concentration of supernatant IL-2 had decreased similarly in all subject groups, suggesting that the 
combined production and consumption of IL-2 during CD4
+ 
Tm cell reactivation was similar across 
the cohorts. An elevation in IFN-γ was observed between day 1 and day 5 of culture in supernatants 
of reactivated CD4
+ 
Tm cells from children with T1D (P=0.021) and siblings (P=0.014), but not in 
the supernatants from the controls (P=0.23), although there was no significant between-group 
difference on day 1 or day 5. During CD4
+ 
Tm cell reactivation, there was no significant change in 
supernatant TNF-α across the cohorts (Fig 3.4 Top panel). 
The reactivated CD4
+ 
Tm cells from children with T1D secreted higher level of IL-4 (P=0.043 and 
P=0.024 respectively) than those from siblings and controls (Fig 3.4 Middle panel), and the 
supernatant IL-4 appeared to be well sustained in CD4
+ 
Tm culture from children with T1D. In 
addition, elevated secretion of IL-10, another Th-2 cytokine, was detected in supernatants of 
reactivated CD4
+ 
Tm cells from children with T1D (P=0.043, Fig 3.4 Middle panel). These data 
suggest that, in addition to typical Th-1 phenotype represented by increased IFN-γ secretion, 
reactivated CD4
+ 
Tm cells from children with T1D were also able to display Th-2 phenotype, 
represented by higher IL-4 and IL-10 secretions,  
There was no significant change in the IL-6 or IL-17 levels during CD4
+
 Tm reactivation across the 
cohorts (Fig 3.4 Middle and bottom panels).  
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Figure 3.4 Cytokine profiles of reactivated CD4
+ 
Tm cells. Secreted cytokines from Th-1, Th-
2 and Th-17 effector lineages were measured in supernatants of reactivated CD4
+ 
Tm cells from 
children with T1D (n = 7), siblings (n = 11) and controls (n = 9) collected on day 1 and 5 of culture. 
Solid orange lines indicate cytokine detection limit evaluated from the linear range of each standard 
curve, and only data above the detection limit were included for analysis. Data are presented as 
median with 25-75 percentiles and the minimum and maximum ranges. Statistic: within group 
comparison between day 1 and day 5 was done by Mann-Whitney test; intergroup comparison was 
by Kruskal-Wallis test and post-hoc multiple comparisons.  
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To complement the secretory cytokine profile measured in supernatants, we further examined 
intracellular expressions of IFN-γ and Th-1-specific transcription factor T-bet in 5-day reactivated 
CD4
+ 
Tm cells by flow cytometry. Comparing to controls (median=18.6%), the proportion of IFN-
γ-producing CD4+ Tm cells was significantly higher in children with T1D (median=31.2%, 
P=0.016, Fig 3.5 A). However, the proportion of IFN-γ-producing CD4+ Tm in siblings was not 
statistically different (median=24.1%, P=0.177) from that in controls, although a stepwise trend of 
increase was evident. Concurrently, a higher proportion of T-bet
+
 cells was observed in reactivated 
CD4
+ 
Tm cells from children with T1D (median=42.6%), when compared with the controls 
(median= 23.4%, P=0.025, Fig 3.5 B). Again, a trend of increase in T-bet
+
 cells was observed in 
reactivated CD4
+ 
Tm cells from the siblings (median=31.1%, P=0.28) compared to controls. 
To further address the Th-2 phenotype within the reactivated CD4
+ 
Tm cells, a preliminary 
experiment was conducted to measure intracellular IL-4 in reactivated CD4
+ 
Tm cells from children 
with T1D (n=3), siblings (n=3), and controls (n=3). An average of 18.5%, 12.9% and 6.8% of the 
reactivated CD4
+ 
Tm cells respectively from children with T1D, siblings and controls were IL-4-
producing cells (Fig 3.5 C).  
Collectively, the cytokine profiles and transcription factors data clearly pointed towards an elevated 
effector response in reactivated CD4
+ 
Tm cells from children with T1D and their siblings. The 
results also suggest that the reactivated CD4
+ 
Tm cells from children with T1D appeared to be 
differentiated toward both Th-1 and Th-2 effector lineages, while the reactivated CD4
+ 
Tm cells 
from siblings were more designated toward the Th-1 effector lineage.  
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Figure 3.5 Intracellular cytokines and transcription factor expression in reactivated CD4
+ 
Tm cells. (A) Representative histograms demonstrate gating of intracellular IFN-γ+ cells in resting 
CD4
+ 
Tm cells (grey filled), reactivated CD4
+ 
Tm cells stained with isotype control mAb (dashed 
line) or anti-IFN-γ mAb (solid line). Scatter plot shows proportion of IFN-γ-expressing cells in 
reactivated CD4
+ 
Tm cells. (B) Representative dot plots show gating of T-bet
+ 
cells, and scatter plot 
compares proportion of T-bet
+
 cells in reactivated CD4
+ 
Tm cells from children with T1D, siblings 
and controls. (C) Dot plots show expression of intracellular IL-4 in reactivated CD4
+ 
Tm cells 
stained with and without IL-4 mAb, and scatter box plot shows proportion of IL-4
+
 cells in 
reactivated CD4
+ 
Tm cells from children with T1D, siblings and controls. Data are presented as 
median. Statistic: Kruskal-Wallis test and post-hoc multiple comparisons. 
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3.3.4 Proliferation of reactivated CD4
+ 
Tm cells from T1D children, siblings and controls.  
Two independent assays, CFSE dilution assay and (
3
H)-thymidine incorporation assay, were used to 
quantitatively determine proliferation of reactivated CD4
+ 
Tm cells from children with T1D, their 
siblings and the controls.  
The CFSE dilution assay measured fluorescence intensities of CFSE in labelled cells, and enabled 
us to trace cellular divisions and determine proliferation kinetics in reactivated CD4
+ 
Tm cells, by 
calculating proliferating index (potential of expansion) and precursor frequency (proportion of 
responding cells). The CFSE dilution assay is a widely used method for proliferation kinetics [202-
204]; however this assay must be optimised in particular for small number of cells because 
excessive amount of CFSE can be toxic to cells [205]. In view of limited number of CD4
+ 
Tm cells 
that can be obtained from children samples (1-2x10
6
/10 ml blood), we validated the CFSE assay 
with CD4
+ 
Tm cells obtained from healthy adult donors. 
After reviewing published protocols [202, 204, 206] and comparing with manufacturer’s procedure 
(Molecular Probes, Life Technologies), we used CFSE at concentrations of 1µM and 2.5µM for 
labelling 1x10
6
 purified CD4
+ 
Tm cells from healthy adults. In order to reduce toxicity, the labelling 
time was reduced to 5 min from the recommended 10 min (Molecular Probe, Life Technologies), 
and labelling was stopped by addition of ice-cold culture media supplemented with 5% v/v FCS. As 
readouts for CFSE assay, we measured changes in FSC (indicative of cell size), apoptosis and 
proliferation in reactivated adult CD4
+ 
Tm cells.  
As shown in Figure 3.6 A, blasting cells (increase in cell size) were observed in reactivated CD4
+ 
Tm cells from day 3, and the proportion and median size of blasting cells (measured as FSC 
median) were comparable between CFSE-unlabelled cells and cells labelled with 1µM or 2.5µM of 
CFSE. The occurrence of apoptosis was examined in reactivated CD4
+ 
Tm cells on day 1, 3 and 5 
of culture, and the proportion of apoptotic cells was similar across all conditions on all three time 
points (Fig 3.6 B). These data suggest that labelling with 1µM or 2.5µM of CFSE did not affect 
viability of the reactivated CD4
+ 
Tm cells.  
We also compared proliferation of reactivated CD4
+ 
Tm cells labelled with 1µM and 2.5µM of 
CFSE, and proliferation index and precursor frequency were determined. As shown in Figure 3.6 C, 
division of CD4
+ 
Tm cells was observed from day 3, and there was no difference in proliferation 
index or precursor frequency between the two concentrations of CFSE labelling. This late start of 
proliferation was consistent with observations from others suggesting that stimulated CD4
+ 
Tm cells 
generally have a 72h lag phase before the onset of proliferation [193].  
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Overall, our data suggest that labelling of 1 x10
6
 purified CD4
+ 
Tm cells with either 1µM or 2.5µM 
of CFSE resulted in similar proliferation kinetics. We also notice that, by day 5 there were generally 
more than 80% of cells had become CFSE dim, and a proportion of cells in both  1µM (mean= 
16%) and 2.5µM CFSE (mean= 7.2%) labelling had completely lost the CFSE dye, having similar 
CFSE fluorescence intensity as the unlabelled cells. Therefore, to ensure sufficient tracking of cell 
divisions and to avoid over-dilution of CFSE, the concentration of 2.5µM of CFSE was used for 
following assays with children samples.  
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Figure 3.6 Validation of CFSE assay with adult CD4
+ 
Tm cells. (A) Representative dot plots 
and histograms demonstrate cell blasting in reactivated CD4
+ 
Tm cells unlabelled with CFSE (n=6), 
and in cells labelled with 1µM (n = 6) or 2.5µM ( n= 9) of CFSE, measured on day 3 and 5 of 
culture. Bar graphs show proportion of blasted cells and size medians of blasting cells (FSC 
median) in unlabelled and CFSE-labelled CD4
+ 
Tm cells. (B) Representative dot plots and bar 
graph show apoptosis on day 1, 3 and 5 in unlabelled and CFSE labelled CD4
+ 
Tm cells. (C) 
Representative dot plots and histograms show proliferation measured on day 3 and 5, and quantified 
in bar graphs. Data are presented as mean ± SEM. Statistic: Kruskal-Wallis test with post-hoc 
multiple comparisons. 
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Having validated the CFSE assay conditions with adult cells, we applied the CFSE assay on 
purified CD4
+ 
Tm cells from our children cohorts, and closely examined the kinetics of CD4
+ 
Tm 
cell proliferation during anti-CD3/anti-28 induced reactivation. Similar to adult cells, the CD4
+ 
Tm 
cells from children subjects displayed a 3-day lag phase of delayed proliferation. Between day 3 and 
day 5, all reactivated CD4
+ 
Tm cells proliferated vigorously, underwent more than four divisions, 
and doubled the initial population by day 5 with proliferation index of 2.32, 2.27 and 2.59, and 
precursor frequency of 47.9%, 42.0% and 54.3%, in children with T1D (n=6), siblings (n=10) and 
controls (n=6) respectively (Fig 3.7 A and B). These results suggest that the degree of population 
expansion and the percentage of responding cells were similar in reactivated CD4
+ 
Tm cells from 
children with T1D, siblings and controls.  
In addition to CFSE assay, we also employed the (
3
H)-thymidine incorporation assay to assess the 
proliferative capability of reactivated CD4
+ 
Tm cells. The (
3
H)-thymidine incorporation assay 
utilized radiolabelled nucleoside, (
3
H)-thymidine, and measured its incorporation into new strands 
of chromosomal DNA, so this assay determined cells proliferation by directly measuring DNA 
synthesis. In this assay, the proliferative capability was determined in both reactivated and resting 
CD4
+ 
Tm cells from children with T1D (n=11), their siblings (n=13) and the controls (n=10). We 
observed that, on day 5 the amount of the (
3
H)-thymine uptake was hundreds of folds higher in 
reactivated CD4
+ 
Tm cells than in resting CD4
+ 
Tm cells, which resembled the background 
radioactive signals, indicating vigorous DNA synthesis in reactivated cells, but not in resting cells. 
However, amongst the reactivated CD4
+ 
Tm cells the (
3
H)-thymine uptake was similar between 
T1D, siblings and controls, suggesting comparable proliferative capability across the cohorts (Fig 
3.7 C left). In a sub-cohort of subjects (T1D n=4, siblings n=5, controls n=4), we also measured 
(
3
H)-thymine incorporation in reactivated CD4
+ 
Tm cells on both 3 and day 5, and the data 
confirmed similar proliferation capabilities in all reactivated CD4
+ 
Tm cells during the course of 
culture (Fig 3.7 C right).  
Therefore, results from both CFSE assay and (
3
H)-thymine incorporation assay concluded that there 
was no difference in the proliferation dynamics in reactivated CD4
+ 
Tm cells across the cohorts. 
These data suggest that the CD4
+ 
Tm cells from neither the children with T1D nor their siblings 
were replicative senescent, exhausted or defective in proliferation.  
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Figure 3.7 Proliferation of reactivated CD4
+ 
Tm cells from children with T1D, siblings and 
controls.  (A) Representative histograms demonstrate cell divisions monitored in reactivated CD4
+ 
Tm cells by CFSE assay on day 1, 3, and 5 of culture. (B) Proliferation index and precursor 
frequency were determined in reactivated CD4
+ 
Tm cells from children with T1D (n=6), siblings 
(n=10) and controls (n=6) on day 3 and day 5 of culture. (C) Left: Proliferation capability measured 
by (
3
H)-thymidine incorporation assay on day 5 of culture in reactivated and resting CD4
+ 
Tm cells 
from children with T1D (n=11), sibling (n=13), and control (n=10). Right: Proliferation capability 
of reactivated CD4
+ 
Tm cells measured on day 3 and 5 of cultures in a sub-cohort of subjects of 
children with T1D (n=4, siblings (n=5) and controls (n=4). Data are presented in box plots as 
median with 25-75 percentiles and the minimum to maximum ranges, and as median in scatter plot. 
Statistics: within group comparison between day 3 and day 5 was by Mann-Whitney test; intergroup 
comparison was by Kruskal-Wallis test and post-hoc multiple comparisons. 
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Since the CD4
+ 
Tm cell pool is comprised of central and effector memory phenotypes, the overall 
comparable proliferative potentials in total reactivated CD4
+ 
Tm cells may be different at subset 
levels between T1D, siblings and controls. Next, we phenotypically distinguished reactivated CD4
+ 
Tm cells into CD4
+ 
Tcm and CD4
+ 
Tem cells by their expression of CD62L, and examined their 
proliferation respectively. We found no intergroup difference in the proliferation of either CD4
+ 
Tcm or the CD4
+ 
Tem subset (Fig 3.8). In human, it has been reported that the Tem cells generally 
have lower expansion potential than the Tcm cells, due to reduced telomere length in the Tem cells 
[131], but this intrinsic constrain can be overridden by providing co-stimulation to CD28, which 
induces telomerase activity [207, 208]. In our culture system, the TCR-driven reactivation was 
accompanied by anti-CD28 co-stimulation, and this may explain the similar proliferation between 
CD4
+ 
Tcm and CD4
+ 
Tem cells. 
Earlier in this chapter, we showed reactivation of CD4
+ 
Tm cells has resulted in increased 
proportion of CD4
+ 
Tem cells in children with T1D and their siblings (Fig 3.3), and speculated that 
this could be due to 1) excessive CD4
+
 Tem proliferation, or 2) poor CD4
+
 Tcm survival, or 3) 
increased CD4
+
 Tcm to CD4
+
 Tem transition. By examining cytokine profiles, we confirmed 
elevated effector responses in reactivated CD4
+
 Tm cells from both children with T1D and siblings. 
Here we further show that the CD4
+
 Tcm and CD4
+
 Tem subsets had comparable proliferative 
potential across the cohorts, therefore the increased CD4
+ 
Tem response in children with T1D and 
their siblings could also be a result of increased CD4
+
 Tcm to CD4
+
 Tem conversion. However, we 
still cannot completely exclude the possibility of poor CD4
+ 
Tcm survival, which will be addressed 
in next chapter.  
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Figure 3.8 Proliferation of CD4
+ 
Tcm and CD4
+ 
Tem cells measured within total 
reactivated CD4
+ 
Tm cells.  After 5 days of reactivation induced by anti-CD3/anti-CD28, CD4
+ 
Tcm and CD4
+ 
Tem cells within the total CD4
+ 
Tm cells from T1D children (n=4), siblings (n=9) 
and controls (n=5) were phenotypically distinguished based on CD62L expression. (A) 
Representative dot plots and histograms demonstrate gating strategy and cell divisions of CD62L
+ 
Tcm and CD62L
- 
Tem cells, assessed on day 5 of culture. (B) Computed proliferation index and 
precursor frequency in CD4
+ 
Tcm and CD4
+ 
Tem subsets. Data are presented as median with 25-75 
percentiles and the minimum to maximum ranges. Statistics: Kruskal-Wallis test and post-hoc 
multiple comparisons. 
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We also reported earlier in this chapter, an elevated activation in reactivated CD4
+ 
Tm cells from 
children with T1D and their siblings, compared to the controls. However, this cannot be explained 
by the comparable proliferation potential in reactivated CD4
+ 
Tm cells observed across the cohorts, 
especially when the precursor frequency, reflecting proportion of responding CD4
+ 
Tm cells, were 
similar between T1D, sibling and control groups. Such discrepancy between high proportion of 
CD25
+
 cells and comparable precursor frequency may be because of that the precursor frequency, 
back-calculated from the total number of cells presented at the end of culture, is a theoretical 
estimate of responding cells in the starting population, only accounting for cell division without 
considering cell survival. Therefore, it is possible that the computed precursor frequency has under-
estimated the true responding population at the beginning of the cultures, because some of which 
have undergone apoptosis and were eliminated from the culture. To further investigate the 
discrepancy between activation response and proliferation response, and to understand the dynamics 
of responses in reactivated CD4
+ 
Tm cells from T1D, siblings, and controls, we combined activation 
(CD25 expression), proliferation (CFSE dilution) and cell survival (Annexin-V
+
 apoptotic cells) 
into one single experiment (Fig 3.9).  
After 5 days of reactivation, majority of CD4
+ 
Tm cells from children with T1D (median= 60.5%) 
and siblings (median= 59%) were activated and went into proliferation, whereas in controls only 
38.4% of CD4
+ 
Tm cells were activated and proliferated (intergroup P=0.044, Fig 3.9 B, Q1
 
population). There was a small proportion of CD4
+ 
Tm cells that were activated but did not 
proliferate, and the percentage of this population (median~10%) was comparable across the cohorts 
(intergroup P=0.67, Fig 3.9 B, Q2 population). Interestingly, there were 30.5% of CD4
+ 
Tm cells in 
controls that did not respond to TCR stimulation, and remained un-activated and non-proliferated. 
This population was apparently less in T1D (median=17.7%) and siblings (median=13.8%) cells 
(intergroup P=0.054, Fig 3.9 B, Q3 population). Lastly, the proportion of proliferated CD4
+ 
Tm 
cells that were no longer CD25-expressing was similar (median~15%) across the cohorts 
(intergroup P=0.53, Fig 3.9 B, Q4 population).  
We next examined apoptosis in each of the Q1, Q2, Q3 and Q4 populations. As expected, most 
apoptotic cells were seen in the un-activated and non-proliferative population, and there was no 
difference between the subject groups (intergroup P=0.703, Fig 3.9 D, Q3 population). However, 
we observed a higher level of apoptosis in the activated and proliferated CD4
+ 
Tm cells from 
children with T1D (median=14.2%), compared with their counterparts in controls (median=4.4%, 
P=0.024) (Fig 3.9 C and D, Q1 population). Similarly, apoptosis was also elevated in the Q1 
population of the sibling cells (median=9.5%). The proportion of apoptotic cells in the Q2 
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(activated but non-proliferative cells) and Q4 (proliferated but non-CD25-expressing cells) 
populations was comparable across the cohorts.  
This experiment dissected activation, proliferation and apoptosis in reactivated CD4
+
 Tm cells, and 
confirmed the heightened activation response in T1D and siblings cells, in contrast to the control 
cells. It further reveals that the activated and proliferated CD4
+
 Tm cells from children with T1D 
also underwent a higher level of apoptosis than those in controls, indicating a higher cell turnover 
during reactivation. It may also explain the comparable proliferation potential, if the reactivated 
T1D CD4
+ 
Tm cells underwent vigorous proliferation, but at the same time also experience higher 
apoptosis and were eliminated from the culture. A similar but less pronounced effect was observed 
in the siblings. 
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Figure 3.9 Relationship between activation, proliferation and apoptosis in reactivated 
CD4
+ 
Tm cells. (A) Representative dot plots show gating of activation and proliferation in resting 
CD4
+ 
Tm cells and reactivated CD4
+ 
Tm cells from children with T1D (n = 4), siblings (n = 7) and 
controls (n = 4). Cells were subdivided based on activation and proliferation into: Q1, activated and 
proliferated population; Q2, activated but non-proliferative population; Q3, un-activated and non-
proliferative population; Q4, proliferated but non-CD25-expressing population. (B) Frequency of 
reactivated CD4
+ 
Tm cells in each subdivision. (C) Representative dot plots demonstrate gating of 
apoptotic cells in the Q1 populations of reactivated CD4
+ 
Tm cells. (D) Proportion of apoptosis 
cells measured in each subdivision of reactivated CD4
+
 Tm cells. Data are presented as median with 
25-75 percentiles and the minimum to maximum ranges. Statistics: intergroup comparison in each 
subdivision was by Kruskal-Wallis test and post-hoc multiple comparisons.  
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 3.4. Discussion 
This chapter tested functional responses exhibited during reactivation of purified blood CD4
+ 
Tm 
cells from children with T1D, their non-diabetic siblings and age-and gender-matched unrelated 
healthy controls. By inducing ex vivo TCR stimulation with anti-CD3 and anti-CD28, we assessed 
activation responses, differentiation of memory phenotypes, cytokine profiles and proliferation 
kinetics in reactivated CD4
+ 
Tm cells, with the aim of establishing immune signatures from the 
CD4
+ 
Tm cells that was specific for children with T1D. 
We measure activation response by determining the proportion of reactivated CD4
+ 
Tm cells that 
express stable activation marker CD25. CD25 is part of high affinity receptor for IL-2 and is 
upregulated after TCR engagement. We found a heightened activation response in reactivated CD4
+ 
Tm cells from children with T1D and their siblings, when compared with the controls. Given that 
there was no apparent pre-activation in circulating blood CD4
+ 
T cell in these subjects (Figure 2.5, 
Chapter 2), and negligible level of activation in CD4
+ 
Tm cells on day 1 of culture, the increased 
activation response observed in 5-day reactivated CD4
+ 
Tm cells from T1D and sibling subjects was 
likely due to an intrinsic heightened sensitivity to activation, which enables these cells to acquire 
activation marker CD25 more readily. A lowered threshold for CD4
+ 
T cell signalling and activation 
has been previously reported to be associated with genetic predisposition in human T1D [209-211], 
but it is intriguing that the non-diabetic siblings seem to the share the similar low threshold of T cell 
activation.  
We questioned that the increased proportion of CD25
+
 cells may be resulted from an increase in 
memory-derived Treg cells in T1D and sibling subjects. Evaluation of intracellular Foxp3 in 
reactivated CD4
+ 
Tm cells showed that the memory-derived Treg cells remained at a constant level 
during the course of reactivation across the cohorts, hence we conclude that the increased frequency 
of CD25
+
 cells was not contributed by memory-derived Treg cells, rather it is a result of enhanced 
activation responses in reactivate CD4
+ 
Tm cells from children with T1D and their siblings. In line 
with this observation, a recent study reported elevated level of soluble CD25 in plasma of T1D 
patients compared to that in healthy controls, reflecting a high surface expression and associated 
high cleavage of CD25 from activated CD4
+ 
T cells in T1D patients [212]. It has also been 
proposed that in healthy subjects in vivo exposure to islet antigens only induced partial CD4
+ 
Tm 
cell activation, whereas in T1D patients autoreactive CD4
+ 
Tm cells could be completely activated, 
possibly due to difference in antigen experience and the aforementioned low activation threshold 
[162]. Collectively, data from us and others suggest that the CD4
+ 
Tm cells in T1D patients are 
more readily to acquire activation marker CD25, and therefore have higher potential to mount a 
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more aggressive immune response, and possibly due to a combination of genetic and environmental 
effect reactivated CD4
+
 Tm cells from the non-diabetic siblings also displayed an enhanced 
activation response.  
The enhanced activation response in CD4
+
 Tm cells from children with T1D and siblings was 
reinforced by a marked increase in proportion of CD4
+ 
Tem cells. Such exaggerated effector 
response was further characterised by cytokine profile and assessments of transcription factors, and 
we found a clear polarisation towards Th-1 effectors in reactivated CD4
+ 
Tm cells from T1D and 
sibling subjects. This Th-1 polarisation was represented by the increased concentration of secreted 
IFN-γ in supernatants from these subjects, as well as an elevated intracellular expressions of IFN-γ 
and Th-1 specific transcription factor T-bet in the reactivated CD4
+ 
Tm cells from children with 
T1D, and to a lesser extent in the siblings. The IFN-γ-producing Th-1 effector phenotype has been 
widely accepted as core mediators during T1D development in both T1D patients [80, 188, 213] 
and animal model of T1D [214-216], and an uprising of such effector phenotype could be 
potentially pathogenic for development of autoimmune responses.  
In addition, a surprising differentiation towards Th-2 lineages was substantially preserved in 
reactivated CD4
+ 
Tm cells from children with T1D, but not from siblings or controls. IL-4 is an 
autocrine cytokine, and primarily functions to promote T cell differentiation towards the Th-2 
phenotype. It is also multifunctional and has a central role in guiding the alternative fates of T cell 
differentiation [217]. The reason for this increased IL-4 production in reactivated CD4
+ 
Tm cells 
from T1D patients is not clear. In NOD mice, IL-4 is conventionally thought to have suppressive 
activity on diabetogenic T cells [218, 219], and can be expressed by insulin-specific CD4
+
 Treg 
cells to exert protection against autoimmune responses [220]. In addition, IL-4 produced by CD4
+
 T 
cells has also been shown to regulate B cells in their antibody production [221]. Therefore, it may 
be speculated that even after T1D onset the CD4
+
 Tm cells are still capable of IL-4 production and 
mounting Th-2 responses, in addition to the competing Th-1 effector phenotype. Furthermore, the 
increased IL-4 production by reactivated T1D CD4
+
 Tm cells may also reflect a modulated pattern 
of antibody production by B cells in T1D patients. In future studies, a correlative assessment may 
be employed to investigate the competition between Th-1 and Th-2 effector responses, as well as 
the relationship between IL-4 productivity by reactivated CD4
+
 Tm cells and autoantibody patterns 
in sera of T1D patients. Another preserved Th-2 cytokine in reactivated CD4
+ 
Tm cells from T1D 
subjects was IL-10, which is also a pleiotropic cytokine with potential regulatory properties. 
However sustained IL-10 production in the reactivated CD4
+ 
Tm cells from children with T1D may 
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be of more pathological significance, given that this cytokine is known to mediate the destruction of 
β-cells in the NOD mouse [216].  
Unlike studies by others [165, 188], we did not find any difference in IL-17 production between the 
reactivated CD4
+ 
Tm cells from children with T1D, siblings and controls. It is probably because we 
studied a specific type of immune cells, the CD4
+ 
Tm cells, whereas others analysed IL-17 
production in a more heterogeneous population such as PBMC [188]. Additionally, the presence of 
proinflammatory cytokines, such as IL-6, has been reported to induce IL-17A production in CD4
+ 
Tm cells from T1D patients [165]. Our result shows a comparable level of IL-6 secretion by 
reactivated CD4
+ 
Tm cells across the cohorts, which in turn may explain the similar concentration 
of secreted IL-17A in all subject groups. However, we did report previously that an expansion of 
IL-17 producing CD4
+ 
T cells in blood differentiate children with T1D from their non-diabetic 
siblings and control children [52]. Based on the cytokine profile from this chapter, it is likely that 
the Th-17 effector phenotype that we previously observed in T1D patient may be raised from the 
naïve compartment rather the memory compartment.  
In contrast to the CD4
+ 
Tem cells, the reactivated CD4
+ 
Tcm cells generally propagate into IL-2-
producing non-effector state. Only a small proportion of CD4
+ 
Tcm cells may differentiate into 
IFN-γ or IL-4-producing CD4+ Tem phenotype, if TCR stimulation persists [130]. While it is 
difficult to evaluate the function and survival of CD4
+ 
Tcm cells without sorting and studying them 
individually, we predicted from the comparable IL-2 production within total reactivated CD4
+ 
Tm 
cells, that there was no apparent functional defect in the CD4
+ 
Tcm cells across the cohorts. 
Proliferation kinetics of reactivated CD4
+ 
Tm cells were closely examined during reactivation, and 
we found that the reactivated CD4
+ 
Tm cells generally had 3 days of lag phase before onset of 
vigorous proliferation, and had doubled the initial population by day 5 of culture. The 3-day lag 
phase of CD4
+ 
Tm cells during reactivation has been mostly reported in animal models (reviewed in 
[193]), and very limited evidence was found in humans. Conclusions from mouse experiments 
suggest that the 3-day lag phase may be due to order of expression of costimulatory molecules, but 
it may also confer a benefit to control to antigens, because the memory T cells are fast to reactivate 
and mount effector functions against recall antigens, the lag phase will allow quick control of the 
antigen preceding the onset of cell division [193]. Our similar finding in human CD4
+ 
Tm cells 
suggests that similar mechanism may also exist in humans. Across the cohorts, the reactivated CD4
+ 
Tm cells from children with T1D, siblings and controls exhibited similar proliferative capabilities in 
response to the TCR-induced reactivation. Even during the late stage of culture, the DNA synthesis, 
measured by (
3
H)-thymidine incorporation was still comparable across the cohorts, suggesting that 
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the CD4
+ 
Tm cells in all subject groups continuously responded to the TCR stimulation, and there 
was no apparent replicative senescent or defective proliferation in children with T1D or their 
siblings.  
By phenotypically distinguishing CD4
+ 
Tcm and CD4
+ 
Tem cells within the total reactivated CD4
+ 
Tm cells, we further evaluated proliferations of CD4
+ 
Tcm and CD4
+ 
Tem cells respectively, and 
again found no statistical difference in proliferation in either the CD4
+ 
Tcm or the CD4
+ 
Tem 
subsets across the cohorts. In addition, we noted that the comparable proliferation potential 
excluded the possibility that the increased proportion of CD4
+ 
Tem cells in T1D culture was due to 
excessive CD4
+ 
Tem proliferation, rather the results have pointed towards the possibility of an 
enhanced CD4
+
 Tcm to CD4
+ 
Tem conversation in T1D and sibling subjects.  
To better understand the dynamics of responses in reactivated CD4
+ 
Tm cells between children with 
T1D, their siblings and controls, and to associate the exaggerated activation responses with 
proliferation, we combined activation, proliferation and cell survival into one single experiment, 
and quantified activated and un-activated CD4
+ 
Tm cells in proliferated and non-proliferative 
populations and assessed apoptosis in each population. Although the CD4
+ 
Tm cells from children 
with T1D and their siblings were very responsive to stimulation and activated promptly, these cells 
also underwent higher level of apoptosis as they proliferated. Therefore, we speculated that CD4
+ 
Tm cells from children with T1D and their siblings may have a higher turnover during reactivation. 
The apoptotic responses in reactivated CD4
+ 
Tm cells from children with T1D and their siblings 
will be in-depth studied in the next chapter.  
In summary, this chapter reports an interesting novel finding that in T1D patients and their siblings, 
CD4
+ 
Tm cells were more readily to acquire CD25
+
 phenotype, and may have promoted an 
increased transition from central to effector memory phenotype, producing an enhanced effector 
cytokine ‘signature’ of IFN-γ, IL-4 and IL-10 in T1D and  IFN-γ in siblings.  
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Chapter 4 Apoptosis of reactivated CD4+ Tm cells from children with T1D, their 
non-diabetic siblings and unrelated healthy controls 
4.1 Introduction  
Memory CD4
+ 
T cells (CD4
+ 
Tm) maintain immune memory against experienced antigens and 
pathogens. Once generated, CD4
+ 
Tm cells persist long term and at stable levels. At resting state, 
the peripheral CD4
+ 
Tm cells are maintained by intermittent low-level stimulatory signals that are 
received through T cell receptor (TCR and CD3 complex) and local cytokine environment [222]. At 
recall immune responses, such as recurrent infections and presence of cognate antigens, CD4
+ 
Tm 
cells respond rapidly and reactivate to mount an effective immune protection against recurrent 
antigens. After recall response, majority of reactivated CD4
+ 
Tm cells, particularly effector memory 
T cells (CD4
+ 
Tem), are eliminated by reactivation induced apoptosis to avoid development of 
autoimmune responses. A residual population of the reactivated CD4
+ 
Tm cells return to resting 
state and intermittent self-renewal until cognate antigens are presented again.   
In autoimmune conditions such as T1D, multiple studies have suggested that due to epitope 
spreading from the inflamed pancreatic islets, the CD4
+ 
Tm cells are chronically exposed to islet 
autoantigens such as GAD65 and proinsulin, and are continuously challenged to reactivate [101, 
126, 162]. However, the fate of repetitively reactivated CD4
+ 
Tm cells in T1D still remains to be 
elucidated. Previous studies have shown that autoreactive T cells in T1D patient may possess 
multiple defects that increase their resistance to apoptosis, including suppressed Caspase-3 
expression [223, 224], and genetic defects in Fas (CD95) expression and function [225]. However, 
studies in patients with other autoimmune disorders such as coeliac disease and multiple sclerosis 
report a high sensitivity in reactivated CD4
+ 
Tm cells to TCR-induced apoptosis [167, 170], and 
studies using NOD mice also showed that pathogenic CD4
+ 
Tm cells were prone to reactivation 
induced apoptosis [166]. Apoptosis, as an important physiological process, is believed to be an 
effective way to maintain peripheral T cell homeostasis and immune tolerance [226, 227]. 
Dysregulation of apoptosis in immune cells, especially T lymphocytes, is critical in development of 
autoimmune diseases (review in [227]), but the contradictory results leave the survival of 
reactivated CD4
+ 
Tm cells in autoimmune conditions inconclusive.  
In the last Chapter (Fig 3.9), we speculated that CD4
+ 
Tm cells from children with T1D and their 
siblings may have a higher turnover during reactivation, characterised by a high level of apoptosis 
during proliferation. In this chapter, we hypothesize that intrinsic differences in CD4
+ 
Tm cell 
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apoptotic responses during reactivation may discriminate children with T1D from their non-diabetic 
siblings and the unrelated healthy controls.  
Apoptosis is initiated by death signals and can occur either by an extrinsic or an intrinsic pathway 
(Fig 4.1). The extrinsic apoptotic pathway is activated by ligation of surface death receptors (e.g. 
Fas) to their cognate ligands (e.g. FasL), and is followed by recruitment of capase-8, formation of a 
death inducing signalling complex (DISC), and downstream induction of effector caspases [228]. 
Apoptosis through the extrinsic pathway can be regulated by controlling the expression of surface 
death receptors (e.g. Fas) and/or the extracellular availability of death-inducing ligands (e.g. FasL). 
It can also be regulated by promoting or inhibiting the function of DISC through caspase-8 
homology molecule such as c-FLIP [229, 230].  
The intrinsic apoptotic pathway is triggered when stress or an injury occurs within the cell. Cellular 
stresses, such as increased calcium influx, growth factor deprivation, metabolic dysfunction, 
oxidative stress and direct DNA damage, can activate the intrinsic apoptotic pathway [231, 232]. 
The intrinsic pathway is mediated by proteins belonging to the BCL-2 superfamily, which can 
either promote or inhibit apoptosis [233]. After engaging with the stress signals, pro-apoptotic 
sensing molecules such as BIM and BAD are activated, and bind to anti-apoptotic molecules such 
as BCl-2, BCl-XL, and BCl-W. The anti-apoptotic molecules are localized on the outer membrane 
of mitochondria, and function to maintain the mitochondrial membrane integrity [234]. The binding 
between pro-apoptotic molecules and anti-apoptotic molecules creates an imbalance on the 
mitochondrial membrane and thereby promotes the activation of apoptotic effectors such as BAK 
and BAX. The activated BAK and BAX accumulate and oligomerize on the outer membrane of 
mitochondria, form channels to permeablize the mitochondrial membrane, and result in the 
subsequent cytoplasmic release of apoptogenic factors, such as cytochrome C [235, 236]. The 
released apoptogenic factors further initiate the downstream activation cascade of effector caspases. 
Therefore, the intracellular balance of pro-apoptotic and anti-apoptotic molecules on the outer 
membrane of mitochondria is crucial in determining survival or death of the cell.  
The extrinsic and intrinsic apoptotic pathways can also cross-talk, and induce death receptor-
triggered and caspase-8-mediated mitochondrial stress via the mediator of BID and truncated(t) BID 
[237, 238].  
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Figure 4.1 A schematic diagram is drawn to demonstrate intrinsic and extrinsic apoptotic 
pathways involved in cell apoptosis.  
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Both intrinsic and extrinsic pathways converge on activation of caspase-3, a key mediator of cell 
death. Once activated from its proenzyme form, caspase-3 promotes apoptosis by inducing 
morphological and biochemical changes in the cell, such as cleaving a range of structural protein, 
which leads to asymmetry of cell membrane, cell blebbing, chromatin condensation and DNA 
fragmentation [239, 240]. As a result of these morphological changes and cell membrane disruption, 
the inward-facing phosphatidylserine is externalised from the inner leaf to the outer leaf of the 
phospholipid cell membrane. The exposure of phosphatidylserine is a signal to macrophages for 
phagocytosis, and it is also an important marker for identification of apoptotic cells.  
Detection of apoptosis can be achieved by using Annexin-V and 7-aminoactinomycin D (7AAD) on 
flow cytometry. Annexin-V is a recombinant protein, which interacts strongly and specifically with 
phosphatidylserine in a calcium-dependent fashion [241, 242]. 7AAD is another common apoptosis 
indicator, which diffuses into cells and intercalates DNA in the later stages of apoptosis, when the 
cell membrane is disrupted.  
In this chapter, we examined apoptosis in TCR-reactivated CD4
+ 
Tm cells from children with T1D, 
their non-diabetic siblings and unrelated healthy control children, by assessing the expression of 
apoptotic markers both on cell surface and within cells. Overall, the data have revealed a novel 
finding that reactivated CD4
+ 
Tm cells from both T1D and sibling groups exhibited an increased 
apoptotic response, when compared to the controls.  
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4.2 Material and Method  
A cohort of children with T1D (n=29), their siblings (n=42), and control children (n=24) were 
studied in this chapter. As described previously in Chapter 3, CD4
+ 
Tm cells were purified from 
fresh PBMC by negative magnetic selection. The purified CD4
+ 
Tm cells were reactivated in culture 
supplemented with autologous serum in the presence of anti-CD3/anti-CD28 mAbs. Resting CD4
+ 
Tm cells cultured without anti-CD3/anti-CD28 were used to compare apoptosis with the reactivated 
CD4
+ 
Tm cells.   
4.2.1 Apoptotic assay 
Apoptosis was evaluated on days 1, 3 and 5 in both reactivated and resting CD4
+ 
Tm cells. 
Annexin-V (PE-conjugated, BD Bioscience; or Alexa Fluro 647-conjugated, BioLegend) and 
7AAD (Sigma-Aldrich) were used to stain cultured CD4
+ 
Tm in Annexin-V binding buffer. 
Apoptosis was defined as total Annexin-V
+
 cells, and was further discriminated as early (Annexin-
V
+
7AAD
-
) or late stage of apoptosis (Annexin-V
+
7AAD
+
). In addition to Annexin-V and 7AAD, 
intracellular expression of activated caspase-3 (PE-conjugated, BD Bioscience) was also measured 
in reactivated and resting CD4
+ 
Tm cells. In some experiments, double staining with caspase-3 and 
transcription factors of Tbet (APC-conjugated, BioLegend) or FoxP3 (Alexa Fluro 488–conjugated, 
eBioscience) was undertaken in reactivated CD4
+ 
Tm cells, to determine which type of effector 
cells were prone to apoptosis. Intracellular staining was carried out as previously described in 
Chapter 3. Surface expression of death receptor Fas (FITC-conjugated, BD Bioscience) and its 
ligand FasL (PE-conjugated, BioLegend) was examined in reactivated CD4
+ 
Tm cells on day 1 and 
day 5. In cross-culture assays, autologous serum was replaced with allogeneic serum derived from 
siblings or unrelated controls, or with fetal calf serum (FCS, Gibco, Life Technologies). For list of 
mAb used in this chapter, please refer to Appendix C. 
4.2.2 Tracking apoptosis during proliferation  
Freshly purified CD4
+ 
Tm cells were labelled with CFSE (Molecular Probes, Life Technologies), as 
previously described in Chapter 3, and then were stimulated for 5 days with an-CD3/anti-28 mAb. 
At harvest, the reactivated CD4
+ 
Tm cells were labelled with mAbs for CD3 (Pacific Blue-
conjugated) and CD62L (PE-conjugated), and then Annexin-V (APC-conjugated). Apoptosis was 
assessed as Annexin-V
+
 cells in each cell division of the total reactivated CD4
+ 
Tm cells, or in 
differentiated CD4
+ 
Tcm and CD4
+ 
Tem subsets defined by CD62L expression. All flow cytometry 
data were analysed by FlowJo software (version 7.6.5, TreeStar Inc.). 
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4.2.3 RT-qPCR assay  
Expression of pro-apoptotic and anti-apoptotic molecules associated with the mitochondria-
associated intrinsic apoptotic pathway was measured in reactivated CD4
+ 
Tm cells on days 1 and 5. 
Harvested cells were lysed in Qiagen RLT buffer, and total RNA was extracted with Qiagen 
RNeasy Mini kit (Qiagen). cDNA was synthesized by using iScript cDNA synthesis kit (Bio-Rad) 
and PCR thermal cycler (Bio-Rad), and the quality and quantity of the cDNA was evaluated on 
NanoDrop (Thermal Scientific). The cDNA templates were mixed with designated primers in 
SYBR green master mix (SYBR Premix Ex TaqII (Tli RNase H Plus, 2x) from Takara, or RT
2
 
SYBR Green qPCR Mastermix (2x) from Qiagen), and the real time quantitative PCR assays were 
performed on Viia7 Real Time PCR System (Applied Biosystems, Life Technologies) to determine 
gene expressions of the pro-apoptotic mediator BIM-L, BAD, pro-apoptotic effector BAK, BAX, and 
the anti-apoptotic BCL-2, BCL-XL and BCL-W. Expression of β-actin (ACTB) was determined and 
used as a house-keeping gene for normalisation. The PCR conditions were: one cycle at 50°C for 2 
min then 95°C for 10 min, and 40 cycles at 95°C for 15 seconds then 55–60°C for 40 seconds 
(annealing temperatures were determined and generally set at 3-5°C below primer melting 
temperature) and 72°C for 30 s. All primers were from GeneWorks (Hindmarsh, SA, Australia), 
and were all blasted to confirm 100% sequence match at: http://blast.ncbi.nlm.nih.gov/Blast.cgi. 
Details of primers and their sequences are listed in Appendix E. 
4.2.4 Apoptosis blocking assay with Fas antagonist  
To block apoptosis by the extrinsic pathway, a Fas antagonist mAb anti-Fas ZB4 (Millipore) was 
used. The efficiency of ZB4 was validated with Jurkat cells, by blocking apoptosis induced by Fas-
crosslinking anti-Fas CH-11 mAb (Millipore). Briefly, Jurkat cells  (0.5 x 10
6
 cells/ml were pre-
treated for 2h with 0, 1, 2.5 or 5µg/ml of ZB4, or its isotype control (IgG1 NALE; BD Bioscience). 
The pre-treated Jurkat cells were then cultured with CH-11 (20µg/ml) for 48h. At cell harvest, Fas 
and Annexin-V expressions were assessed by flow cytometry. Having validated the apoptosis 
blocking efficiency, a medium effective dose of 2.5µg/ml of ZB4 was selected for Fas-blocking 
assay with reactivated CD4
+ 
Tm cells from children subjects. As for the Jurkat cells, freshly purified 
CD4
+ 
Tm cells (0.5 x 10
6
 cells/ml) were pre-treated for 2h with 2.5µg/ml of ZB4 or isotype control 
IgG1 (2.5µg/ml), and then were reactivated for 5 days with anti-CD3/anti-CD28 mAbs. CD4
+ 
Tm 
cells cultured without ZB4 or isotype control were used as untreated controls for comparisons.  
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4.2.5 Statistical Analysis 
As described in previous chapters, Kruskal-Wallis test and post-hoc Dunn’s multiple comparisons 
was used for intergroup comparisons, and Mann-Whitney test was used for within group 
comparisons. Correlation was evaluated by Spearman’s test, and rank correlation coefficient r was 
reported if the correlation was significant. Statistical analysis was performed on GraphPad Prism 
software version 6.03. 
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4.3 Results 
4.3.1 Reactivated CD4
+ 
Tm cells from children with T1D and siblings are more susceptible to 
apoptosis  
Apoptosis was determined by Annexin-V and 7AAD, in both reactivated and resting CD4
+ 
Tm cells 
purified from peripheral blood of children with T1D (n= 29), their siblings (n=42) and controls 
(n=24) (Fig 4.2A).  
In reactivated CD4
+ 
Tm cells, apoptosis occurred similarly on day 1 and day 3 in all cultures, but 
was significantly increased in T1D and sibling cultures on day 5, compared to controls (Fig 4.2 B 
left). To address whether such high level of apoptosis in reactivated CD4
+ 
Tm cells from T1D and 
siblings were associated with reactivation, we measured apoptosis in resting CD4
+ 
Tm cells, and 
found that the that all resting CD4
+ 
Tm cells underwent similar rate of apoptosis and all had 
comparably large proportion of apoptotic cells on Day 5 (Fig 4.2 right). These data confirmed that 
the increased apoptosis in reactivated CD4
+ 
Tm cells from children with T1D and their siblings was 
a result of TCR stimulation, and suggest that these cells were more susceptible to reactivation-
induced apoptosis. However, a familial analysis showed that there was no correlation in apoptosis 
of the reactivated CD4
+ 
Tm cells between children with T1D and their siblings (P=0.467) (Fig 4.2 
C). Further analysis showed that the intergroup difference in apoptotic response between reactivated 
CD4
+ 
Tm cells was restricted to early stage apoptosis (Annexin-V
+
/7AAD
-
 cells) rather than late 
stage apoptosis (Annexin-V
+
/7AAD
+
 cells) (Fig 4.2 D).   
We also evaluated apoptosis by measuring intracellular activated form of caspase-3 (Fig 4.3A). 
Caspase-3 is a hallmark of cell apoptosis. It exists in cells in an inactivated proenzyme form, and 
can be activated by upstream apoptotic initiators. Once activated, caspase-3 promotes apoptosis by 
inducing irreversible morphological and biochemical changes in the cell [239, 240]. We found that 
the frequency of caspase-3
+
 cells were higher in reactivated CD4
+ 
Tm cells from T1D (n=8) and 
siblings (n=11) when compared to controls (n=8), closely resembling the results seen in Annexin 
binding assay. The level of intracellular expression of activated caspase-3, measured as median 
fluorescent intensity (MFI), also indicated enhanced up-regulation of this apoptosis executioner 
protein in reactivated CD4
+ 
Tm cells from T1D and siblings (Fig 4.3B). Therefore, by using 
Annexin-V and caspases-3 staining, we confirmed that reactivated CD4
+ 
Tm cells from children 
with T1D and siblings were more susceptible to apoptosis, but there was still no correlation in 
caspases-3 expression between CD4
+ 
Tm cells from children with T1D and CD4
+ 
Tm cells from 
their siblings (P=0.467). 
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Figure 4.2 Apoptosis in reactivated and resting CD4
+ 
Tm cells. (A) Representative dot plots 
show gating steps used to define apoptotic cells: gates are set to exclude debris and then include 
apoptotic cells (Annexin-V
+ 
7AAD
+/-
 populations). (B) Proportion of apoptotic cells in reactivated 
and resting CD4
+ 
Tm cells measured on day 1, 3 and 5 of cultures. (C) Familial analysis of 
apoptosis in reactivated CD4
+ 
Tm cells from children with T1D and their siblings (n=41). (D) Early 
stage and late stage apoptosis in reactivated CD4
+ 
Tm cells measured on day 5. Data are presented 
as median in scatter plots, and in box plots as median, 25-75 percentiles and minimum to maximum 
ranges. Statistics: Kruskal-Wallis test and post-hoc multiple comparisons.  *P < 0.05, **P < 0.01, 
***P<0.001.  
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Figure 4.3 Expression of activated caspase-3 in reactivated CD4
+ 
Tm cells. (A) 
Representative histograms show proportions of caspase-3+ cells in reactivated (red) and resting 
(grey) CD4+ Tm cells, measured on day 1, 3 and 5 of cultures from cohorts of T1D (n=8), siblings 
(n=11) and controls (n=8). (B) Left: frequency of caspase-3+ cells in reactivated CD4+ Tm cells. 
Right: intracellular expression of caspase-3 protein in reactivated CD4
+ 
Tm cells, as determined by 
fold increase in MFI compared to resting CD4
+ 
Tm cells. (C) Familial analysis of caspases-3
+
 cells
 
in reactivated CD4
+ 
Tm cells measured on day 5 from children with T1D and their siblings (n=11). 
Data are presented as median in scatter plots, and in box plots as median, 25-75 percentiles and 
minimum to maximum ranges. Statistics: Kruskal-Wallis test and post-hoc multiple comparisons.   
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4.3.2 Apoptosis in reactivated CD4
+ 
Tm cells was cell autonomous and independent of the 
source of supplemented serum.  
Having shown increased apoptosis in reactivated CD4
+ 
Tm cells from children with T1D and their 
siblings, we then asked whether the autologous serum used during culture could influence the 
apoptosis of CD4
+ 
Tm cells. In replacing of autologous serum, we cross-cultured CD4
+ 
Tm cells 
with allogeneic sera from siblings or unrelated controls, or FCS. Again, increased levels of 
apoptosis were observed in reactivated CD4
+ 
Tm cells from T1D and siblings on day 5, regardless 
of the serum used in culture (Fig 4.4). These results suggest that the increased apoptosis in 
reactivated CD4
+ 
Tm cells from children with T1D and their siblings was cell autonomous, 
dependent on factors intrinsic to the CD4
+ Tm cells, and wasn’t due to cell interactions with serum 
factors.  
 
 
 
Figure 4.4 Apoptosis in cross-culture assay. Percentages of apoptotic cells in the reactivated 
CD4
+ 
Tm cells, measured on day 1 and day 5, in cultures with either autologous, allogeneic (from 
siblings or unrelated control children) or FCS (T1D n=10, siblings n=10, controls n=6). Data are 
presented as mean ± SEM. Statistics: comparison between day 1 and day 5 within the same subject 
group was done by Mann-Whitney test; intergroup comparison of day 5 apoptosis was done by 
Kruskal-Wallis test and post-hoc multiple comparisons.  
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4.3.3 Cellular and molecular assessment of apoptosis in reactivated CD4
+ 
Tm cells  
To understand the cellular and molecular mechanisms underlying the increased apoptosis in T1D 
and sibling groups, we examined the expression of surface death receptor Fas and its ligand FasL on 
the reactivated CD4
+ 
Tm cells across the cohorts. There was no intergroup difference in Fas or FasL 
expression on day 1. On day 5, Fas expression was detected in reactivated CD4
+ 
Tm cells from all 
three subject groups, but the proportion of Fas
+
 cells was significantly higher in T1D (82.7%) and 
siblings (81.2%) than in control cells (60.7%, P=0.041, P=0.013 respectively) (Fig 4.5B, left). In 
contrast to the widespread expression of Fas, FasL was expressed on smaller proportion of 
reactivated CD4
+ 
Tm cells, but the T1D (10.5%) and siblings (9.3%) again had an increased 
expression of FasL when compared to the controls (2.0%, P=0.0034, P=0.0069 respectively) (Fig 
4.5B, right).  
This observation raised the possibility that the increased rate of apoptosis in reactivated CD4
+ 
Tm 
cells from T1D and siblings was mediated through the Fas/FasL interactions, where increased FasL 
expression induced fratricide on neighbouring Fas-expressing cells. To test this possibility, we used 
a Fas antagonist anti-Fas ZB4 mAb. ZB4 is a non-apoptosis inducing mAb, known to neutralise 
surface Fas and therefore block Fas/FasL interaction. The efficiency of ZB4 to block Fas-induced 
apoptosis was validated in Jurkat cells. We found that ZB4 pre-treatment masked Fas expression in 
Jurkat cells and decreased apoptosis induced by a Fas-crosslinking mAb CH-11, in a dose-
dependent manner (Fig 4.6). Therefore, ZB4 was effective in blocking Fas-mediated apoptosis, and 
by pre-treating the CD4
+ 
Tm cells with ZB4 we expected to prevent or reduce apoptosis in 
reactivated CD4
+ 
Tm cells, if the apoptosis was Fas-mediated. However, we failed to see significant 
changes in apoptosis in reactivated CD4
+ 
Tm cells from any subject groups, even though ZB4 
successfully masked Fas-expressions on all reactivated CD4
+ 
Tm cells, when compared with 
untreated cells or cells treated with isotype control (Fig 4.7A and B). Therefore, the apoptosis in 
reactivated CD4
+ 
Tm cells was unlikely Fas-mediated, although high surface Fas expression and 
detectable FasL
+
 cells were evident in reactivated CD4
+ 
Tm cells from T1D and siblings.   
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We then investigated the apoptosis in reactivated CD4
+ 
Tm cells by examining mitochondria 
associated intrinsic pathway. Gene expressions of a group of Bcl-2 superfamily molecules were 
measured in reactivated CD4
+ 
Tm cells. These molecules included the pro-apoptotic mediator BIM 
and BAD, apoptotic effectors BAK and BAX, and the anti-apoptotic molecules BCL-2, BCL-XL, 
and BCL-W. In the reactivated CD4
+ 
Tm cells, there was evidence of increased gene expression of 
BAD and BAX in T1D, and increased gene expression of BIM, BAK and BAX in siblings. 
Conversely, expression of the anti-apoptotic molecules were comparable and did not increase in all 
three subject groups (Fig 4.8). These data suggest that the intrinsic apoptotic pathway may be 
responsible for the increased susceptibility to reactivation-induced apoptosis in CD4
+ 
Tm cells from 
children with T1D and their siblings.  
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Figure 4.5 Expression of death receptor Fas and its cognate ligand FasL on reactivated 
CD4
+ 
Tm cells. (A) Representative dot plots demonstrating expression of Fas and FasL measured 
on day 5 in reactivated CD4
+ 
Tm cells from the T1D (n=11), sibling (n=22) and control (n=11) 
groups. (B) Percentage of Fas
+
 and FasL
+
 cells in reactivated CD4
+ 
Tm cells, measured on day 1 
and 5 of cultures. Data are presented as box plot with median, 25-75 percentiles, and minimum to 
maximum ranges. Statistics: within group comparison between day 1 and day 5 was done by Mann-
Whitney test, and intergroup comparison was done by Kruskal-Wallis test and post-hoc multiple 
comparisons.   
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Figure 4.6 Validating efficiency of the antagonistic anti-Fas ZB4 mAb to block Fas-
induced apoptosis in Jurkat cells. Jurkat cells treated with (solid line) and without (dashed line) 
Fas-crosslink mAb CH-11 (20µg/ml) were given 0, 1, 2.5 or 5 µg/ml of ZB4 or 5µg/ml of isotype 
control mAb. (A) Representative dot plots show apoptosis (Annexin
+
/7AAD
+/-
 cells) induced in 
Jurkat cells by CH-11 mAb in the presence of isotype control mAb or increasing concentrations of 
ZB4. (B) ZB4 effectively masked Fas expression on Jurkat cells and reduced the CH-11-induced 
apoptosis in Jurkat cells. Data are from 2 independent experiments with duplicates and are 
presented as mean ± SEM. 
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Figure 4.7 Antagonistic anti-Fas ZB4 mAb masked Fas expression but did not reduce 
apoptosis in reactivated CD4
+ 
Tm cells from children with T1D and their siblings. CD4
+ 
Tm 
cells pre-treated for 2h with 2.5µg/ml of ZB4, or isotype IgG1, or no treatment were reactivated in 
cultures by anti-CD3/anti-CD28 for 5 days. (A) Representative dot plots show proportions of Fas
+
 
cells and Annexin-V
+
 cells in 5-day reactivated CD4
+ 
Tm cells, cultured under different treatment 
conditions. (B) ZB4 effectively masked Fas expression on reactivated CD4
+ 
Tm cells across the 
cohorts, but the proportions of apoptotic cells remained unchanged (T1D n=5, siblings n=9, controls 
n=5). Data are presented as box graphs with median, 25-75 percentiles and minimum to maximum 
ranges. Statistics: comparisons between treatments within same subject group were done by Mann-
Whitney test.  
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Figure 4.8 Gene expressions of pro-apoptotic and anti-apoptotic molecules in reactivated 
CD4
+ 
Tm cells from children with T1D, siblings and controls. Expression of pro-apoptotic 
transcripts of BIM-L, BAK, BAX, BAD and anti-apoptotic transcripts of BCL-2, BCL-XL and BCL-W 
were measured by real time qPCR on day 1 and day 5 in reactivated CD4
+ 
Tm cells from T1D 
(n=5), siblings (n=9) and controls (n=5). Data are presented as box plot with median, 25-75 
percentiles and minimum to maximum ranges. Statistics: within group comparison between day 1 
and day 5 was done by Mann-Whitney test, and intergroup comparison was done by Kruskal-Wallis 
test and post-hoc multiple comparisons.  
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4.3.4 Tracking apoptosis in reactivated CD4
+ 
Tm during their proliferation 
Since the apoptosis in reactivated CD4
+ 
Tm cells occurred during dynamic processes of 
proliferation and differentiation, we tracked the occurrence of apoptosis over CD4
+ 
Tm proliferation 
for more than 4 divisions. As shown in Fig 4.9, in T1D and siblings, apoptosis occurred to a similar 
extent in both undivided cells (division 0) and divided cells (division 1 to >4), whereas in controls 
apoptosis was predominately found in undivided cells and significantly reduced over divisions, 
especially in cells that have divided more than twice (division 0 vs. division 2, P=0.032; division 0 
vs. division 3, P=0.018; division 0 vs. division 4, P=0.017; division 0 vs. division >4, P=0.045). 
Then we tracked the occurrence of apoptosis in functionally different subsets of Tcm and Tem cells 
within the total reactivated CD4
+ 
Tm cells. Firstly, we took the approach of gating on total apoptotic 
cells, and then within the total apoptotic cells we defined CD4
+ 
Tcm and CD4
+ 
Tem cells based on 
CD62L expression (CD62L
+ 
Tcm cells and CD62L
- 
Tem cells, Fig 4.10 A). We observed that CD4
+ 
Tem cells accounted for vast majority of the apoptotic population, contributing to 82.0%, 82.8% 
and 86.3% of total apoptotic cells in reactivated CD4
+ 
Tm cells from T1D, siblings and controls, 
respectively. In contrast, only a small proportion of CD4
+ 
Tcm cells were apoptotic (T1D median= 
17.6%, sibling median=16.5%, and control median=10.6%, Fig 4.10 B). Therefore, CD4
+ 
Tem cells 
appeared to be the major subset contributing to CD4
+
 Tm cell apoptosis in all three subject groups.  
We also examined contribution to apoptosis from an alternative approach by gating on reactivated 
CD4
+ 
Tcm and CD4
+ 
Tem cells first, and then analysing the proportion of apoptotic cells in each 
subject group (Fig 4.10 C). Approximately 50% of the CD4
+ 
Tem cells in T1D (P=0.014) and 
siblings (P=0.032) became apoptotic, significantly higher than those in controls (median=32.3%, 
Fig 4.10 D). In contrast, the CD4
+ 
Tcm cells remained relatively resistant to apoptosis in all subject 
groups (T1D median=10.70%, sibling median=9.16%, and control median=4.30%), but the Tcm 
lineage of T1D and siblings still showed greater rates of apoptosis compared with control subjects 
(P=0.026 and P=0.045 respectively). Therefore, we can conclude that CD4
+ 
Tem cells were 
generally more sensitive to reactivation-induced apoptosis than the CD4
+ 
Tcm cells; however the 
CD4
+ 
Tem cells from children with T1D and their siblings displayed an increased susceptibility to 
apoptosis when compared to controls. 
In chapter 3, we showed that TCR-induced reactivation resulted in imbalanced composition within 
CD4
+
 Tm cells, featuring increased proportion of CD4
+ 
Tem cells, in children with T1D and their 
siblings (Fig 3.3, chapter 3), and then we proposed 3 possibilities that: 1) CD4
+
 Tem cells in T1D 
subjects and sibling had excessive proliferative capability, or 2) their CD4
+
 Tcm cell had poor 
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survival, or 3) there was increased CD4
+
 Tcm to CD4
+
 Tem transition in these subjects. Our 
proliferation data disproved the first possibility (Fig 3.8, chapter 3), and here the apoptotic data of 
reactivated CD4
+
 Tcm cells (Fig 4.10) also disagrees with the second possibility, therefore it is very 
likely that the increased CD4
+ 
Tem response in children with T1D and their siblings was be a result 
of increased CD4
+
 Tcm to CD4
+
 Tem conversion. However, it appears that the CD4
+ 
Tem 
phenotype in in children with T1D and their siblings was poorly maintained.  
 
Figure 4.9 Apoptosis tracked during proliferation of reactivated CD4
+ 
Tm cells from T1D, 
siblings and control children. T1D n=6, siblings n=10, and controls n=5. (A) Representative 
histograms demonstrate gating strategy used to define cell divisions based on CFSE dilutions. 
Representative dot plots illustrate Annexin-V axis and respective gating in each cell division. (B) 
Proportion of apoptotic cells within each cell division was determined on day 5 in all reactivated 
CD4
+ 
Tm cells. Data are presented as mean ± SEM on bar graph. Statistics: Kruskal-Wallis test and 
post-hoc multiple comparisons. * denotes intergroup comparison in each cell division, # denotes 
within group comparison vs. division 0. 
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Figure 4.10 Apoptosis in CD4
+ 
Tcm and CD4
+ 
Tem cells measured in 5-day reactivated 
CD4
+ 
Tm cells. (A) Representative dot plots for gates used in determining CD62L
+ 
Tcm and 
CD62L
- 
Tem populations within total apoptotic cells. (B) Percentage of CD4
+ 
Tcm and CD4
+ 
Tem 
cells within apoptotic gate (T1D n=10, siblings n=15, control n=12). (C) Representative dot plots 
for gating strategy used in determining apoptosis within CD4
+ 
Tcm and CD4
+ 
Tem cells. (D) 
Percentage of apoptotic cells within CD4
+ 
Tcm and CD4
+ 
Tem gates (T1D n=12, sibling n=21, 
control n=11).  Data are presented as median in scatter plots and as mean ± SEM in bar graphs. 
Statistics: Kruskal-Wallis test and post-hoc comparisons. 
  
CHAPTER 4 APOPTOSIS OF REACTIVATED CD4
+ 
Tm CELLS 
107 
 
In order to understand which functional subset of effector cells was prone to apoptosis, we 
compared apoptosis in Th-1 cells and Treg cells, derived from reactivated CD4
+ 
Tm cells. This is 
important to address, because Th-1 effector cells are known to drive autoimmunity in T1D patients 
[100, 243], while Treg cells contribute to self-tolerance [244]. By intracellular double staining for 
caspase-3 and T-bet, and for caspases-3 and FoxP3 (Fig 4.11A), we investigated apoptosis in Th-1 
and Treg cells. We found 20.3% and 15.1% of Caspase-3
+ 
T-bet
+
 cells in reactivated CD4
+ 
Tm cells 
from T1D and siblings respectively, higher than that in controls (median= 6.38%, P=0.012 and 
P=0.058 respectively). These apoptotic Th-1 effector cells accounted for 62.5% and 47.3% of total 
capase3
+
 cells T1D and siblings, whilst only 27.8% in controls (P=0.029 and P=0.068 respectively), 
suggesting that a larger proportion of apoptotic CD4
+ 
Tm cells in T1D and siblings were Th-1 
effectors, whilst in controls the apoptotic population may contain more cells from the Th-2 and Th-
17 lineages. In contrast to Th-1 effectors, caspase-3
+
FoxP3
+
 cells were negligible (median < 5%, 
data not shown) in all reactivated CD4
+ 
Tm cells, which is in line with our results from chapter 3 
where we showed that proportion of CD4
+ 
Tm-derived Treg cells was constant over the course of 
reactivation and comparable across the cohort (Fig 3.2 C, Chapter 3). These data suggest that 
enhanced Th-1 effector response in reactivated CD4
+ 
Tm cells from T1D subjects and their siblings 
were poorly maintained and sensitive to apoptosis, whereas the memory-derived FoxP3
+
 Treg cells 
were relatively resistant to reactivation-induced apoptosis.   
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Figure 4.11 Apoptosis in Th-1 effector cells derived from reactivated CD4
+ 
Tm cells. (A) 
Representative dot plots demonstrate intracellular double staining with caspases-3 and T-bet or their 
isotype control mAbs in 5-day reactivated CD4
+ 
Tm cells. (B) Box plots show percentages of 
caspases-3
+
T-bet
+ 
cells in total reactivated CD4
+ 
Tm cells and in total caspases-3
+
 CD4
+ 
Tm cells 
from T1D (n=5), siblings (n=7) and controls (n=5). Data are presented as median, 25-75 percentiles 
and minimum to maximum ranges. Statistics: Kruskal-Wallis test and post-hoc comparisons.  
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4.4 Discussion  
In this chapter, we found that reactivated CD4
+ 
Tm cells from diabetic children and their siblings 
exhibited an increased apoptotic response, when compared to controls. This increased apoptosis was 
a reactivation-induced cell autonomous response, independent of culture conditions, associated with 
increased capase-3 activation. It occurred in a Fas-independent manner involving up-regulation of 
transcripts associated with the mitochondrial associated intrinsic apoptotic pathway.  
Elimination of reactivated T cells by apoptosis after immune responses is a safeguard against the 
development of autoimmunity. Alterations in T cell apoptosis in T1D and other autoimmune 
diseases has been previously reported, and is becoming an important focus in T1D research. T cell 
resistance to apoptosis, resulting from suppressed caspase-3 expression [223, 224] and/or genetic 
defects in Fas expression [225] has been suggested as for contributing to autoimmunity in patients 
with T1D and other autoimmune diseases. In our study, we did not observe any defect in expression 
of activated caspases-3 in reactivated CD4
+ 
Tm cells from T1D patients. In fact, the caspases-3 
expression strongly supported Annexin-V binding data, and both suggested increased apoptosis in 
reactivated CD4
+ 
Tm cells from T1D and siblings. The discrepancy on caspases-3 expression 
between our results and other studies may be explained by the different subsets of T cells that were 
tested. Reports from previous studies were based on examination of total T cells or total 
lymphocytes, whereas our study focused on a more specific subgroup of T cells, the CD4
+ 
Tm cells. 
The varying findings may indicate specific subsets of T cells respond to reactivation differently, and 
this may reflect their individual roles in the development of T1D. Indeed, the susceptibility of CD4
+ 
Tm cells to reactivation-induced apoptosis has been reported in patients with other autoimmune 
disorders such as coeliac disease and multiple sclerosis [167, 170], as well as studies using NOD 
mice [166], and collectively these studies have proposed that increased sensitivity to apoptosis can 
act on one hand as a protective mechanism to limit expansion of excessively activated T cells, and 
on the other it is responsible for lymphopenia and subsequent immunogenic exposure to 
autoantigens, which can lead to autoimmunity.   
To understand the underlying mechanisms of the increased apoptosis in reactivated CD4
+ 
Tm cells 
from T1D and siblings, we investigated in both the extrinsic and the intrinsic apoptotic pathways. 
For the extrinsic pathway, we examined expression of Fas and FasL in reactivated CD4
+ 
Tm cells, 
and did not see reduced Fas expression in T1D or siblings cells, different from other studies that 
have reported Fas reduction in effector CD4
+ 
T cells in T1D patients [245] or in mouse model of 
T1D [246, 247]. Instead, we observed increased level of Fas expression on reactivated CD4
+ 
Tm 
cells in T1D and siblings, when compared with controls. This is probably related to the increased 
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activation responses of these cells, as reported in chapter 3. It should be noted that the previously 
reported Fas reduction in T1D was only restricted to poly-reactive T1D patients with additional 
autoimmune conditions [225, 245], and our cohort of children with T1D had no other autoimmune 
disease. We also observed FasL expressions on a proportion of reactivated CD4
+ 
Tm cells from 
T1D and siblings, but not in control cells. FasL-expressing CD4
+ 
T cells and its association with β 
cells destruction has been reported in NOD mice [125, 248-250]. In humans, previous studies have 
only shown infiltration of FasL-expressing CD4
+ 
T cells in inflamed pancreatic islets of T1D 
patients [85]. Our data, as we believe, is the first to report CD4
+ 
Tm cells from T1D patient can give 
rise to FasL
+
 cells upon reactivation, and it is possible that some of these FasL
+
 effectors may have 
the potential to become pathogenic to inflamed β cells. Interestingly, FasL expression was also 
observed in reactivated CD4
+ 
Tm cells from siblings, suggesting a possible shared genetic 
inheritance, however, the fact that siblings were free of diabetes indicates difference in their 
immune regulations of FasL
+ 
CD4
+ 
Tm cells.   
Although the Fas/FasL system has been previously reported to be responsible in elimination of 
reactivated CD4
+ 
T cells and shutting down immune responses after contraction phase in humans 
[251-253], we found that this mechanism was dysfunctional in reactivated CD4
+ 
Tm cells from T1D 
and siblings. The Fas-antagonist ZB4 mAb masked Fas expression on CD4
+ 
Tm cells, thereby 
blocked Fas/FasL interaction, but failed to prevent apoptosis in reactivated T1D and sibling CD4
+ 
Tm cells. However, given that high surface Fas expression and detectable FasL
+
 cells were evident 
in reactivated CD4
+ 
Tm cells from T1D and siblings, we cannot exclude the possibility that the Fas 
function may be defective in reactivated CD4
+
 Tm cells from T1D and sibling, and such defects can 
include: 1) defective Fas trimerisation upon FasL binding, 2) inability of Fas in forming functional 
DISC, or 3) insufficient in downstream signal transduction through the caspases cascade (e.g. 
caspases-8). Recent studies suggest that correct Fas localisation and assembly on cell membrane 
lipid raft microdomains determines efficiency in Fas signalling in human CD4
+ 
Tm cells [254, 255]. 
In addition, cytokines such as IL-2 have been suggested to potentiate Fas and FasL mediated 
reactivation-induced apoptosis in CD4
+ 
T cells, due to its ability to promote FasL expression and 
supress Fas-signalling inhibitor c-FLIP [256-258]. In our study, to best mimic physiological 
conditions we supplemented autologous serum instead of recombinant IL-2, and this may have 
resulted in insufficient signal for apoptosis through the Fas/FasL pathway. Therefore, the apoptotic 
response in reactivated CD4
+ 
Tm cells from children with T1D and their siblings was unlikely 
elicited through the Fas-mediated extrinsic pathway.  
For the intrinsic apoptotic pathway, we compared gene expressions of associated pro-apoptotic and 
anti-apoptotic molecules in reactivated CD4
+ 
Tm cells, and discovered evidence for activation of 
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the intrinsic apoptotic pathway in T1D and sibling cells, but not in control cells. The higher levels 
of BAD transcripts in T1D and BIM transcripts in siblings indicated intracellular activation of pro-
apoptotic sensing machinery, possibly to due to calcium influx induced-cell stress [231] or cytokine 
deprivation [232]. The upregulation of apoptotic effectors BAK and BAX in reactivated CD4
+ 
Tm 
cells from T1D and siblings suggested an imbalance of pro- and anti-apoptotic effects on the 
mitochondrial membrane [259, 260]. A direct impact of such an imbalance would be disruption and 
permeabilization of the mitochondrial membrane. Therefore, despite the constant expression of anti-
apoptotic BCL-2, BCL-XL, and BCL-W, the upregulated pro-apoptotic molecules may have out-
weighted anti-apoptotic protection and contributed to the increased apoptosis in reactivated CD4
+ 
Tm cells from children T1D and their siblings.   
The combined investigations of caspase-3 expression, the Fas/FasL system and the mitochondria 
associated intrinsic apoptotic pathway confirmed accelerated apoptosis in reactivated CD4
+ 
Tm 
cells from T1D and siblings, but we are still unsure of the underlying cause. Initially, we thought 
that the TCR stimulation used to induce CD4
+ 
Tm cell reactivation was higher than physiological 
concentration of antigenic stimuli that the CD4
+ 
Tm cells would normally be exposed to in vivo, and 
as a result the CD4
+ 
Tm cells were over-stimulated in vitro and underwent higher apoptosis. 
However, this is strongly arguable by the evidence that CD4
+ 
Tm cells from controls maintained 
relatively lower level of apoptosis. In addition, the TCR stimulation condition was carefully titrated 
(Chapter 3), and an optimised dose of anti-CD3/anti-CD28 stimulation was obtained to effectively 
induce activation and proliferation of CD4
+ 
Tm cells without causing increased apoptosis. 
Therefore, the increased apoptosis in CD4
+ 
Tm cells from children with T1D and their siblings was 
not due to over-stimulation. 
The increased apoptosis may be a consequence of the exaggerated activation and effector responses 
in the reactivated CD4
+ 
Tm cells (as discussed in chapter 3). Generally exaggerated effector 
responses are regulated by enhanced apoptotic elimination to maintain T cell homeostasis and 
prevent autoimmunity. Within the reactivated CD4
+ 
Tm cells, we found that effector memory 
phenotype were generally more sensitive to reactivation-induced apoptosis, whereas those retaining 
Tcm phenotype were generally relatively resistant. This result suggests a cell autonomous 
difference between CD4
+ 
Tem and CD4
+ 
Tcm phenotypes in their susceptibility to apoptosis, and 
this difference may be due to an intrinsic constrain in CD4
+ 
Tem cells, resulted from higher in vivo 
turnover and shortened telomeres [130, 254, 261]. Despite the general similarity in CD4
+
 Tem 
sensitivity to apoptosis, we also found that the CD4
+ 
Tem cells from T1D patients and their siblings 
displayed an increased sensitivity to apoptosis (responsible for eliminating approximately 50% of 
the reactivated CD4
+ 
Tem cells) when compared to controls (32.3%). Additionally, within the CD4
+ 
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Tem cells from T1D and siblings, we found that Th-1 effector cells expressing T-bet were prone to 
apoptosis, which supports previous findings that Th-1 effector cells were susceptible to apoptosis 
during reactivation [262, 263]. Overall, the increased apoptosis in reactivated CD4
+ 
Tm cells from 
T1D and sibling subjects is likely resulted from their exaggerated reactivation and effector 
responses.  
It is worth noting that the increased apoptosis in reactivated CD4
+ 
Tm cells from children with T1D 
inversely correlates with their reduced blood CD4
+ 
Tm count (P=0.028, Spearman r=-0.51), 
suggesting that the susceptibility to reactivation-induced apoptosis may be responsible for an altered 
in vivo dynamics of blood CD4
+ 
Tm cells in T1D. Interestingly, there was no such correlation 
observed between CD4
+ 
Tm apoptosis and blood CD4
+ 
Tm count in siblings. 
Taken together, the results from this chapter have provided new evidence that, after T1D onset the 
immune system may be still capable of regulating the immune memory towards self-tolerance, by 
increasing elimination of effector cells during reactivation. However, it is still not sufficient to 
constrain the exaggerated activation and effector responses in reactivated CD4
+ 
Tm cells from 
children with T1D, and to a lesser extent from the siblings. The direct consequence of such 
imbalance in vivo may permit the persistence of an effector memory even when the recall response 
is over, and thereby increasing the risk of developing autoimmunity. One possible reason for such 
imbalanced may be the defective Fas/FasL system, which is generally responsible for shutting down 
exaggerated effector responses. Future study dissecting the Fas/FasL pathway may be of interest in 
understanding the Fas/FasL system in the reactivated CD4
+ 
Tm cells in T1D.  
Lastly, although CD4
+ 
Tm cells from children with T1D and their siblings displayed similar 
susceptibility to apoptosis during TCR-induced reactivation, we cannot rule out the possibility that 
apoptosis could differ at the clonotype level. Therefore, it would be of our key interest in future 
research to evaluate CD4
+
 Tm responses, particularly effector response and apoptosis, against islet-
specific antigen challenge, such as GAD, insulin and proinsulin.  
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Chapter 5 General Discussion and Future Directions 
5.1 Summary of key findings 
This PhD study focused on peripheral blood CD4
+ 
Tm cells, which are believed to play a pivotal 
role in mediating autoimmune responses during the chronic development of T1D [155]. The 
ultimate proof of CD4
+
 Tm cells in driving disease was framed in recent clinical trials that showed 
drug-mediated blocking of T cell activation slowed β-cell destruction [135], and drug-mediated 
depletion of CD4
+
 Tm cells preserved C-peptide level in newly diagnosed T1D patients [136]. 
Disease progression could also be prevented in the NOD mouse model by guiding CD4
+ 
Tm cells 
away from an effector memory phenotype towards a regulatory memory phenotype [138]. These 
studies have clearly point towards CD4
+
 Tm cells as a promising immune target for T1D treatment.  
However, the immunological characteristics of CD4
+
 Tm cells and immunological events involved 
in regulating CD4
+ 
Tm cells in T1D patients are still not fully understood. 
We began our investigation with a general hypothesis that circulating CD4
+
 Tm cell counts and 
immunological responses in reactivated CD4
+
 Tm cells discriminate T1D patients from their non-
diabetic siblings and unrelated healthy individuals. By using a unique cohort of age- and gender-
matched children with T1D, their non-diabetic siblings and unrelated healthy control children, we 
undertook a detailed immunological study including circulating CD4
+ 
Tm cell counts, and 
activation, proliferation, effector responses and apoptosis in reactivated CD4
+ 
Tm cells during TCR 
stimulation induced by anti-CD3/anti-CD28 mAb.  
We found that T1D was associated with a reduced circulating CD4
+
 Tm cell count, and a similar 
reduction in circulating CD4
+
 Tm cells was also evident in the siblings. The reduced circulating 
CD4
+
 Tm cell counts in T1D patients and siblings were resulted from a decrease in the CD4
+
 Tcm 
cells. In addition, T1D patients and their siblings were also associated with lymphopenia and 
reduced circulating CD3
+
 T, CD8
+
 T and CD8
+
 Tm cells counts, particularly relevant to young 
patients and siblings aged between 5-9 years. In contrast to the reduced CD4
+
 Tm cell and 
lymphocyte counts being common in T1D patients and their siblings, a reduction in neutrophil and 
monocyte counts was associated with T1D only. The reduced number of circulating neutrophils in 
diabetic patients observed in this study has also been recently reported by others [264, 265]. Taken 
together, these results suggest that shared genetic/environmental factor may have an impact on the 
T cell branch of the adaptive immune system in both T1D patients and their siblings, whilst 
affecting the neutrophil/monocyte branch of the innate immune system in only T1D patients.  
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By inducing TCR stimulation with anti-CD3/anti-CD28 mAb, we investigated the immunological 
responses of reactivated CD4
+ 
Tm cells in children with T1D, siblings and controls. No intergroup 
difference in proliferation was found in reactivated CD4
+ 
Tm cells, suggesting no proliferative 
senescence or defective replication in CD4
+ 
Tm cells from T1D patients. However, differences were 
observed in cell phenotypes post-reactivation, where the reactivated CD4
+
 Tm cells from children 
with T1D and their siblings acquired CD25
+
 phenotype at a significantly higher proportion when 
compared to the controls. In human T1D, genetic predisposition associated with lowered threshold 
for CD4
+ 
T cell signalling and activation has been previously reported [209-211]. In line with our 
data, altered CD4
+
 T activation threshold has also been suggested as a marker for autoimmune 
progression in at-risk individuals [209], and others have reported that CD4
+ 
Tm cells from at-risk 
individuals can be activated more completely with late-stage activation marker CD134 when 
compared with control subjects [162]. Physiological consequences of the increased activation 
responses in CD4
+ 
Tm cells of T1D patients and their siblings remain elusive, but it is possible that 
such heightened activation response may be capable to mount a more aggressive effector response.  
Indeed, we found that reactivated CD4
+ 
Tm cells from T1D patients and siblings have promoted 
increased effector responses, through effective transition from central memory (CD62L
+
) to effector 
memory (CD62l
-
) phenotype. These exaggerated effector responses were characterised by elevated 
IFN-γ and IL-10 in T1D patients and increased IFN-γ production in the siblings. However, these 
exaggerated CD4
+
 Tem responses were also accompanied by an increase in Fas-independent 
mitochondria-associated apoptotic response, which eliminated approximately 50% of CD4
+ 
Tem 
cells in T1D and siblings in comparison to only one third of CD4
+
 Tem cells in controls. 
Additionally, the increased apoptotic response in reactivated CD4
+ 
Tm cells from T1D patients 
inversely correlates with their reduced blood CD4
+ 
Tm counts, suggesting that the susceptibility to 
reactivation-induced apoptosis may be associated with an altered in vivo dynamics of blood CD4
+ 
Tm cells in T1D.  
Together, the new insights from this study substantiate the role of CD4
+
 Tm cells in T1D, and have 
provided evidence that the CD4
+
 Tm cells in T1D are prone to activation and capable of mounting 
exaggerated disease-associated effector responses. However, the hyperactive phenotype and the 
exaggerate effector responses were counterbalanced by an increased apoptotic response. These data 
suggest that after T1D onset the immune system may still be capable of regulating CD4
+ 
Tm-
derived effector cells via apoptotic elimination, although it is insufficient to constrain the 
heightened effector responses. The non-diabetic siblings displayed a similar CD4
+ 
Tm immune 
profile, step-wise resembling their diabetic counterparts but to a lesser extent. To address the 
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remarkable similarities in CD4
+ 
Tm immune profiles between T1D patients and their siblings, we 
performed pair-wise familial analysis on major findings over the entire study, but failed to see 
significant correlations in CD4
+
 Tm counts or CD4
+ 
Tm immune responses between T1D patients 
and their siblings. Despite the fact that the siblings may possess genetic risks (both HLA- and non-
HLA-associated) of developing T1D, and many of the immunological defects occur prior to diabetic 
onset and even before detectable autoantibodies, the level of similarity observed in this study has 
exceeded the justification for shared genetic predisposition (e.g. less than 15% of heterozygote 
siblings are in risk to develop T1D). Therefore the similar CD4
+ 
Tm profile between T1D patients 
and their siblings is unlikely to be a familial trait. Further study evaluating CD4
+
 Tm responses, 
particularly effector response and apoptosis, against islet-specific antigen challenge (such as GAD, 
insulin and proinsulin) may help to distinguish T1D patients from their non-diabetic siblings at 
clonotype level.  
Nonetheless, this study approached the immunology of type 1 diabetes (T1D) from a new 
perspective by looking at the CD4
+ 
Tm cells at a population level, and reported that human T1D is 
associated with a “global” alteration in CD4+ Tm cells from cell numbers in the circulation, 
activation responses, effector functions and susceptibility to apoptosis, when compared with healthy 
controls. This finding provides new insights for human T1D, which could be associated with 
metabolic and physiological impacts on the adaptive CD4
+ 
Tm cells in a systematic scale and 
irrespective of antigenic specificity. Indications from this study may help further defining 
mechanisms underlying T1D pathophysiology and leading to new research for therapeutic targeting. 
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5.2 Future directions 
5.2.1 Islet specific antigen stimulation 
In this study, we utilised a pan-TCR polyclonal stimulation with agonists of anti-CD3 and anti-
CD28 mAb to induce reactivation in the CD4
+ 
Tm cells. Whether an exaggerated effector response 
herein induced in CD4
+
 Tm cells by this polyclonal TCR stimulation also operates across other T 
cell lineages (e.g. CD8
+
 T cells) as well as in response to antigen-specific stimulation (e.g. GAD, 
insulin or proinsulin) is warranted in future research.  
As a preliminary experiment, we recruited a 15 years old high-risk sibling (GAD Ab
+
 and IA-2 
Ab
+
) and a healthy adult control to study CD4
+
 Tm cell responses against islet-specific antigen 
GAD65 peptide (PepTivator, Miltenyi Biotec). As a positive control, tetanus toxoid (TT) antigen 
(Commonwealth Serum Laboratory) was included in the assay, and both subjects had been 
immunized against tetanus. PBMC were separated from whole blood, and fraction containing a 
mixture of CD4
+
CD45RO
+ 
Tm cells and antigen presenting cells (HLA-DR
+
, CD11c
+
 and CD16
+
 
cells) was purified from PBMC by negative magnetic separation on automated magnetic cell sorter 
(AutoMACS, Miltenyi Biotec). The mixture of CD4
+ 
Tm cells and antigen presenting cells were 
labelled with CFSE and challenged with GAD65 peptide (0.1µg/million cells as per manufacturer’s 
protocol) or TT antigen (5µg/million cells) [266] for 7 days, in culture supplemented with heat-
inactivated autologous serum. GAD65- and TT-specific antigenic responses were evaluated as 
proportion of responder cells (CFSE
dim
). Resting CD4
+
 Tm cells were used as unstimulated control. 
We were able to detect TT-specific response in CD4
+
 Tm cells from both subjects, but only 
observed GAD65-specific response in CD4
+
 Tm cells from the high-risk sibling (Fig 5.1).  
In this study, we were constrained by the limited blood volumes from paediatric subjects. In future 
study, this constrain may be overcome by involving adolescents and young adults with T1D, their 
siblings and age- and gender-matched healthy controls.  
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Figure 5.1 CD4
+ 
Tm cells response to islet antigen specific stimulation. Blood CD4
+ 
Tm cells 
purified from a high risk sibling and a healthy adult were stimulated in culture with GAD65 peptide 
or tetanus toxoid (TT) antigen, or unstimulated (resting) for 7 days. Antigen-specific response was 
evaluated as proportion of responders cells (CFSE
dim
) in comparison to unstimulated resting CD4
+
 
Tm cells.  
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5.2.2 Redirect the uncommitted CD4
+
 Tcm  
A key finding in this study is the increased transition from central memory (CD62L
+
) to effector 
memory (CD62l
-
) phenotype in reactivated CD4
+ 
Tm cells from T1D patients and their siblings, and 
the associated exaggerated Tem responses. However, it is evident that there was still a relatively 
large proportion (~40%) of Tcm cells left uncommitted in both T1D and siblings.  
While it is difficult to tolerise committed Tem cells, it may be possible to promote the uncommitted 
Tcm cells through re-educational cytokine polarization, so that these uncommitted Tcm cells can be 
assigned with a new commitment at reactivation to ameliorate or even overcome the Tem response. 
In our proliferation data, we observed equivalent proliferation index in Tcm and Tem cells across 
the cohort. The proliferated Tcm cells that still retained CD62L
+
 phenotype were those 
uncommitted Tcm cells [130, 132]. With the growing appreciation to the plasticity of CD4
+ 
Th 
cells, it is becoming clear that differentiation of CD4
+ 
T cells, particularly the uncommitted “stem 
cell like” CD4+ Tcm cell, can be engineered by providing controlled milieu of cytokines during 
reactivation. For example, study with mice has shown that CD4
+ 
Tcm cells with Th-1 lineage can 
produce typical Th-2 cytokine IL-4, when reactivated in the context of an innate response that 
favours Th2 development [267]. The plasticity of FoxP3
+
 Treg cells are also well documented in 
both human and mice, especially in autoimmune disease settings [191, 268, 269]. The exact 
mechanism of CD4
+
 T cells plasticity is not clear, but study of epigenetic modification during CD4
+
 
T cell differentiation has found that transcription factors associated with Th-1 phenotype, such as T-
bet was particularly marked by histone modification preventing inhibition and enhancing 
transcription, whereas transcription factors associated with other CD4
+
 T subsets, such as GATA3 
(Th2), RORC (Th17) or FoxP3 (Treg), were less marked hence allowing their transcriptional 
flexibility [270].  
Therefore, it is reasonable that the uncommitted “stem cell like” CD4+ Tcm cells may have the 
ability to be developed into regulatory phenotype, such as IL-10 producing cells, to ameliorate or 
even overcome autoimmune responses in T1D. This will be an interesting topic for future research 
in T1D.  
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5.2.3 Role of innate immunity in T1D 
An important difference between children with T1D and their non-diabetic siblings was their 
neutrophil and monocyte counts, when compared with controls. Both neutrophil and monocytes 
belong to the innate immune system, playing major role in clearing infections and response to 
inflammatory. It has been shown that innate effector cells including both neutrophils and monocytes 
infiltrate islets at the onset of T1D [264, 271]. Data from this study and our previous reports have 
consistently shown reduced neutrophil [52] and monocyte [52, 174] counts in children with T1D. 
The decrease in blood neutrophils in T1D patients has also been reported by others, and it could be 
due to neutrophil death [272] or increased neutrophil migration into tissues [264]. Blood monocytes 
are precursors for macrophage and dendritic cells, and are responsible for antigen presentation to 
CD4
+
 T cells. Our preliminary study further delineated the monocytes into three subsets: classical 
(CD14
++
CD16
-
), intermediate (CD14
++
CD16
+
) and non-classical (CD14
-
CD16
+
) monocytes, 
according to the international nomenclature [273]. We found that the reduction in blood monocytes 
in children with T1D was due to the decrease in intermediate monocytes but not in the classical or 
non-classical monocytes (Fig 5.2). The intermediate monocytes represent a small proportion of 
monocytes, in a transitional stage between the classical and non-classical monocytes. They are 
shown to have highest capacity of antigen presentation amongst the three subset of monocytes 
[274], produce highest amount of IL-10, and are found to expand in infectious and inflammatory 
diseases such as asthma and sepsis [274]. The reason for the reduced intermediate monocytes in 
children with T1D is unknown, but it is quite possibility that these transitional stage monocytes 
with high antigen presentation capacity and IL-10 production ability may have exited circulation 
and migrated into specific tissues where inflammation is taking place.  
Future study considering both the innate and adaptive immunity and focusing on the interactions 
between the two arms of the immune system will be important for understanding the sequential 
events involved in progression to T1D.  
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Figure 5.2 Absolute number of blood monocytes in children with T1D, siblings and 
controls. (A) Representative dot plots demonstrate gating strategies for blood monocytes. (B) 
Classical (CD14
++
CD16
-
), intermediate (CD14
++
CD16
+
) and non-classical (CD14
-
CD16
+
) 
monocyte counts in children with T1D (n=9), siblings (n=16) and controls (n=12). Data are 
presented as median (bar). Statistics: Kruskal-Wallis test and post-hoc comparisons.  
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5.2.4 A future longitudinal study 
Lastly, this study is limited by is cross-sectional design. In future, a longitudinal study monitoring 
the changes in circulating CD4
+
 Tm cell count and functional responses in CD4
+
 Tm cells, 
particularly in newly diagnosed T1D patients and at-risk siblings, will be valuable for further 
assessing the role of CD4
+
 Tm cells in disease progression.  
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Appendices 
Appendix A.  Research Ethics  
Appendix A1 Ethics approval for recruiting children with T1D, their siblings and control children 
was originally obtained in 2004 from Mater Hospital Human Research Ethic Committee for Ethics 
number MHS-HREC 771C, and was extended to March 2017. 
Original ethics approval 
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Ethics Amendment approved to extend the study to 2014.  
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Ethics Amendment approved to extend the study to 2017.  
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Ethics Amendment approved to include Michael Bian as a co-investigator.  
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Approved volume of blood to be collected from participating children subjects.  
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Appendix A2 Current ethics approval for collecting blood samples from healthy adult donors. 
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Appendix B.  Patient information Sheets as in April 2013 version 
Appendix B1 Control group 
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Appendix B2 Type 1 diabetes and sibling groups 
 
 
  
APPENDICES   
160 
 
 
 
 
 
APPENDICES   
161 
 
 
 
 
 
APPENDICES   
162 
 
  
APPENDICES   
163 
 
Appendix C.  Full patient information.  
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Appendix D.  Monoclonal antibodies and staining regents used in this thesis  
Purified unconjugated antibodies 
Antibody Manufacture Catalogue  Fluorophore Clone Isotype 
Anti-Fas Millipore 05-338 Purified ZB4 Ms, IgG1 
Anti-Fas Millipore 05-201 Purified CH-11 Ms, IgM 
CD3 eBioscience 16-0037-85 Purified OKT3 MS IgG2a 
CD8*   Purified OKT8 IgG2a 
CD11c Beckman Coulter IM0717 Purified BU15 Ms IgG1 
CD14 Beckman Coulter IM0643 Purified RMO52 Ms IgG2a 
CD16 Beckman Coulter IM0813 Purified 3G8 MsIgG1 
CD19 Beckman Coulter IM1313 Purified J3-119 Ms IgG1 
CD20 Beckman Coulter IM1342 Purified B9E9 Ms IgG2a 
CD28 BD  556620 Purified CD28.2 Ms IgG1κ 
CD34 BD 347660 Purified My10 Ms IgG1 
CD45RA Beckman Coulter IM0537 Purified ALB11 Ms IgG1 
CD56 Beckman Coulter 6602705 Purified N901 Ms IgG1 
CD66 BD 551355 Purified B6.2 Ms IgG1 
CD235A BD 555569 Purified GA-R2 Ms IgG2 
HLA-DR*   Purified L243 IgG2a 
Mouse IgG1 Isotype  BD 554721 Purified NALE 107.3 Ms, IgG1 
* Unconjugated CD8 and HLA-DR were prepared in our laboratory from hybridomas obtained 
from the American Culture Collection.  
Fluorescence conjugated antibodies for cell surface staining 
Antibody Manufacture Catalogue  Fluorophore Clone Isotype 
CD3 BD 560365 Pacific Blue UCHT1 Ms IgG1 
CD4 BD 340133 FITC SK3 MS IgG1 
CD8 BD 557746 PE-Cy7 RPA-T8 Ms IgG1 
CD25 (IL-2Rα) BD 555434 APC M-A251 Ms IgG1 
CD45 BD 560178 APC-H7 2D1 MS IgG1 
CD45RA BD 347723 FITC L48 Ms IgG1 
CD62L (L-selectin) BD 559772 APC DREG-56 Ms IgG1 
CD62L (L-selectin) BD 555544 PE DREG-56 Ms IgG1 
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CD45RO BD 555493 PE UCHL1 Ms IgG2a 
CD45RO BioLegend 304221 PercP-Cy5.5 UCHL1 Ms IgG2a 
CD95 (Fas) BD 340479 FITC DX-2 Ms IgG1 
CD127 (IL-7rα) BD 557938 PE hIL-7R-M21 Ms IgG1 
CD178 (FasL) BioLegend 304406/7 PE NOK-1 Ms IgG1 
 
Fluorescent conjugated antibodies for intracellular staining 
Antibody Manufacture Catalogue  Fluorophore Clone Isotype 
Caspase-3 BD 550821 PE C92-605 Rabbit IgG 
Foxp3 eBioscience 12-4776-42 PE PCH101 Rat IgG2a 
Rat IgG2a PE BD  554689 PE R35-95 Rat IgG2a 
Foxp3 eBioscience 53-4776-42 AF-488 PCH101 Rat IgG2a 
Rat IgG2a AF-488 eBioscience 53-4321-80 AF-488 eBR2a Rat IgG2a 
IFN-g BD 559326 PE 4S.B3 Ms IgG1 
IL-4 BD 554516 PE 8D4-8 Ms IgG1 
Mouse IgG1 PE BD 554680 PE MOPC-21 Ms IgG1 
T-bet BioLegend 644803 AF-647 4B10 Ms IgG1 
Mouse IgG1 AF-647 BioLegend 400130 AF-647 MOPC-21 Ms IgG1 
 
Other staining reagents 
Antibody Manufacture Catalogue  Fluorophore 
7-Aminoactinomycin D  Sigma-Aldrich A9400 Percp-Cy5.5 
Annexin-V BD 556422 PE 
Annexin-V BioLegend 640920 APC 
CFSE Life Technologies C34554 FITC 
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Appendix E.  Primers used for RT-qPCR in this thesis  
Primers 
Encoded 
Protein 
Sequence 
Primer 
Conc. 
Melting 
Temp 
Supplier 
ACTB Beta actin 
F: 5'-CCT GTA CGC CAA CAC AGT GC-3' 2µM 61°C GeneWorks 
R: 5'-ATA CTC CTG CTT GCT GAT CC-3' 2µM 59°C GeneWorks 
Anti-Apoptosis 
BCL2 
B-cell 
lymphoma-2 
protein 
F:5'-TGG GAT GCC TTT GTG GAA CTA T-3' 2µM 61°C GeneWorks 
R:5'-AGA GAC AGC CAG GAG AAA TCA AAC-3' 2µM 61°C GeneWorks 
BCLXL 
(BCL2L1) 
B-cell 
lymphoma-
extra large 
F: 5'-GGT CGC ATT GTG GCC TTT-3' 2µM 61°C GeneWorks 
R:5'-TCC TTG TCT ACG CTT TCC ACG-3' 2µM 61°C GeneWorks 
BCLW 
(BCL2L2) 
B-cell 
lymphoma-
extra large 
F: 5'-CTG ACC CGG CTC CAC GCT GG-3' 2µM 65°C GeneWorks 
R:5'-TCT GCC ACC AGA GCC CGT GT-3' 2µM 63°C GeneWorks 
Pro-Apoptosis 
BIM 
Bcl-2 
interacting 
molecule 
F: 5'-ATC CYC AAG ACA GGA GCC C-3' 2µM 61°C GeneWorks 
R: 5'-ATG GAA GCC ATT GCA CTG AGA-3' 2µM 61°C GeneWorks 
BAD 
Bcl-2-associate 
death promoter 
F: 5'-GCA GCC ATC ATG GAG GCG CT-3' 2µM 58°c GeneWorks 
R: 5'-CTG GGC TCC TCC CCC ATC CC-3' 2µM 62°c GeneWorks 
BAK 
Bcl-2 
antagonist/killer 
protein 
F: 5'-GGC TGA TCC CGT CCT CCA CTG AG-3' 2µM 62°c GeneWorks 
R: 5'-CCT GGG CTA CCT GCT CCT CAG AAG C-3' 2µM 64°c GeneWorks 
BAX 
Bcl-2-
antogonist X 
F: 5'-GCC CTT TTG CTT CAG GGT TTC-3' 2µM 61°c GeneWorks 
R: 5'-TGA GAC ACT CGC TCA GCT TC-3' 2µM 61°c GeneWorks 
All primers were synthesized and purchased from GeneWorks, and blasted to confirm 100% 
sequence match at: http://blast.ncbi.nlm.nih.gov/Blast.cgi. During real time quantitative PCR, 
annealing temperature is generally set 3-5°C below primer’s melting temperature. 
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Appendix F.  Journal articles arisen from this study 
Appendix F1 A first author paper published on Diabetes. Published online before print 
December 31, 2014, doi: 10.2337/db14-1151. 
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Appendix F2 A co-author paper published in 2011 on Journal of Cellular and Clinical 
Immunology.  
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Appendix G. Reference Range of Clinical Full Blood Count-Mater Hospital of Brisbane 
 
